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Advancements in medical technology coupled with a more thorough 
comprehension of oncologic diseases has resulted in a burgeoning number of aggressive 
treatment options available to cancer patients and a gradual loosening of the association 
between cancer and timely death.  With the advent of extended life expectancies, 
however, the need to investigate the human and overall life impact of cancer diseases and 
treatments has increased dramatically (Langenhoff et al., 2001).  This need to examine 
considerations of quality of life becomes even more essential in the context of high-risk 
treatments, such as cytoreductive surgery plus hyperthermic intraperitoneal 
chemotherapy (CS+HIPEC), an extensive procedure offered to select candidates with 
peritoneal carcinomatosis from a variety of primary origins (Levine et al., 2007).  A 
biopsychosocial model of research and clinical care (e.g. Wilson & Cleary, 1995) 
underscores the many levels and interrelationships of clinical, demographic, and 
psychosocial variables impacting survivors of such an invasive medical procedure, yet a 
paucity of methodologically sound psychosocial studies with these long-term CS+HIPEC 
survivors exists.  
The purpose of this investigation was to enhance our understanding of the 
multidimensional quality of life (QOL) and sleep quality of survivors who have lived 12 
or more months post-CS+HIPEC.  Additionally, the contributions of surgical and 
biological variables to long-term QOL were examined, as were changes in QOL scores 
 
over time in a subset of the sample. This descriptive data acquired enriches our 
knowledge of CS+HIPEC survivors‟ quality of survivorship, informs prospective 
candidates‟ treatment decision making processes, and enhances the standard of care by 
serving as a foundation for future psychosocial interventions.  
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CHAPTER I
INTRODUCTION 
 
 
“[W]hen one is faced with cancer, the valiant action is to fight.  It is our duty to take up 
arms, to go into battle, to join others in the fight.  To do less is somehow less heroic, less 
honorable.  We are at war with cancer…”  
(Edes, 2008, p. 2483) 
 
 
Under the guise of an often underestimated influence, cultural metaphors and 
diction stealthily infiltrate our individual and collective perceptions, layering us with 
implicit pressures that seep in and guide our actions.  Albeit not always negative, these 
existing messages warrant additional attention when their presence sways and potentially 
prioritizes one life-altering decision (i.e., seeking treatment) over another that is equally 
valid (i.e., not seeking treatment).  In cancer treatment, those who elect treatment are 
rightfully revered; yet, acknowledging the heroism of those who choose death, death 
preceded by months or years of quality, is equally warranted.  Edes (2008) eloquently 
elucidated the reasoning underpinning some patients‟ decisions not to seek treatment in 
the following: “When at war, you must focus on the enemy, not on the beauty of the 
world around you.  When in battle, you must be constantly vigilant for signs of danger, 
not distracted by opportunities for joy.  When preparing to fight you must be disciplined 
and attuned to the mission, not relaxing with family” (p. 2483).  For those who are 
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diagnosed, no treatment-related decision is “right” and none is “wrong”.  Electing not to 
undergo extensive treatment, however, is far from losing a fight.  For some, it is
personifying the belief that there are more important things to do with precious time.  
Every individual deserves to make the decisions that optimally suit her or his goals, and 
the availability of accurate quality of life data alongside the existing quantity of life data 
is one way to equip individuals with holistic knowledge for making informed decisions.   
 Researchers investigating the impact and efficacy of oncology treatments examine 
a vast array of patient variables that become increasingly complex and integrated as focus 
broadens from the single cell and organ systems, to the holistic individual, to ultimately 
the individual functioning in a micro/macrocosm (Wilson & Cleary, 1995).  Researchers 
may focus on biological or physiological variables (e.g., neutrophil count, pulmonary 
function test results), treatment-related morbidity or psychological symptoms (e.g., 
fatigue, anhedonia), functional impairments (e.g., difficulties bathing or climbing stairs), 
subjective ratings of health perception, overall quality of life ratings, or mortality rates 
and survivorship experiences.  Treatment “success,” then, may be quantified using any of 
the aforementioned.  Researchers from different disciplines often diverge in their 
opinions of which outcome variables should be prioritized and, to further confound the 
situation, medical clinicians and patients also may prioritize alternate outcome variables 
(e.g., survival rate versus psychosocial impact).  These differing priorities may never 
emerge in doctor-patient dialogue (Halyard & Ferrans, 2008), despite the fact that 
treatment selections may vary based on the outcome measure perceived to be of most 
importance. 
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In the not-so-distant past, oncology treatments were grossly measured only in 
terms of death, cure, and toxicity rates (Cella & Tulsky, 1993; Langenhoff, Krabe, 
Wobbes, & Ruers, 2001). With advancements in technology, coupled with a more 
thorough comprehension of oncologic diseases, a burgeoning number of aggressive 
treatment options are now available to patients.  As a consequence, many types of cancer 
are no longer automatically associated with timely death and minimal life expectancies 
(Cella et al. 1993), and words/phrases such as survivorship, cure, and mounting 
chronicity have become widely used in the oncology vernacular.  In tandem with this 
steady shift has been a mushrooming interest on the part of researchers and society alike 
in learning about the impact of diseases and treatments on patients‟ and their loved ones‟ 
lives (Langenhoff et al., 2001).  As more cancer patients face cure and extended life 
expectancies, quality of life demands equal emphasis and credence in treatment 
evaluation compared to quantity of life.  
Quality of Life 
Quality of life (QOL) is a concept with roots dating back to antiquity, yet a 
definition of the term as well as valid and reliable tools for its measurement are 
comparatively recent developments (Cella et al., 1993).  Cella and Cherin (1988) defined 
QOL as “patients‟ appraisal of and satisfaction with their current level of functioning 
compared to what they perceive to be possible or ideal” (p. 70).  Most researchers agree 
that QOL as a construct is subjective, in flux, multidimensional and, ideally, based on the 
patient‟s perspective (Cella & Tulsky, 1990).  Likewise, it is a dual-sided construct, 
encapsulating not only downward declines in functioning, but attending also to positive, 
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wellness aspects of one‟s current functioning (Cella & Cherin, 1988).  The primary 
dimensions of QOL supported by factor analysis and proposed by Cella et al. (1993) 
include physical, functional, social, and emotional dimensions. Instruments to measure 
QOL, then, not only must assess these four domains but must also be sensitive to changes 
over time (Cella et al., 1993).   
When researching patients‟ QOL in a medical context, it is important to measure 
objectively the extent of the medical problems, obtain a patient-rated appraisal of the 
extent of the dysfunction, and assess how the patient‟s subjective appraisal compares 
with her or his expectations (Cella et al., 1990).  Objective measurements of medical 
complications allow for quantification of the extent of problems and the acquisition of 
data detailing distinct advantages and disadvantages of the respective treatment.  
Objective measurements and even symptom reports alone remain insufficient, however, 
as the unique effects of these symptoms on life functioning and quality is what is desired 
by those targeting the psychosocial impact of treatment (Ferrans, 2007).  Therefore, the 
patient‟s subjective ratings are needed to shed insight into the distress associated with the 
condition and the degree to which it is tolerable to that respective individual (Cella et al., 
1990).  Consistently noted in these patient-rated outcomes is a high rate of variability, as 
patient characteristics and a plethora of additional variables unrelated to patients‟ 
biological or physiological well-being impact subjective experiences (Cella et al., 1990).  
If one acknowledges this myriad of individual appraisals of synonymous objective events 
(e.g., treatment results or disease progression), however, he or she must, in turn, also 
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acknowledge the importance of measuring these subjective experiences alongside the 
“objective” medical reality (Cella et al., 1993).   
Numerous professional oncology organizations similarly have recognized the 
importance of measuring both the objective and subjective realities of patients and have 
incorporated these ideals into recent guidelines and standards.  For example, in their 1995 
guidelines for cancer treatment and assessment, The American Society of Clinical 
Oncology (ASCO) concluded that measuring survival in the absence of other outcome 
variables is insufficient; “the quality of survival and cost of maintaining or improving it 
must also be assessed” (American Society of Clinical Oncology, 1996, p. 673).  
Likewise, in their requirements for approval of new anticancer drugs adopted in 1985, the 
FDA listed survival and QOL as the two key efficacy parameters (Johnson & Temple, 
1985) on which a proposed drug must have a favorable effect in order to be approved.  
The attention to QOL issues by these aforementioned influential organizations illustrates 
the collective belief in the importance of attending to issues of quantity (i.e., survival) 
and quality (i.e., multidimensional life impact) in cancer treatment.  
A Biopsychosocial Model 
Also conceptualizing measures of health as interrelated and existing on a 
continuum of increasing complexity, Wilson and Cleary (1995) integrated two 
paradigms, one held by biomedical researchers with one held by social scientists, in their 
five-level conceptual model of patient outcomes (i.e. biological/physiological, symptom 
status, functional status, health perceptions, and quality of life).  Among other insights, 
this model highlights the plethora of layered, relational variables (from the single cellular 
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level outward to more abstract measures of well-being) that impact a survivor‟s current 
existence.  The equally-important and bidirectional influences of these variables on 
survivor functioning underscore the need for research and clinical attention to both 
“hard” and “soft” patient outcome variables in any medical context.  
As new and aggressive treatments enter the oncology scene, this equal attention to 
biological and psychosocial dimensions of functioning becomes especially important for 
researchers.  Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy 
(CS+ HIPEC) is such an example of an aggressive procedure gaining acceptance for 
patients with intra-abdominal malignancies that have spread throughout the peritoneal 
cavity (Stewart, Shen, & Levine, 2008).  
CS+HIPEC as a Treatment of Peritoneal Carcinomatosis 
The peritoneal cavity is the space within the abdomen, bound by thin membranes, 
that contains the intestines, the stomach, and the liver (National Cancer Institute, n.d.).  
Peritoneal carcinomatosis occurs following the intracavitary dissemination of tumors 
from various surrounding areas, including ovarian and gastrointestinal carcinomas and 
sometimes sarcomas and mesothelioma (Levine et al., 2007).  The movement of 
malignancies into the peritoneal cavity is considered a terminal diagnosis, as this 
carcinomatosis progressively spreads, ultimately leading to bowel obstruction and 
subsequent death in approximately six months if untreated (Stewart et al., 2008).  Typical 
systemic therapy (i.e., chemotherapies that travel through the bloodstream and impact 
cells all over the body; National Cancer Institute, n.d.) is strictly palliative in nature for 
individuals with peritoneal surface disease, as systemic therapies ineffectively move 
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through the peritoneal-plasma partition (Stewart et al., 2008).  That is, survival is not 
significantly increased by administration of systemic therapies.  Cytoreductive 
(debulking) surgery alone allows removal of macroscopic disease, thereby preventing 
short-term bowel obstruction (Sugarbaker, 1989), but microscopic disease inevitably 
remains in the peritoneal cavity and returns in a matter of time (Stewart et al., 2008).  
Individuals with peritoneal disease, however, often have no extra-abdominal disease, 
meaning the disease is concentrated in one regional area.  This localization of metastases 
within the peritoneum in combination with the absence of ancillary metastases makes an 
aggressive localized approach a suitable option (Stewart et al., 2008).  
CS+HIPEC is an aggressive, multimodal technique that offers patients with 
peritoneal carcinomatosis the possibility of extended life.  Surgeons performing this 
extensive procedure combine cytoreductive surgery (to remove the macroscopic disease) 
with chemoperfusion (i.e., bathing organs, tissues, or a specific part of the body with high 
doses of chemotherapeutic agents; National Cancer Institute, n.d.) directly into the 
peritoneal cavity to attack the microscopic and residual disease (Levine et al., 2007).  
Chemoperfusion administered immediately following CS is advantageous for numerous 
reasons (Levine et al., 2007).  First, administering intracavitary chemoperfusion allows 
the tumors to be exposed to drug levels much higher than those achievable with standard 
systemic therapy.  Second, the peritoneal surfaces are all exposed following the CS, so 
drug distribution is more efficient.  Finally, by not administering numerous cycles of 
systemic therapy, the patient is not exposed to repeated bouts of chemotherapy and 
related morbidities (Levine et al., 2007).   
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Adherence to stringent patient selection criteria is essential for attainment of 
positive post-CS+HIPEC outcomes and, even in the best of circumstances, morbidity and 
mortality rates remain high (Stewart et al., 2008).  Specifically, in a review of 501 
procedures on 460 patients, Levine et al. (2007) reported a 4.8% 30-day mortality rate, 
43% morbidity rate, 22.2-month median survival, and five-year survival rate of 27.8%.  
The primary tumor site (Levine et al., 2007), resection status (i.e., the achieved level of 
visible tumor removal and cytology findings post-operation, as classified by the 
following: RO- total removal of all visible tumor and negative cytologic findings or 
microscopic margins; R1- total removal of all visible tumor and positive postperfusion 
cytologic findings or microscopic margins; R2a- slight amounts of remaining visible 
tumor, nodules measuring less than or equal to 0.5 cm; R2b- large amounts of visible 
tumor remaining and nodules greater than 0.5 cm but less than or equal to 2 cm; R2c- 
gross disease remaining with nodules greater than 2 cm; Levine et al., 2007) and 
pathological characteristics of the respective individual‟s disease (Yan, Black, Savady, & 
Sugarbaker, 2007), among other variables, introduced additional variability in 
postoperative outcomes and prognoses.  Without this procedure, however, all individuals 
with peritoneal carcinomatosis have grim survival expectancies.  
Despite the treatment‟s existence for over 20 years, limited behavioral science 
studies have been conducted with individuals who have opted for this procedure 
(McQuellon & Duckworth, 2009).  Understanding the QOL impact of this aggressive 
procedure on survivors will inform treatment evaluation, health team behavior and care, 
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future patient decision-making and expectation adjustment, and post-operative 
psychosocial interventions designed for these patients and their families.  
Sleep Quality 
Also important and largely understudied within this population is sleep quality, a 
specific component of QOL that largely impacts patients‟ well being.  Unlike other 
psychosocial and biopsychosocial variables associated with cancer treatment, sleep 
quality remains understudied in cancer patients, potentially because it is conceptualized 
as a normal or transitory reaction to diagnosis or treatment or as a secondary reaction to 
an alternate psychological or medical problem (Savard & Morin, 2001).  Sleep concerns 
in the context of cancer care may trace their roots to any number of factors, including 
predisposing factors (e.g., a personal history or psychological disorder), factors that only 
recently triggered their onset (e.g., adjusting to diagnosis, pain), and factors that maintain 
disordered sleep (e.g., hindering sleep behavior) (Savard & Morin, 2001).  In addition to 
its association with QOL, sleep quality has been associated with shorter life expectancy, 
immunosuppresion, mood disorders and fatigue (Savard & Morin, 2001).  In one of the 
few studies examining the QOL of long-term (i.e., three or more years post-treatment) 
survivors of CS+HIPEC, McQuellon et al. (2003) noted that poor sleep was one of the 
top three psychosocial concerns of participants within the timeframe of one month prior 
to the study.  Despite this finding, a paucity of data exists relative to the sleep quality of 
persons who have received CS+HIPEC.  Collecting QOL and sleep quality data on 
individuals who have received this procedure will be advantageous for surgeons, patients, 
and the mental health clinicians working with them.  
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Purpose of the Study 
The purpose of this study was to gather more descriptive demographic, QOL, and 
sleep quality information on CS+HIPEC survivors one or more years post-procedure, as a 
paucity of information on these long-term survivors currently exists.  More specifically, 
the intent was to attain a multidimensional understanding (by means of the Medical 
Outcomes Study 36-Item Short Form Health Survey (SF-36); Ware & Sherbourne, 1992) 
of the following dimensions of QOL:  
 limitations in physical activities because of health problems;  
 general mental health (including psychological distress and well-being); 
 limitations in social activities because of physical or emotional problems; 
 limitations in usual role activities because of physical health and emotional 
problems;  
 bodily pain; 
 vitality (including energy and fatigue); 
 general health perceptions  
A comprehensive understanding of sleep quality and sleep disturbances in CS+HIPEC 
survivors also was obtained via administration of the Pittsburgh Sleep Quality Index 
(Buysse, Reynolds, Monk, Berman, & Kupfer, 1989).  Further, since pre-surgery QOL 
data was collected by alternate WFUBMC-affiliated researchers from a subset of 
individuals who received CS+HIPEC, statistical analyses allowed an examination of 
changes in QOL across the time period since surgery for this subset of participants.  The 
12 or more month QOL scores also were compared to population norms.   
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Statement of the Problem 
 Despite the introduction of CS+HIPEC into the surgical oncology scene over 20 
years ago and its outlook as a promising multimodal therapy for individuals with 
peritoneal carcinomatosis (Sticca, 2003), few QOL studies of this population have been 
performed (McQuellon & Duckworth, 2009).  Specifically, following a review of the 
literature, only nine QOL studies of this population were located.  Of these nine studies, 
many were methodologically flawed or had an insufficient sample size from which to 
draw any reliable statistical or clinical conclusions (McQuellon & Duckworth, 2009).  
Further, patients 12 or more months post-treatment remain inadequately represented 
within these studies.   
Subsumed under and largely impacting QOL, Kvale and Shuster (2006) noted the 
tendency for cancer patients to underreport sleep-related concerns, despite high estimates 
of cancer-related insomnia.  Sleep disturbances negatively impact patients‟ QOL by 
means of heightening patients‟ senses to suffering in any or all realms of their lives, 
reducing coping abilities, increasing their sense of pain and general malaise, and altering 
disease severity perceptions (Kvale & Shuster, 2006), yet many patients are not 
systematically asked about the quality of their sleep (Savard & Morin, 2001).  
Concurrently, Berger, Sankaranarayanan and Watanabe-Galloway (2007) noted the 
overall dearth of scrupulousness in sleep disturbances measurement within the cancer 
field in general and the disturbing trend for those clinicians who do measure sleep quality 
in adults with cancer to do so via a non-comprehensive, one-item statement.  Measuring 
solely one parameter of sleep quality is insufficient (Berger et al., 2007), as this does not 
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capture the detailed nature of the problem or how it changes over time.  Utilization of a 
brief, yet psychometrically sound, instrument, however, elucidates the prevalence and 
nature of sleep disturbances within the population so these concerns do not remain 
underreported (Kvale & Shuster).  
 A mental health professional working in psychosocial oncology and hospice 
strives to better understand the QOL of understudied populations and ultimately apply 
that understanding in means useful to the patients, from diagnosis through treatment and 
into survivorship.  As surgical oncologists continue to hone both their understanding and 
multimodal treatment of peritoneal carcinomatosis, behavioral scientists and clinicians 
must keep pace.  A clearer understanding of the QOL and sleep quality of patients 
undergoing CS+HIPEC is needed at all stages of their cancer journey. 
Research Questions 
Accordingly, this study is designed to address the following research questions: 
 
1. What are the QOL subscale scores (i.e. Physical Functioning, Role Physical, Bodily 
Pain, General Health, Vitality, Social Functioning, Mental Health, Role Emotional) and 
component scores (Physical Component Score and Mental Component Score) of 
participants, as measured by the Medical Outcomes Study 36- Item Short-Form Health 
Survey (SF-36) instrument, and how do they compare to those of general population 
norms? 
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2. Regarding those participants for whom pre-surgical data is available, what differences 
exist between pre-surgical QOL subscale scores and 12 or more-month QOL scores for 
participants who received CS+HIPEC and have survived? 
 
3. What is the sleep quality of participants, as defined by one‟s global and component 
scores on the Pittsburgh Sleep Quality Index (PSQI)? 
 
4. What relationship exists between sleep quality, age at CS+HIPEC, months since 
surgery, and QOL subscale scores?  
 
5. What are the respective contributions of resection status (RO/R1, R2a, R2b, and R2c) 
and primary tumor site in predicting QOL subscale scores at 12 or more months? 
Need for the Study 
 Individuals with peritoneal carcinomatosis can expect dismal outcomes without 
treatment, typically progressing to death in less than one year (Levine et al., 2008).  
When faced with the option of certain, impending death or a chance of longer-term 
survival, many patients will opt for a procedure without hesitancy, regardless of the 
potential accompanying psychosocial correlates.  In such a matter of life or death, where 
one treatment serves as the only option for extended life, many people may question the 
utility of studying QOL.  For numerous reasons, however, psychosocial data must hold a 
prominent role in treatment recommendations and decisions. 
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QOL studies are an essential component of treatment evaluations for a multitude 
of reasons, one being they provide information not often depicted by measures that target 
more singular and restricted life aspects, such as physical symptoms (Ferrans, 2007).  
With QOL measures, one is able to capture more broadly the “ripple effect of the change 
in symptoms produced by the intervention” (p. 22).  For example, instead of assessing 
pain levels in isolation by means of a singular symptom assessment, QOL instruments 
acquire information on not only pain levels, but also how this experienced pain diffuses 
into a survivor‟s work life, completion of daily chores, and socialization practices.  In 
other words, the larger life impact of physical and mental symptoms experienced as a 
consequence of the procedure is obtained via these instruments.  
This QOL information can serve as one of many important endpoints for 
consideration in the evaluation of an aggressive treatment as well as who is considered a 
suitable and optimal candidate in the first place (Cella et al., 1993).  Gathering QOL data 
from different treatment populations enhances knowledge of the typical trajectory for 
QOL fluctuations after varying treatments.  The availability of this post-treatment QOL 
information permits patients to be informed consumers and decision-makers as they 
consider various options of care and also helps them adjust their post-treatment recovery 
expectations.  These data may be especially weighted in the decision making of 
individuals who are poor surgical candidates to begin with or who enter treatment with a 
substandard prognosis.  These individuals likely have less remaining time to live 
regardless of treatment, and quality of life should be the ultimate focus in palliative 
medicine (Kvale & Shuster, 2006).   
15 
 
QOL data also inform researchers, physicians and mental health professionals of 
the psychosocial needs of post-treatment patients (Cella et al., 1993).  Too often, patients 
travel great distances to receive the CS+HIPEC procedure and then receive little, if any, 
follow-up when they return home, leaving the biopsychosocial team unaware of how they 
are faring.  Alternately, some individuals may present for follow-up medical visits with 
needs that are not explicitly addressed in the typical medical encounter.  By collecting 
QOL data and monitoring psychosocial variables, team members acquire detailed 
information about the multidimensional functioning of the patient.  This awareness, in 
turn, fosters cognizance of and energy towards patients‟ psychosocial needs on the part of 
all medical and mental health parties, potentially leading to improved clinician-patient 
relations (Sugarbaker et al., 1982) and the development of empirically-based 
interventions.   
Sleep quality is one factor impacting QOL that also remains understudied within 
this population.  Serving as an essential refuge for all individuals, sleep additionally 
offers those who are coping with cancer some reprieve from the pain and psychological 
burden that they all–too-often confront during their waking hours (Kvale & Shuster, 
2006).  Kvale and Shuster (2006) described the numerous mechanisms through which an 
adult cancer patient‟s behavioral and physiologic rhythms may be disrupted, ultimately 
impacting sleep quality.  Behavioral disruption of sleep may result as a consequence of 
changes in a patient‟s normal daily living routine (e.g., less daily activity and more day 
time spent in bed).  Poorly managed pain and physical symptoms may affect sleep onset 
and maintenance.  Additionally, psychosocial stressors (e.g., distress, anxiety and 
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depression), respiratory compromise (e.g., weakened lung capacity or tumors hindering 
respiration), and immune system alterations resulting from treatments or advancing 
disease also may impact the sleep cycle (Kvale & Shuster, 2006).  Any or all of the 
aforementioned factors may contribute to diminished sleep quality, ultimately decreasing 
overall QOL of CS+HIPEC patients.  
A thorough understanding of the sleep quality of these survivors has yet to be 
captured.  Considering the impact of sleep quality on everyday functioning, the increased 
prevalence of insomnia in persons with cancer and even higher incidences in those with 
advanced disease (Kvale & Shuster, 2006), and the potential impact of relatively simple 
psychosocial interventions on patients‟ sleep quality, sleep quality within the cancer 
arena deserves more investigation than it often receives via ancillary study questions 
(Berger et al., 2007).  Informed by empirical data relating to post-treatment QOL and 
sleep quality, mental health professionals will be able to develop psychosocial and 
symptom management interventions for patrons of this procedure, thereby giving equal 
weight to the quality and quantity of life concerns. 
Unfortunately, an insufficient number of adequately sized, methodologically 
sound QOL studies with individuals post-CS+HIPEC have been conducted despite the 
treatment‟s growing popularity and promise since its inception over 20 years ago 
(McQuellon & Duckworth, 2009). Numerous reasons exist as to why insufficient QOL 
studies with this population have been conducted and published.  First, only a handful of 
surgical teams routinely perform this procedure on large numbers of patients each year 
(Stewart et al., 2008).  Researchers first must gain access to these patients and then 
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realize that many likely have traveled long distances from their homes to seek treatment 
from these specialized surgeons.  Following hospital discharge, these patients then may 
scatter geographically and be more difficult to contact.  In addition to geographical 
dispersion, only a subset of these patients becomes long-term survivors; the majority will 
go on to die from their disease (Stewart et al., 2008).  A researcher studying longer-term 
survivors of CS+HIPEC (i.e., one year or more post-surgery) must then realize that a 
significant number of these patients have already died within this timeframe.  Something 
categorically different about those who survive 12 or more months following surgery 
therefore likely exists, and those who were never discharged from the hospital or who 
experienced significant post-treatment morbidity and then death will not be represented 
in the data.  A paucity of data still continues to exist on these longer-term survivors as 
well. 
Next, because of the invasiveness of the procedure, hospital stays often are 
lengthy, and patients typically experience significant morbidity, even mortality (Stewart 
et al., 2008).  This high degree of post-treatment morbidity impairs patients‟ functioning 
and ability to complete study instruments. Completing study instruments may be 
physically burdensome due to a lack of strength or psychologically burdensome if the 
respective individual has experienced significant obstacles.  The end result of missing or 
incomplete data, however, is the same.  Unfamiliarity with study instruments also may 
make the instruments appear convoluted or daunting to the patients (Cella & Tulsky, 
1993).  Explaining instruments and analyzing them for missing data in a timely fashion 
requires a great deal of time and energy on the part of the researcher.  These variables 
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often combine to make patient recruitment and retention difficult, ultimately leading to 
small sample sizes.  The small cohorts found in many of the aforementioned studies of 
QOL in patients following CS+HIPEC unfortunately render the finding of statistical and 
clinical conclusions difficult and make sound generalizations from the data impossible.  
A combination of numerous obstacles (including geographical dispersion, 
significant patient morbidity and mortality, patient burden considerations and incomplete 
or missing data) complicate the data collection process with patrons of this procedure, yet 
these obstacles must be strategically overcome.  Simply because the invasive treatment 
has concluded for these individuals, their cancer experiences have not.  Patients who 
follow behind them in the future deserve to have this information at their dispense, while 
health professionals currently working with those who already have made the journey 
need to be sufficiently knowledgeable to offer these patients quality medical and mental 
health care.  
 In summary, CS+HIPEC is a promising treatment for individuals with peritoneal 
carcinomatosis, offering the possibility of extended life in the face of an aggressive 
disease.  As the procedure gains acceptance and recognition, more individuals likely will 
become candidates.  Concurrently, behavioral science researchers must do their part to 
study the QOL and other neglected psychosocial variables, including sleep quality, of 
these individuals post-treatment to inform patient decision making and informed consent, 
standardized patient selection criteria and ultimately psychosocial interventions post-
treatment.  
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Definition of Terms 
Cytoreductive surgery (CS):  An extensive operative procedure performed by 
surgical oncologists. The ultimate goal is to remove (to the extent that it is both safe for 
the patient and technically feasible) all gross tumor and involved organs, peritoneum, or 
tissue (Levine et al., 2007, p. 944). 
 
Cytoreductive surgery + hyperthermic intraperitoneal chemotherapy 
(CS+HIPEC): The performance of extensive cytoreductive surgery (with the goal of 
resecting all gross disease) followed by heated chemoperfusion to address remaining 
microscopic residual tumors (Levine et al., 2007, p. 944). 
 
Hyperthermic intraperitoneal chemotherapy: “After CS [is] completed, peritoneal 
perfusion inflow and outflow catheters [are] placed percutaneously into the abdominal 
cavity.  Temperature probes [are] placed on the inflow and outflow catheters just outside 
the exit sites from the abdomen.  The abdominal skin incision [is] closed temporarily 
with a running cutaneous suture to prevent leakage of peritoneal perfusate. A perfusion 
circuit [is] established… Flow rates of approximately 600/1,000 mL/min [are] maintained 
using a roller pump managed by the perfusionist. The circuit continue[s] through a single 
roller pump, through a heat exchanger, and then to the patient.  Constant temperature 
monitoring [is] performed at all temperature probes. Once a stable perfusion circuit [is] 
established and outflow temperature exceed[s] 38.5 [degrees] C, the chemotherapy [is] 
introduced into the perfusion circuit.  A maximum inflow temperature of 42.5 [degrees] 
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C [is] tolerated during perfusion, with a target outflow temperature at the pelvis of 40 
[degrees] C.  The abdomen [is] gently massaged throughout perfusion to improve drug 
distribution to all peritoneal surfaces.  Total planned perfusion time after the initial 
addition of [the chemotherapeutic agent] is 120 minutes” (Levine et al., 2007, p. 945). 
 
Morbidity: The adverse effects caused by a treatment (National Cancer Institute, 
n.d.). 
 
Mortality: Death or death rate  
 
Nychthemeron: a 24-hour period 
 
Ostomy: “The surgically formed artificial opening that serves as the exit site for 
connections that the surgeon has made from the bowel or intestine to the outside of the 
body” (Thomas, 1997, p. 1370-1371) 
 
Palliative medicine: A branch of medicine that focuses on relieving or alleviating 
pain and symptoms without curing underlying problems (Thomas, 1997) 
 
Performance status: The Eastern Cooperative Oncology Group standardized 
criteria used to grade the toxicity, response, or general functional status of oncology 
patients. The ECOG performance scores include zero (fully active, able to perform all 
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pre-disease activities within impairments), one (some restrictions in physically 
demanding activities but able to ambulate and perform less strenuous work), two 
(ambulatory and can take care of self but unable to work; moving around greater than 
50% of waking time), three (only limited self grooming is possible; in bed or in a chair 
greater than 50% of waking time), four (confined to bed or chair; fully disabled; cannot 
perform self care), five (dead) (Oken et al., 1982). 
 
Perfusion: the bathing of an organ or tissue with a fluid; In regional perfusion, a 
specific area of the body containing localized cancer receives high doses of 
chemotherapeutics through a blood vessel (National Cancer Institute, n.d.). 
 
Peritoneal: Of or relating to the parietal peritoneum (the tissue that lines both the 
abdominal wall and pelvic cavity) and the visceral peritoneum (the tissue that covers 
most of the organs in the abdomen (National Cancer Institute, n.d.). 
 
Peritoneal carcinomatosis: The spread of intra-abdominal malignancies 
throughout the peritoneal cavity, resulting in an unvaryingly terminal condition with a 
median life expectancy of six months (Stewart et al., 2008). 
 
Peritoneal cavity:  The space within the abdomen, bound by thin membranes, that 
contains the intestines, the stomach, and the liver. (National Cancer Institute, n.d.). 
 
22 
 
Psycho-oncology: A sub-field of oncology and mental health from which 
specialists examine the psychological, social, and behavioral dimensions of cancer from 
two vantage points: 1) the psychosocial- the psychological responses of both patients and 
their family members at all stages of disease, from diagnosis to survivorship; 2) the 
psychobiological- psychological, social, and behavioral issues that influence morbidity 
and mortality (Holland, 1998, p. 3). 
 
Quality of life (QOL): QOL refers to “patients‟ appraisal of and satisfaction with 
their current level of functioning compared to what they perceive to be possible or ideal” 
(Cella & Cherin, 1988, p. 70) 
  
Resection status: determined post-CS by means of the following classification 
scheme: “R0, complete removal of all visible tumor and negative cytologic findings or 
microscopic margins; R1, complete removal of all visible tumor and positive 
postperfusion cytologic findings or microscopic margins; R2a, minimal residual tumor, 
nodule(s) measuring < [or equal to] 0.5 cm; R2b, gross residual tumor, nodule > 0.5 cm 
but < [or equal to] 2 cm; and R2c, extensive disease remaining, > 2cm” (Levine et al., 
2007, p. 944) 
 
Sleep quality: “Quantitative aspects of sleep, such as sleep duration, sleep latency, 
or number of arousals, as well as more purely subjective aspects, such as „depth‟ or 
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„restfulness‟ of sleep… [T]he exact elements that compose sleep quality, and their 
relative importance, may vary between individuals” (Buysse et al., 1989, p. 194). 
 
Systemic therapy: chemotherapies that travel through the bloodstream and impact 
cells all over the body (National Cancer Institute, n.d.) 
Brief Overview 
This study is presented in five chapters. The first chapter has provided an 
introduction to cytoreductive surgery + hyperthermic intraperitoneal chemotherapy 
(CS+HIPEC), the constructs of quality of life (QOL) and sleep quality, and the 
importance of measuring these constructs in patients after treatment.  Also provided is the 
purpose of the study, the statement of the problem, the research questions, the need for 
the study, and definitions of key terms.  The second chapter contains a review of the 
literature related to CS+HIPEC, the QOL of patients post-CS+HIPEC, the sleep quality 
of adult cancer patients and survivors, as well as QOL and sleep quality assessment.  The 
third chapter contains the methodology to be used in this study, including participants, 
sampling method, instruments and data analyses.  The fourth chapter presents the results 
of this research according to each research question.  Finally, the fifth chapter 
summarizes the study and includes limitations and recommendations for future research 
in the area of assessment of quality of life and sleep quality in patients who have received 
CS+HIPEC.
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CHAPTER II
LITERATURE REVIEW 
 
 In 1884, in a desolate area now referred to as the upper West side of Central Park, 
construction began on the first cancer treatment center in the United States - The New 
York Cancer Hospital (Rowland, 1998).  The pervasive belief of the time was that cancer 
was contagious, so this remote location was strategically chosen for purposes of isolation 
and the building was intentionally constructed to discourage the spread of hypothesized 
cancer-related germs between patients.  The NY Cancer Hospital continued to house 
individuals with minimally understood and largely incurable diseases until 1948, when it 
was moved to an alternate location on the East side of NYC and renamed Memorial 
Hospital for Cancer and Allied Diseases (Rowland, 1998).  Although the advent of 
antibiotics, anesthesia, and effective therapies was on the horizon (Rowland, 1998), 
doctors at this and a burgeoning number of other facilities commonly refrained from 
telling patients their respective diagnoses, as their prognoses and life expectancies 
remained grim.  In 1960, this initial treatment facility with a growing number of patrons 
was once again renamed, acquiring the familiar title of Memorial Sloan-Kettering Cancer 
Center.  Alongside subsequent medical discoveries and augmented technologies, this 
facility also steadily acquired the reputation of a renowned, state-of-the art 
comprehensive cancer research and treatment facility (Rowland, 1998).  This impetus for 
growth and advancement within the field of cancer care was spurred by not only the high
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prevalence of cancer within society but also the variety of diagnoses subsumed under the 
auspices of the cancer family that doctors routinely confronted.   
Prevalence and Incidence Data 
Cancer is defined as a sizeable number (approximately one hundred) of 
multifarious diseases that vary in nature (i.e. growth rate, invasiveness, prognosis, 
responsiveness to treatment and average age of onset) as a consequence of the cell type of 
primary origination (Klug, Cummings, Spencer, & Palladino, 2009).  Despite these 
behavioral variations of members of the cancer family, these diseases all share some 
fundamental molecular properties that serve to place them under the auspices of the 
cancer family.  Cell proliferation (or atypical cell growth and division) and metastasis (a 
process in which cancer cells spread to and subsequently invade other parts of the body) 
are the two underlying properties shared by all cancers (Klug et al., 2009).  In healthy 
cells, genes regulate the rate and place of cell growth and division stringently.  When 
genes become mutated or are expressed inaccurately, however, these processes can go 
awry, leading to unregulated cell proliferation and spread (Klug et al., 2009).  
Cancer is precipitated by internal factors (including hormones, inherited 
conditions, metabolic-induced mutations, and immune conditions) and external 
carcinogens (including chemicals, radiation, tobacco, and infectious organisms, among 
many others) (American Cancer Society, 2009).  A combination or sequence of any of the 
aforementioned may be sufficient to cause or maintain cancer.  In the sense that genes 
control cell growth and division, all cancer is genetic.  Only a small percentage 
(approximately 5%) of cancers is truly hereditary, however, being passed down through 
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generations (American Cancer Society, 2009).  Most cancers develop following genetic 
damage incurred throughout one‟s lifetime.  Typically, many errors in the DNA (the 
cell‟s genetic material) must occur prior to carcinogenesis, meaning cancer development 
is often a multistage process (American Cancer Society, 2009).  If DNA damage is 
incurred prior to cell division, healthy cells will work to repair damage to the DNA 
sequence.  Many individuals have accrued mutations, however, in sections of genes that 
regulate apoptosis (cell death), cell growth and cell repair.  In these individuals, if the 
genetic material of the cell is not repaired prior to cell division, heritable mutations are 
passed on to daughter cells and more damaged cells may proliferate (American Cancer 
Society, 2009). 
The risk of developing cancer increases with age, translating into the majority of 
cases occurring in middle-aged or older individuals (American Cancer Society, 2009).  
Approximately 77% of all cancers are diagnosed in individuals who are 55 years of age 
or older.  The American Cancer Society defines one‟s lifetime cancer risk as the 
“probability that an individual, over the course of a lifetime, will develop or die from 
cancer” (American Cancer Society, 2009, p. 1).  American men have almost a one in two 
lifetime risk of developing cancer, while the lifetime risk of American women is slightly 
higher than one in three.  Relative risks, or the “measure of the strength of the 
relationship between risk factors and a particular cancer” (p. 1) also can be estimated.  
For example, a male who smokes is approximately 23 times more likely to develop lung 
cancer than a male who does not smoke tobacco (i.e. relative risk is 23).  Inherited 
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conditions, lifestyle choices, and exposures all impact relative risks (American Cancer 
Society, 2009). 
In January 2005, the National Cancer Institute estimated that approximately 11.1 
million Americans who have received a diagnosis of cancer at some point in their lives 
were still living (American Cancer Society, 2009).  The American Cancer Society 
estimates the diagnosis of 1,479,350 new cancer cases in 2009, excluding non-invasive 
carcinoma (except those involving the bladder), basal cell, or squamous cell skin cancers 
(American Cancer Society, 2009).  The most frequent cancer diagnoses include lung and 
bronchus cancer (219,440 new cases in 2009, both sexes), breast cancer (194,280 new 
cases in 2009, both sexes), prostate cancer (192,280 new cases, males), and colon cancer 
(106,100 new cases in 2009, both sexes).  Approximately 562,340 Americans are likely 
to die from their respective cancer diagnosis in 2009, equating to approximately 1,500 
cancer-related deaths each day (American Cancer Society, 2009).  These rates make 
cancer the second leading cause of death in Americans, second only to heart disease, 
accounting for approximately one out of every four U.S. deaths.  The total cost of cancer 
in America in 2008, as estimated by the National Institutes of Health, was $228.1 billion 
(i.e., $93.2 billion in direct medical costs; $18.8 billion in indirect costs, including loss of 
work productivity; and $116.1 billion in indirect mortality-related costs, including loss of 
work productivity as a consequence of premature death) (American Cancer Society, 
2009). 
Cancer survival rates are extremely variable, given the type of cancer and 
diagnostic stage (American Cancer Society, 2009).  Even with relative survival estimates 
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for specific cancer types, great individual variation is noted.  Collectively, survival rates 
have improved greatly over time due to screenings and earlier diagnosing as well as 
enhanced treatments and technologies.  Illustrating these trends in improved survival are 
the five-year survival rates across time for all diagnoses, increasing from 50% in 1975-77 
to 66% in 1996-2004 (American Cancer Society, 2009). 
Prevalence and Incidence of Peritoneal Carcinomatosis 
 Without the application of or access to augmented technologies and treatments, 
however, survival estimates often remain grim for individuals with certain diagnoses.  
For example, in a multicenter study of 370 individuals with peritoneal carcinomatosis, the 
mean and median survival times were 6.0 months and 3.1 months, respectively (Sadeghi 
et al., 2000).  For individuals who do not seek treatment for peritoneal carcinomatosis, 
death comes quickly and often is preceded by many complications.  Peritoneal 
carcinomatosis is common in individuals with certain primary diagnoses, including colon, 
rectum, ovary, stomach, and appendix cancer.  The American Cancer Society anticipated 
106,000 new colon cancer diagnoses, 21,130 stomach cancer diagnoses, 40,870 rectal 
cancer diagnoses, and 21,550 ovarian cancer diagnoses in 2009 (American Cancer 
Society, 2009).  Of these, approximately 10-15% of the individuals who develop 
colorectal cancer in 2009 (Dawson, Russell, Tong, & Wisbeck, 1983; De Bree et al., 
2004; Shen, Stewart, & Levine, 2009), 50% of those diagnosed with gastric cancer 
(Sugarbaker & Yonemura, 2000; Shen et al., 2009), and approximately 75% of those with 
ovarian cancer (Deraco, Respagliesi, & Kusamura, 2003; Shen et al., 2009) can anticipate 
having peritoneal dissemination. 
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Appropriate treatments targeting the primary diagnosis may prevent these 
peritoneal metastases in the first place.  Shen et al., (2009) noted the potential for 
increased survival with the CS+HIPEC procedure for those who already have contained 
peritoneal metastases.  Individuals with better performance statuses (i.e., The Eastern 
Cooperative Oncology Group standardized scores, ranging from zero (fully active and 
performing all pre-disease activities) to five (dead), that are assigned by the medical 
practitioner as an indicator of the general functional status of an oncology patient) (Oken 
et al., 1982) currently achieve a median survival of 21.7 months post-CS+HIPEC, while 
those with poorer performance statuses achieve a median survival of 9.5 months.  
Compared to the respective mean and median survival times for those with peritoneal 
metastases who do not pursue treatment (6.0 months and 3.1 months, respectively; 
Sadeghi et al., 2000), these estimates denote substantial extensions of life.  
The review of the treatment- and disease-related challenges confronted by 
individuals who receive CS+HIPEC that follows provides the reader with an 
understanding of what patients actually endure in hopes of achieving these extensions of 
life.  Specifically, a detailed overview of the anatomy and physiology of peritoneal 
metastases and the recommended surgical techniques and chemotherapeutic agents 
utilized for their treatment illustrates the physical demands encountered by these 
individuals. 
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Cytoreductive Surgery + Hyperthermic Intraperitoneal Chemotherapy 
(CS+HIPEC) 
 Sticca (2003) referred to the aggressive treatment of intra-abdominal 
malignancies as one of the remaining frontiers in oncology, presumably because of the 
high morbidity and mortality rates (Stewart, Shen, & Levine, 2008), the unproven and 
unaccepted benefits for some individuals with peritoneal carcinomatosis (Sticca, 2003), 
the small number of surgical oncology teams who routinely perform this procedure 
(Levine, 2004), and the inevitable death awaiting those who do not receive such 
treatment (Stewart et al., 2008).  Certain surgical oncologists, however, are becoming 
more skilled and comfortable in performing this procedure.  They are familiarizing 
themselves with the terrain, becoming more adept at selecting appropriate surgical 
candidates and ultimately offering some candidates the possibility of extended life 
(Stewart et al., 2008). 
Peritoneal Metastases 
 Intimately involved in numerous bodily functions, including intestinal motility, 
breathing, and lymphatic and other bodily fluid circulatory exchange (Spratt, Edwards, 
Kubota, Lindberg, & Tseng, 1986), the peritoneum is the “serous membrane reflected 
over the viscera and lining the abdominal cavity” (Thomas, 1997, p. 1449).  The 
mesothelium (or lining) of the peritoneum has many papilla, or projections, that serve to 
increase the total surface area of the peritoneum and enhance the rate of fluid diffusion 
(Spratt et al., 1986).  The peritoneal cavity can be divided into the greater and lesser 
cavities, with the greater peritoneal cavity housing the majority of the abdominal viscera.  
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Within the greater peritoneal cavity, the visceral peritoneum protects and sustains the 
location of the viscera in its mesentery, or folds (Thomas, 1997).  The parietal 
peritoneum lines both the pelvic and abdominal walls as well as the undersurface of the 
diaphragm (Thomas, 1997). Cells within the peritoneum secrete serous fluid that serves 
to moisten the surfaces of the abdominal organs, permitting them to slide along one 
another as the shape of the intestinal tract alters throughout the course of digestion and 
absorption (Thomas, 1997).  The lesser peritoneal cavity has a frontal boundary that is 
bound to the back side of the stomach wall; the underside and left lateral margins are 
marked by the anterior side of the transverse mesocolon; the dorsal surface of the lesser 
peritoneal cavity is peritoneum that rests above the pancreas; while the right side 
boundary is the gastrohepatic ligament‟s medial border (Spratt et al., 1986).  
Unfortunately, the peritoneal cavity, its mesothelial lining, and the viscera it surrounds 
are all susceptible to both primary and metastatic cancers (Spratt et al., 1986).  
 Numerous intra-abdominal malignancies may extend through the peritoneum 
(Stewart, Shen, & Levine, 2008), precipitating mucin-producing cells to spread 
throughout the peritoneal cavity, also known as peritoneal carcinomatosis (Sugarbaker, 
1989).  Specifically, this peritoneal carcinomatosis seems to occur in one of three distinct 
patterns: through direct extension from the primary origin, by means of the spread of 
tumor cells through the peritoneal fluid, and via trauma or surgical procedures (Stewart, 
Shen, & Levine, 2005).  Secondary peritoneal involvement may have a variety of 
presentations (Spratt et al., 1986), which is determined by the extent of parietal or 
visceral peritoneum involvement, the characteristics of the primary tumor (e.g. colon, 
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appendix, ovary, etc), the extent to which alternate surrounding structures have been 
impacted, and whether lymphatic invasion has occurred (Spratt et al., 1986).  Clinically, 
patients may present with pain, intestinal obstruction, or ascites (i.e., buildup of 
peritoneal fluid and obstruction of fluid outflow, ultimately leading to abdominal 
distension (Spratt et al., 1986; Thomas, 1997)), among others (Spratt et al., 1986).  
 Peritoneal carcinomatosis is most frequently found around the stomach and colon 
(Sugarbaker, 1989).  Specifically, the omentum (a double fold of peritoneum that is 
attached to the stomach and other abdominal viscera and contains a cavity referred to as 
the omental bursa (Thomas, 1997)) often is heavily involved, creating an omental cake of 
tumor that is typically attached to the stomach and colon (Sugarbaker, 1989).  Following 
stomach and colon involvement, the pelvic peritoneum is most frequently affected.  The 
undersurfaces of the hemidiaphragm, the right suprahepatic space between the liver and 
diaphragm, the undersurface of the liver, and many other areas within the peritoneal 
cavity are commonly encased in tumor, resulting in single masses of organs (Sugarbaker, 
1989).  Interestingly, with the exception of two anatomic sites that are relatively 
immobile, most small bowel surfaces remain free of tumor metastasis, presumably due to 
the peristalsis movements (Sugarbaker, 1989). 
 Individuals with peritoneal metastases from differing primary origins can 
anticipate different disease experiences and outcomes based on, among other things, the 
histopathology of the primary disease itself, the potential for distant metastases, and the 
presence or absence of genetic mutations within the host (Sticca, 2003).  Sticca (2003) 
noted the accumulation of evidence for the success of CS+HIPEC in the presence of low-
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grade peritoneal malignancies, in which the odds of dissemination of disease to the 
outside of the peritoneal cavity are low.  Such an example of a low-grade malignancy is 
pseudomyxoma peritonei (PMP).  In fact, CS+HIPEC is now considered the “standard of 
care in these low-grade malignancies, converting a once uniformly fatal condition to a 
readily curable disease (greater than 75% long-term survival in some series)” (Sticca, 
2003, p. 484).  By contrast, colonic adenocarcinoma is considered a moderate to high-
grade tumor, making long-term disease-free survival less probable (Sugarbaker, 1989).  
Colonic adenocarcinoma is more invasive, making its surgical removal more difficult.  
Although it rarely spreads through blood or lymph channels, colonic adenocarcinoma will 
invade the intra-abdominal structures and implant itself on a plethora of surfaces within 
the peritoneal cavity (Sugarbaker, 1989).  Likewise, its residual tumor is more solid and 
has more advanced vasculature, making it more adept at removing chemotherapeutic 
agents via capillary networks and lymphatic channels (Sugarbaker, 1989) and equating to 
less tumor penetration by the respective chemotherapeutic agent.  These characteristic 
differences in tumor grade should be taken into treatment consideration.  
Rationale for CS+HIPEC 
 Without treatment, peritoneal carcinomatosis is a homogeneously fatal disease, 
bearing a median survival of six months (Stewart et al., 2008).  Without intervention, 
hosts will experience bowel obstruction, poor intestinal function, and/or ascites, quickly 
followed by subsequent death (Spratt et al., 1986; Stewart et al., 2005; Stewart et al., 
2008).  Until recently, this aforementioned fate was inevitable (Sticca, 2003).  The use of 
systemic chemotherapy agents for peritoneal carcinomatosis is palliative in nature, 
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yielding little, if any, extension in survival (Stewart et al., 2008).  Chemotherapeutics 
administered systemically demonstrate poor penetration of tumors within the peritoneal 
cavity (Stewart et al., 2005; Sticca, 2003), largely because of the peritoneal-plasma 
partition.  Likewise, any drug given orally or intravenously arrives at the tumor through 
the circulatory system, all-the-while being diluted by the vascular pool and ultimately 
reaching these drug-resistant tumors at a diluted dose (Spratt et al., 1986).  The presence 
of other healthy corporeal tissues and organs limits higher drug dose possibilities and 
therefore potential effectiveness on drug-resistant tumors (Spratt et al., 1986).  That is, 
the patient experiences the toxicity of systemic chemotherapy administration with little 
benefit in return. Similarly, cytoreductive surgery alone may effectively remove 
macroscopic disease from the peritoneal cavity and reduce symptom burden, yet these 
benefits are only temporary.  Residual microscopic disease inevitably remains and will 
continue to grow (Stewart et al., 2008). These options, then, do not offer the individual 
significant survival benefits and actually carry many potentially severe side effects.   
If peritoneal metastases are localized, and distant metastases are non-existent, the 
disease is considered locoregional, warranting consideration of corresponding aggressive 
locoregional approaches, such as CS+HIPEC (Sticca, 2003; Stewart et al., 2008).  
Cytoreductive surgery is used to resect involved viscera (e.g. hysterectomy, splenectomy, 
oophorectomy, large/small bowel resection) and gross tumor within the peritoneal cavity 
(Stewart et al., 2008).  Stewart, et al. (2008) noted the constant correlation between the 
completeness of the CS and survival, indicating survival is positively correlated with the 
amount of macroscopic disease that the surgeon is able to remove.  This resection is 
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essential, as the chemotherapeutic drugs are only able to penetrate disease a few 
millimeters (Stewart et al., 2004).  If only small amounts of microscopic disease remain, 
the localized chemotherapy perfusion should reach the remaining residual disease and 
overcome these drug-resistant cancers (Spratt et al., 1986; Stewart et al. 2008).  
Verwaal et al. (2003) randomized 105 individuals with peritoneal carcinomatosis 
of a colorectal origin to standard treatment (i.e., systemic chemotherapy) or experimental 
treatment (i.e., CS+HIPEC).  Verwaal reported a median survival of 12.6 months for the 
standard treatment individuals and 22.3 months for the experimental treatment 
individuals (p = 0.032), suggesting a significant difference in survival time between 
treatments.  The mortality rate of the experimental group, however, was eight percent.  
Experimental individuals who had a complete cytoreduction of no more than five of the 
seven abdominal regions involved by tumor at the time of surgery fared better in terms of 
survival.  Verwaal concluded that CS+HIPEC significantly improves survival estimates 
for patients with peritoneal carcinomatosis of colorectal origin, yet only if complete 
cytoreduction is attainable or no more than five out of the seven abdominal regions are 
involved by tumor.  
Utilizing this procedure, then, specialized and experienced surgical oncologists 
who wisely select their surgical candidates have been able to give individuals with 
peritoneal metastases long-term survival (Stewart et al., 2008).  Despite this success, 
Levine (2004) noted that the “operative procedures attendant to aggressive cytoreduction 
are lengthy and challenging, associated with morbidity, and utilize a great deal of 
hospital, blood bank, and house officer resources” (p. 351).  For these reasons, there are 
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less than 25 active centers with individuals who perform this procedure within the United 
States, and an even smaller number with experience in treating over 100 cases (Levine, 
2004).   
Cytoreductive Surgery 
 Given that a positive correlation exists between completeness of cytoreduction 
and survival (Stewart et al., 2008), the goal of CS should be the complete removal of all 
macroscopic disease and the opening of all abdominal adhesions (Sugarbaker, 1989) 
rather than partial debulking.  Good surgical candidates, then, are those who are 
medically and emotionally fit to undergo the extensive CS (i.e., good performance status) 
and who have disease that is localized and considered completely or significantly 
resectable (Stewart et al., 2008).  Pre-operative imaging permits surgeons to judge an 
individual‟s candidacy for surgery, plan operative techniques, and spare individuals with 
extra-peritoneal disease from unnecessary surgery (Stewart et al., 2004).  These operative 
images do have their limitations, however, especially relative to disease within the 
peritoneal and pelvic cavities (Stewart et al., 2004).  More disease than anticipated may 
be present once an individual‟s cavity is opened for exploration, often to the extent that 
the planned chemotherapeutic perfusion post-surgery is aborted.   
 In the operation room, a large midline incision is performed for the surgical 
exploration (Stewart et al., 2004).  The surgeon enters the peritoneal cavity with the 
intent to remove all gross tumor from the visceral and peritoneal surfaces, usually with 
ball-tipped electrocautery on pure cut and high voltage (Sugarbaker, 1989).  Strong 
traction exists between healthy and tumor tissue, and, using such an instrument, the 
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surgeon is able to remove strictly the tumor and affected surfaces of the peritoneum, 
ultimately leaving the underlying viscera, healthy tissue and fat in adequate shape 
(Sugarbaker, 1989).  Great care and skill must be utilized around structures with high 
amounts of collagen (e.g. ureters, large blood vessels), as severe damage may be 
incurred.  Irrigation with cool water is often utilized during the procedure to protect these 
structures (Sugarbaker, 1989).  Additionally, great care must be taken around the 
diaphragmatic muscle, as perforations or certain types of contact may precipitate 
diaphragmatic contractions (Sugarbaker, 1989).  Expert levels of knowledge and 
experience as well as great familiarity with surgical tools, then, are requisites.  
Sugarbaker (1989) listed the advantages of using ball-tipped electrocautery for such a 
procedure, including its speed and precision of dissection, its ability to clearly hit a line 
of dissection between tumor and healthy tissue, and the hefty amounts of tumor it permits 
the surgeon to remove in one procedure without the great amount of blood loss one might 
anticipate from dissection.  A laser smoke evacuator also is commonly used to remove 
particles, smoke and odor from the surgical space (Sugarbaker, 1989).  
 If significant tumor burden is present, removal of involved viscera (e.g. spleen, 
ovaries, uterus, etc.) and the stripping of the peritoneum from the abdominal wall are 
necessary (Stewart, et al., 2008).  If essential organs are affected by tumor burden, 
electrocautery will then be utilized so that they may be left within the host.  Next, 
anastomoses (i.e. the surgical connection of two tubular structures (Thomas, 1997)) will 
be completed prior to or following the HIPEC as needed. If an ostomy (i.e., surgically 
formed, artificial exit sites leading from the intestine or bowel to the outside of the body) 
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(Thomas, 1997) is needed, the surgeon will perform the procedure following the 
perfusion of chemotherapy (Stewart et al., 2008).  A cytoreduction classification scheme 
based on the amount of gross disease and microscopic margins remaining is the utilized 
so that a uniform grading system of the surgical component of the procedure is in place 
(Stewart et al., 2008).  
 Following the removal of as much macroscopic disease as possible, catheters are 
placed through the abdominal wall, to the side of the rectus muscles, and sutured at the 
peritoneal level (Sugarbaker, 1989).  The abdominal cavity is then flushed with a solution 
that contains antibiotics.  The solution also serves to remove remnant tissue and blood 
and prevent infection and the formation of adhesions (Sugarbaker, 1989).  Prior to 
closing the abdominal cavity, remaining debris that could potentially clog the catheters 
(e.g. tissue) must be removed, and a cessation of bleeding should be achieved.  Drains are 
placed in the lower flank for subsequent fluid removal (Sugarbaker, 1989).  
Intraperitoneal Chemotherapy 
 No matter how complete the CS, surgery alone will not remove all microscopic 
and residual peritoneal disease.  Without the utilization of chemotherapeutics to attack 
the residual disease, recurrent peritoneal carcinomatosis is inevitable, and long-term 
survival is unrealistic (Sugarbaker, 1989).  Attempting to overcome drug-resistant tumors 
that would require dangerous or impractical cytotoxic agent dosages or administration 
schedules if administered orally or intravenously, doctors of the 1970‟s began 
investigating with the peritoneal perfusion of cytotoxic agents to target localized disease 
(Spratt et al., 1986).  
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With the largest surface area of any serous membrane in the human body, the 
peritoneum has an extensive absorptive area consisting of a vast capillary and lymphatic 
network (Spratt et al., 1986).  Optimal drugs for HIPEC, then, are those that are not 
quickly absorbed from the cavity, such that high concentrations of the drug remain in the 
vicinity of the tumor (Spratt et al., 1986).  Levine et al. (2008) noted that these are 
typically drugs with high molecular weights that do not generally dissolve in lipids.  By 
utilizing indwelling catheters, doctors have been able to achieve high concentrations of 
such drugs in the cavity yet low levels of these agents systemically (Spratt et al., 1986).  
These drugs ideally should be administered in large volumes of fluid so that the abdomen 
is distended and the drugs reach all cavity areas (Sugarbaker, 1989).  Spratt et al. (1986) 
listed numerous desirable characteristics of drugs and the peritoneal drug delivery 
environment, including tumors with small diameters that are confined to the surface of 
the peritoneum, an abdomen cleared of obstructions or adhesions so that drug circulation 
within the cavity is unobstructed, utilization of a drug that is slow to be absorbed by the 
peritoneum yet readily clears the peritoneal plasma membrane, and drugs that are quickly 
cleared and excreted from systemic circulation.  Either an open (i.e., covering the 
abdomen with a plastic sheet while administering chemotherapy) or closed (i.e., 
surgically closing the abdominal cavity while administering chemotherapy) technique can 
be utilized for the administration of the chemotherapy (Stewart et al., 2005).  Proponents 
exist for both techniques.  
In addition to better understanding the optimal means of drug administration for 
these tumors, researchers also learned the importance of timing relative to this procedure.  
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Considering these drugs attack tumor by means of diffusion, tumor cells on the surface of 
the peritoneum or free floating inside the cavity are exposed to the most potent levels of 
drugs (Spratt et al., 1986).  With subsequent layers of tumor, however, the drug becomes 
less potent and therefore less effective.  Only capable of penetrating microscopic disease 
a few millimeters, chemotherapeutic perfusion should occur when gross tumor has been 
removed and adhesions have been opened (Stewart et al., 2008).  Such a corporeal 
environment exists during CS, with all peritoneal surfaces exposed (Levine et al., 2007).  
Sugarbaker (1989) stated intraperitoneal drugs should be administered within the first 
five post-operative days, prior to the formation of post-operative adhesions that may 
prevent optimal drug diffusion.   
In addition to issues related to mode and timing of administration, a rationale for 
hyperthermia in the context of the drugs was suggested.  Specifically, hyperthermia has a 
synergistic effect on chemotherapeutic agents, making them more potent than if utilized 
in a non-heated form (Stewart et al., 2008).  Mitomycin-C (MMC) is the most commonly 
used drug for intraperitoneal chemotherapy at this time, although other agents are utilized 
and being explored (Stewart et al., 2008).  Spratt et al. (1986) noted that fluids that are 
42-50 degrees Celsius are tolerated relatively well, incurring minimal damage to healthy 
tissues.  After 30 hours of exposure to fluids that are 42 degrees Celsius, three to four 
hours of exposure to fluids that are 45 degrees Celsius, or after minutes of exposure to 
fluids that are warmed to 50 degrees Celsius, neoplasms will experience a thermal death 
(Spratt et al., 1986).  The utilization of heated drugs, then, may maximize results.  
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CS+HIPEC at Wake Forest University Baptist Medical Center. A review of 
the intricacies of this procedure performed by the surgeons at WFUMBC demonstrates 
how all of the previously reviewed steps are combined and provide clarity about the 
medical procedures received by study participants (all of whom received CS+HIPEC at 
WFUMBC), as specifics of the procedure may differ between institutions.  The surgical 
oncologists at WFUBMC utilize a closed (as opposed to open) technique, reasoning the 
closure of the abdominal cavity during perfusion will result in more effective 
chemotherapy penetration and will concurrently result in less exposure of the team to the 
toxic agents while in the operating suite (Stewart et al., 2005).  Patients are passively 
cooled to 34-35 degrees Celsius throughout cytoreduction, during which the peritoneum 
is stripped of the abdominal wall and any non-vital viscera with tumor burden are 
removed.  Following complete cytoreduction, perfusion catheters with temperature 
probes are placed through the skin.  Under the left and right hemidiaphragms are two 
inflow catheters, while outflow catheters with drainage bulbs are positioned in the pelvis 
(Stewart et al., 2005).  The main abdominal incision is then temporarily sutured so as to 
prevent leakage of the perfusate.  A perfusionist establishes a perfusion circuit with 
approximately three Liters of solution flowing at an approximate rate of 800 to 1000 mL 
per minute (Stewart et al., 2005).  To further enhance drug distribution, the abdomen is 
gently massaged throughout the perfusion.  A roller pump and heat exchanger are used to 
continuously move the fluid and maintain the desired temperature.  The inflow 
temperature is not permitted to exceed 42.5 degrees Celsius, while an outflow 
temperature of 40 degrees Celsius is sought (Stewart et al., 2005).  When outflow 
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temperatures climb above 39 degrees Celsius, 30 mg of MMC is added to the solution.  
After approximately one hour, another ten mg of MMC is added so as to maintain dosage 
concentrations (Stewart et al., 2005).  The total perfusion time with MMC is 
approximately two hours.  Following completion of the perfusion, the cavity is rinsed 
with approximately two to three Liters of Ringer‟s solution and passively drained 
(Stewart et al., 2005).  The incision is once again opened and catheters are removed. 
Anastomoses are created as needed, and a final inspection of the abdomen occurs.  The 
patient is then surgically closed, and any necessary procedures (e.g. ostomies) are 
completed.  Finally, patients are transplanted to the post-anesthesia care unit and 
subsequently the intensive care unit (Stewart et al., 2005).  
In a review of their experience with 501 procedures, Levine et al. (2007) offered 
their surgical statistics with patients from WFUBMC.  Of these 501 procedures, 460 
procedures were on patients receiving their first CS+HIPEC; 37 were receiving their 
second CS+HIPEC; and four were receiving their third treatment.  Influenced largely by 
the location and extent of the disease, the mean operating time was 560 minutes (+/- 175 
minutes; range 250-1080 minutes).  The median days in the intensive care unit and 
hospital were two and nine days, respectively, while the mean hospital stay was 15.3 days 
(+/-17.9 days).  The surgeons listed 13 primary sites of origin, in addition to one “other” 
category. Of the primary sites, appendix (35.4%), colon/rectum (28.9%), ovary (10%), 
and stomach (9.1%) were the most common. In addition to the peritoneal resections, 
Levine et al. (2007) also listed 16 potential organs of resection and the percentage of 
individuals who lost the respective organ.  Most commonly resected organs in these 501 
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procedures included omentum (59.1%), colon (42.9%), small bowel (35.1%), spleen 
(33.1%), and gallbladder (17.8%). A total of 20.1% of patients received ostomies.  The 
30-day morbidity and mortality rates were 43.1% and 4.39%, respectively (Levine et al., 
2007).  The most common post-operative complications included pneumonia, 
hematologic toxicity, sepsis, respiratory failure, wound infection, anastomotic leak, and 
enterocutaneous fistula.  Finally, Levine et al. (2007) found significant differences in 
survival based on primary site of origin (p = 0.0001): colorectal (16.4 months), appendix 
(63.5 months), gastric (6.1 months), mesothelioma (27.1 months), sarcoma (28.1 
months), ovarian (28.5 months).  The overall median survival rate was 22.2 months, 
while the overall survival rates at one, three, and five years were 66.8%, 40.0%, and 
27.8% (Levine et al., 2007). 
Factors Associated with Success 
 The survival rates based on primary site of origin provided by Levine et al. (2007) 
demonstrate significant variability, suggesting some candidates will have a longer 
predicted survival period than others.  In addition to primary tumor site, alternate factors 
likely impact survival and surgical success rates, including the completeness of the 
cytoreduction, regardless of the primary diagnosis (Levine et al., 2007).  Additionally, the 
level of skill, experience and knowledge possessed by the respective surgical team seems 
to play a large role.  Levine et al. (2008) and Smeek, Verwaal, and Zoetmulder (2006) 
suggested the presence of a steep learning curve, involving not only improvement in 
techniques over time but also better candidate selection with more operating experience.  
Stewart et al. (2005) revealed the following selection criteria that are utilized at 
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WFUBMC: the prospective candidate must be medically fit to undergo the extensive 
CS+HIPEC; extra-abdominal disease cannot be present; the surgeon must deem the 
peritoneal carcinomatosis completely or substantially resectable; parenchymal hepatic 
metastases cannot exist; and bulk retroperitoneal disease cannot be present.  These 
stringent selection criteria are essential so that disruptive, invasive surgical procedures 
are not performed on individuals who will not benefit substantially or who are in the 
palliative stages of life.  At the same time, however, Stewart et al. (2005) noted, “only a 
handful of patients who are potential candidates for this therapy actually receive it, and 
this is underscored by the relatively small number of patients accrued to phase II studies 
even at large „perfusion centers‟” (p. 773).  Many more individuals with peritoneal 
metastases, then, could have a chance for long-term survival with this procedure.  Finally, 
McQuellon and Duckworth (2009) suggested the importance of incorporating ongoing 
QOL assessment throughout the trajectory of this experience so that correlate 
psychosocial issues do not go unaddressed.  A biopsychosocial approach encourages this 
multidimensional care. 
Risks and Toxicity 
 CS+HIPEC offers individuals with peritoneal metastases the possibility of 
achieving long-term survival when such a possibility would not exist otherwise.  
Unfortunately, on numerous occasions, these results are not achieved altogether or are not 
achieved without substantial cost in the form of morbidity (Sugarbaker, 1989) and 
temporary reductions in QOL.  With a post-procedure median estimated survival time of 
less than two years (Levine et al., 2007), patients and their loved ones must decide 
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whether the potential benefits outweigh the potential costs, given their respective 
conditions.  Levine et al. (2007) advocated for detailed pre-operative discussions with 
prospective patients and families so that every prospective candidate is truly an informed 
consumer.  Morbidity and mortality rates as well as psychosocial considerations should 
all be important topics of discussion in these talks. 
 Complications are common with this extensive procedure, and death is certainly a 
realistic occurrence as well (Sugarbaker, 1989).  After reviewing reports from centers 
with surgical teams who perform CS+HIPEC, Stewart et al. (2008) reported that post-
procedure morbidity rates are high, ranging from 27-56%, while mortality rates range 
from 0-11%.  Often, a grading system is implemented to rate the severity of these 
complications and to provide the surgeons with a systematic means of recording the 
extent of the complications experienced by their patients (e.g., I- a diagnosable problem 
that does not require treatment; II- a complication warranting medical intervention; III- a 
problem with potentially severe ramifications yet was resolved conservatively with 
medical intervention; IV- a problem warranting emergency intervention, typically in the 
form of surgery or regression to the ICU; V- death) (Sugarbaker et al., 2006).  Likewise, 
complications may be categorized by means of their association with various aspects of 
the procedure itself (e.g., the invasive surgical procedure, catheter-related, the localized 
concentration of the drugs, systemic toxicity, etc) (Spratt et al., 1986).  Regardless of the 
classification scheme, the morbidity rates relative to this procedure are high, thereby 
making the acute recovery stage complicated and lengthy hospitalizations, often far from 
home, commonplace. 
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For instance, in their review of 103 consecutive CS+HIPEC procedures on 
patients in Sweden, van Leeuwen, Graf, Pahlman, and Mahteme (2008) reported a 56.3% 
morbidity rate and the death of one patient post-procedure.  Of those who had 
complications, respiratory concerns, abscesses, systemic sepsis, neutropenia, urinary tract 
infections, and small bowel fistulas were the most frequent.  Approximately one third of 
these 103 individuals required additional surgical or invasive procedures to correct their 
complications (van Leeuwen et al., 2008).  Smeek et al. (2006) also reported a high 
complication rate, including a 54% toxicity rate and a surgical complication rate of 38%.  
Primary complications in these individuals included perforations or suture leaks of the 
small bowel, gastrointestinal fistulas and abscesses.  Sugarbaker et al. (2006) reviewed 
their own morbidity and mortality rates following 356 procedures and revealed a 2.0% 
30-day post-procedure mortality rate (i.e. seven persons).  One hundred and forty three 
patients, with line sepsis, urinary tract infections and insufficient hemoglobin levels 
occurring frequently, experienced one or more grade III complications.  One or more 
grade IV events occurred in 67 patients and included hematological, cardiovascular and 
gastrointestinal complications.  For 11.2% of these patients, a return to the operating 
room was required on account of anastomotic leaks, post-operative bleeding and fistulas, 
among others (Sugarbaker et al., 2006).  These statistics shared by surgical teams with 
extensive experience with this procedure demonstrate both the frequency and gravity of 
some of these complications.  If offered the possibility of extended life, however, many 
patients are willing to take the risk and endure such morbidities. 
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Many surgeons report correlations between the number of morbidities 
experienced post-operatively and the patient‟s stage of carcinomatosis, the length of the 
operation, and the number of anastomoses performed (Stewart et al., 2008).  Spratt et al. 
(1986) also noted the negative correlation between a surgeon‟s experience with the 
procedure and the number of complications, again suggesting the presence of a steep 
learning curve and the need to select the respective surgical team sagely.  Although most 
patients proceed to recover from their complications, most will eventually die from 
recurrent disease (Stewart et al., 2008).  Additionally, many will never return to or attain 
their desired level of physical functioning and well being (McQuellon & Duckworth, 
2009).  These possibilities may combine to make this surgical decision difficult. 
Although many hurdles and complications are possible, with CS+HIPEC, surgical 
oncologists are able to offer individuals with peritoneal metastases the possibility of 
achieving extended life.  With this possibility for extended life, however, comes a 
concurrent need to study the quality of their survivorship and whether the costs of the 
procedure are justified in the minds of its patrons.  In summary, the appearance of a 
sufficient number of survivors within a cancer diagnostic or treatment group is the 
essential and precipitating factor for the commencement of survivorship studies within 
that respective population, and the number of individuals who have had CS+HIPEC for 
peritoneal metastases continues to increase. 
Survivorship in Oncology 
 The aforementioned story behind the growth and transformation of Memorial 
Sloan-Kettering Cancer Center in many ways parallels the story of American society‟s 
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perception and regard of a cancer diagnosis and the study of survivorship issues in cancer 
care.  In the early 1900‟s, patients were often “humanely” spared from hearing their 
diagnosis, as such a diagnosis was, more often than not, equated with an untimely and 
disfiguring death (Rowland, 1998). Therefore, secrecy, isolation, and social stigma 
encircled the lives of those diagnosed with this disease.  With enhanced understanding of 
the disease coupled with medical advances in anti-microbial and disease fighting agents, 
however, oncology clinicians began experiencing some successes relative to extending 
patients‟ lives.  
Specifically, doctors‟ first curative successes occurred within the pediatric 
oncology arena, preventing central nervous system relapse in children with Acute 
Lymphoblastic Leukemia (ALL) (Ganz, 2003; Rowland, 1998).  Since ALL is the most 
prevalent form of childhood cancer, the ramifications of curative possibilities were 
quickly recognized.  Prior to this advent, cancer survivors simply did not exist in 
sufficient numbers to warrant attention to or research of survivorship issues in cancer 
patients (Rowland, 1998).  Yet, alongside these medical advances, a new concept was 
being integrated into the cancer lexicon and experience- that of survivorship.  Following 
the ALL breakthroughs, medical researchers began moving beyond strictly curative 
efforts to consider the quality of life post-treatment (Rowland, 1998). 
 This emphasis on life following treatment, and even life following cancer for 
many fortunate individuals, has continued to expand over time.  In 1985, Fitzhugh 
Mullan detailed his personal cancer journey and survivorship issues in a writing entitled, 
“Seasons of Survival” (Mullan, 1985).  The following year, he and a group of other 
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advocates established the National Coalition for Cancer Survivorship (NCCS).  As a first 
order of business, these progressive thinkers challenged the current definition and 
concept of a survivor, at that time conceptualized strictly as a person who remains free of 
disease five years following her or his diagnosis (Rowland, 1998).  Recognizing that 
survivorship issues commence at diagnosis and take varying forms throughout the 
remainder of life, the NCCS members argued that an individual diagnosed with cancer 
should be able to consider and refer to her or himself as a “survivor” from the point of 
diagnosis and for the remainder of her or his life, regardless of the cause of death 
(Rowland, 1998).  This broader, more encompassing concept of a survivor gave credence 
to the unique concerns confronted by persons with cancer from the moment of their 
diagnosis and began to inform thinking and research within the U.S.  Consequently, the 
field of psychosocial oncology developed to train researchers and clinicians who have the 
requisite combination of drive, skills, ethic, and vision to serve this population and 
advance the understanding of survivorship issues.  
Survivorship Research 
 Attention to survivorship and health outcomes relative to cancer care is essential 
for numerous reasons.  For starters, a growing number of individuals are being diagnosed 
with cancer.  Specifically, the aging of the population translates to a growing number of 
elderly persons who will be diagnosed with cancer, making research related to health 
outcomes pertinent for a larger number of people (Ganz, 2003).  A major goal of 
survivorship researchers is to better understand the holistic impact of therapies, 
maximizing potential for cure and minimizing negative health effects (Rowland, 1998).  
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If numerous treatment options are available and patients have preferences for some 
toxicities over others, research on survivorship and health outcomes should inform 
decision-making (Ganz, 2003).  Accurate information on primary treatments, their 
respective short- and long-term effects and any interactions between treatment-related 
effects and existing medical and mental health conditions is therefore essential.
 Unfortunately, most of our research and current knowledge of treatment effects 
pertains to the acute and immediate effects of treatment rather than the long-term effects 
(Ganz, 2003), and less is known relative to treatment-related morbidity and interactions 
with comorbid conditions.  Some patients may be accepting of any late effects of 
treatment simply because the associated therapy gives them the possibility of extended 
life; others may be less amenable to impaired functioning (Ganz, 2003) and may 
therefore want as much information as possible to decide whether to enter treatment in 
the first place.  Regardless of patient preference, treatment-related decision-making 
should be informed by sound research, and any accumulated research should be 
incorporated into decision-making and systematic assessment following treatment (Ganz, 
2003).  Sound research also should serve as the basis of creation and implementation of 
evidence-based interventions that encourage healthy mental and physical adaptation 
(Rowland, 1998).  
 Reflecting on the growth and development of survivorship issues, many trends 
within the research are evident (Rowland, 1998).  Broadly speaking, researchers have 
moved from strictly descriptive studies to intervention studies, from small cohort studies 
to large, multi-institutional studies following international cohorts over time, from 
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examining purely observable symptoms to researching mind-body impacts of drugs and 
interventions (Rowland, 1998).  Although reviewing all of the trends is beyond the scope 
of this dissertation, it is important to highlight the existence of these trends and remaining 
gaps in need of researchers‟ attention.  Specifically, Rowland (1998) noted the paucity of 
information related to underrepresented cancer sites and treatments (e.g. individuals with 
peritoneal metastases who have had CS+HIPEC) as well as individuals from low income, 
low education, ethnoculturally diverse, and rural backgrounds.  Similar to survivorship 
issues in general, survivorship issues relative to specific diagnoses or novel treatments 
are not as salient until a sufficient number of persons begin surviving the disease or 
treatment, respectively.  Researchers studying specific groups of survivors previously 
underrepresented within the literature on account of poor prognoses must work within 
that defined population and not make inferences beyond that sub-population (Ganz, 
2003).  In other words, as survivorship research progresses, the health outcomes of a 
potential array of diagnoses and novel treatments and their interactions with pre-existing 
characteristics and conditions may lead to unique post-treatment outcomes that warrant 
individualized research.  
Quality of Life as an Outcome Measure 
 While studying survivorship issues within specific cancer or treatment-related 
populations, researchers may utilize a number of outcome measures, including some that 
are patient-rated in nature (Rowland, 1998).  As medicine has become more patient-
centered and patients have steadily become collaborative partners in their own health, 
such subjective, patient-rated measures have gained value and utility (Travado, 2006), 
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permitting the health team insight into the subjective world of the patient and her or his 
personal tolerance of its quality.  One example of a patient-based outcome measure is 
quality of life assessment.  
 Rather than an altogether novel construct, QOL is a fresh referent for the 
longstanding concept of general welfare (Cella & Tulsky, 1993).  References to this early 
QOL predecessor are apparent in the Declaration of Independence (i.e., the entitlement to 
seek happiness) and in the Preamble to the Constitution (i.e., the advancement of the 
general welfare of citizens), providing evidence for the existence of a similar construct 
throughout time (Cella & Tulsky, 1993).  Definitions and measurement strategies of this 
evolving construct have taken different forms, often reflecting the zeitgeist, or spirit of 
the time.  In the Great Depression, for example, QOL often was determined by means of 
finances and the possession of objects (Cella & Tulsky, 1993).  As the 1960‟s approached 
(e.g. President Johnson‟s Great Society), the fluid definition of QOL began taking a more 
subjective, intrinsically-driven form, rather than an objective (i.e. possession of goods), 
form.  With this morphing of the construct came a need for researchers to obtain 
subjective, patient-reported inputs and a simultaneous concern about the reliability of this 
subjective data (Cella & Tulsky, 1993). 
To this day, many continue to hold that an individual‟s quality of life is, as a 
construct, extremely difficult to measure, with some even arguing that it is an intangible 
construct altogether (Rowland, 1998).  Undoubtedly, many factors coalesce to impact 
one‟s perception of quality of life, and the relative merit each person gives to these 
factors often varies (Cella & Tulsky, 1993).  Confusion also remains as to whether the 
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overall goal is to measure QOL or health-related quality of life (HRQOL), that is, QOL 
as a whole or QOL strictly as it pertains to cancer-related health.  The often 
interchangeable use of these two terms causes discrepancies relative to what is actually 
being measured and how to interpret results.  
Additionally, Roland (1998) noted the inherent difficulty of accurately measuring 
the QOL of cancer patients over time.  Specifically, the adaptive nature of human beings 
often results in what is referred to as a response shift.  With response shift, humans 
become less distressed by something that was initially distressing or disabling, as they 
make accommodations or alter their expectations.  The respective stressor(s) or 
symptom(s) impairing QOL might continue to exist in the same, or an even more potent, 
form, yet individuals have accommodated and therefore rate their QOL as better than 
before (Rowland, 1998).  These response shifts make the interpretation of the recovery 
trajectory and QOL difficult to ascertain.  Finally, the differing perspectives of patients, 
mental health practitioners and physicians relative to the importance and weight of the 
scores as well as how to incorporate them into individualized health plans differs 
(Travado, 2006). 
 Despite these and other challenges related to QOL measurement and 
interpretation, countless researchers still hold that it is a construct of great importance, 
and patients and patient advocacy organizations demand continued attention to the 
psychosocial needs of patients (Travado, 2006).  The existence of this construct in cancer 
care alone serves as a reminder of how far we have progressed in cancer care since the 
days of measuring success in the crude categories of death, cure, or disability 
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(Langenhoff, Krabbe, Wobbes, & Ruers, 2001).  Gathering QOL information allows the 
health care team to gain access to needs that might have otherwise remained unknown or 
unacknowledged (Davies, 2009).  Physicians and patients often have differing priorities 
(Halyard & Estwing Ferrans, 2008), and QOL data serves to underscore the subjective 
impact of a diagnosis or treatment alongside the observable, objective response.  Some 
researchers have even demonstrated the predictive power of QOL scores relative to 
patient survival and response to treatment (Halyard et al., 2008).  This type of estimated 
response gleaned through QOL scores becomes even more salient in a palliative setting, 
when patients have limited life expectancies and quality of life should be of the utmost 
importance (Langenhoff et al., 2001).  Some researchers are interested precisely in this 
type of cost-benefit analysis of treatments, in the incorporation and estimation of adjusted 
quality years gained as a consequence of treatments.  In the future, they envision more 
integration and use of these utility figures that integrate morbidity and mortality estimates 
with QOL data, resulting in estimates such as quality-adjusted life years (QALYs) or 
quality-adjusted time without symptoms of disease and toxicity of treatment (Q-TWIST) 
(Langenhoff et al., 2001).  Although many future developments are needed in the 
practical application of such analyses, the future emphasis on considerations of quality in 
the context of cancer care is evident.  In the art of comprehensive care, where patients‟ 
holistic well-being is the focus of attention and patients are increasingly becoming 
collaborative partners in their own care, acceptable QOL should be one of many outcome 
measures of interest (Langenhoff et al., 2001). 
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 Langenhoff et al. (2001) pointed out the numerous definitions of QOL within the 
literature and argued there is no “best” definition when it comes to QOL.  For example, 
The World Health Organization defined QOL as “individuals' perceptions of their position 
in life in the context of the culture and value systems in which they live and in relation to 
their goals, expectations, standards and concerns,” thereby reflecting the construct‟s 
subjective nature and the relative importance of an individual‟s cultural, environmental and 
social systems (WHOQOL User Manual, 1998, para. 5).  As noted in the previous chapter, 
Cella and Cherin (1988) defined QOL as “patients‟ appraisal of and satisfaction with 
their current level of functioning compared to what they perceive to be possible or ideal” 
(p. 70).  Numerous variations in QOL definitions exist, with differing levels of 
specificity, yet most researchers concur that the construct of QOL and its respective 
measurement should be multidimensional, subjective (i.e. patient-rated), responsive to 
change over time (Langenhoff et al., 2001), and dual-sided in nature, incorporating 
negative aspects of the disease and treatment effects as well as positive life aspects, such 
as well-being (Cella & Cherin, 1988).  
The precise number of principal aspects or domains composing QOL is, again, a 
subject of debate.  Langenhoff et al (2001) stated that the consensus within the field is 
that the construct of QOL has three principal domains (i.e. physical, psychological, and 
social) plus a global assessment that yields information about the participant‟s appraisal 
of her or his overall QOL.  Rowland (1998), on the other hand, argued that QOL 
encompasses a minimum of four primary areas of importance.  At its core, according to 
Rowland (1998), QOL includes a physical component (i.e. physical health and 
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symptoms), an emotional component (i.e. one‟s mood as well as cognitive and affective 
status), a functional component (i.e. one‟s ability to engage in daily living activities) and 
a social component (i.e. support, role functioning and financial burden) (Rowland, 1998).  
These aforementioned discrepancies in definitions and number of domains within the 
construct are highlighted throughout the various QOL instruments as well.  Ultimately, 
the goals of the research should guide definition and instrument selection (Langenhoff et 
al., 2001). 
In general, three categories of QOL instruments exist, and instrument selection, 
again, depends on the respective research goals (Langenhoff et al., 2001) and intended 
use of the acquired QOL data.  QOL instruments may be classified as generic, cancer 
general or cancer disease-specific (Lipscomb, Snyder, & Gotay, 2007).  Designed for use 
with an array of diseases and medical treatments, generic QOL instruments permit 
comparisons across varying treatments and conditions.  It is precisely this generic quality 
and lack of specificity, however, which may make them less sensitive to some of the 
clinically relevant and unique aspects of a subgroup‟s experience (Langenhoff et al., 
2001).  Similarly, cancer general QOL instruments are generic in nature but have a 
narrower focus of strictly oncologic diseases.  Disease-specific QOL instruments, on the 
contrary, were developed with a unique diagnostic or treatment-group‟s experiences in 
mind.  They include domains that are particularly salient to the respective subgroup and 
may be designed to be more sensitive to changes within these domains (Langenhoff et al., 
2001).  
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If relatively little is known about the QOL of a subgroup, a disease-specific 
measure has yet to be developed, or norm-based comparisons are of particular interest, a 
generic QOL instrument may be the best choice.  If a valid and reliable disease-specific 
measure exists for the subgroup of interest and a detailed profile of salient QOL 
impairments for this respective population is of interest, the disease specific measure is 
the likely choice.  Many researchers who have both categories of QOL instruments at 
their disposal may use a combination of the two categories (Langenhoff et al., 2001) so 
that both group comparisons and a detailed profile of the subgroup of interest are 
possible.  Ultimately, no one instrument is the “gold standard”, fitting all conditions for 
all disease and treatment groups (Langenhoff et al., 2001).  Research goals must guide 
instrument selection. 
 Despite the lack of agreement on a “best” definition of QOL and the varied 
number of hypothesized domains, all QOL instruments should meet certain standards.  
The U.S. National Cancer Institute created the Cancer Outcomes Measurement Working 
Group (COMWG) in 2001 with the goals of evaluating and progressing patient-rated 
outcome measurement (HRQOL in particular)  (Lipscomb et al., 2007).  The COMWG, 
in turn, adopted revised Medical Outcome Trust (MOT) criteria to evaluate QOL 
instruments.  Adhering to MOT evaluation criteria, COMWG evaluators examine the 
following underpinnings of any QOL instrument to gauge its relative strengths and 
weaknesses: the conceptual and measurement model, reliability, validity, responsiveness, 
interpretability, burden/alternative modes of administration, and cultural and language 
adaptations (Lipscomb et al., 2007).  
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The conceptual model should underscore the selection of concepts, domains and 
their interrelationships in relation to how they measure the overall construct.  Lipscomb 
et al. (2007) noted that the measurement model should, in optimal circumstances, be “the 
operational counterpart to the conceptual model, with the specified domains taking 
concrete form as constructs to be measured via the items included in the instrument” (p. 
146).  
Responsiveness refers to the ability of an instrument to detect changes over time, 
while sensitivity refers to the ability of an instrument to highlight differences within a 
cross-section of individuals (p. 146).  In general, the larger number of items within a 
scale and the more response alternatives associated with each item (i.e. a minimum of 
five response choices per item), the more responsive to change the instrument is over 
time (Langenhoff et al., 2001).  This need for sensitivity and responsiveness to change 
must be balanced, however, with practical considerations relative to length and ease of 
completion within cancer populations.  Timing of administration should be consciously 
scheduled, keeping considerations of the disease and treatment trajectory as well as study 
design in mind (Langenhoff et al., 2001).  Assessing change over time also requires 
multiple administrations, one prior to treatment and, at minimum, one following 
treatment at a strategic point (Nayfield, Ganz, Moinpour, Cella, & Hailey, 1992).  
Interpretability refers to the ease with which meaning can be gleaned from a 
quantitative score on an instrument (Lipscomb et al., 2007).  Burden encompasses the 
work load (i.e., energy, time, etc.) on both the participant and administrator.  The mode of 
administration (i.e., self-report, observer ratings, interview, computer-assisted 
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approaches, performance ratings) may directly impact the degree of burden on both 
parties.  Apart from the validity and reliability considerations that are pertinent to any 
instrument, the final QOL rating category entails cultural and language adaptations, that 
is their availability as well as their conceptual and linguistic equivalence (Lipscomb et 
al., 2007).  Consideration of the aforementioned evaluation criteria further assist 
researchers in selecting QOL instruments that optimally fit their research goals or the 
purposes of the respective clinical trial. 
Challenges in Researching QOL 
 Despite this increased advocacy and appreciation for the utility of QOL 
information provided by participating survivors, there remain many challenges inherent 
in accurately measuring QOL.  Access to patients in various diagnostic and treatment 
groups as well as their retention is a recurrent hurdle (Cella & Tulsky, 1993).  An 
impaired health status may contribute to missing or misunderstood items or inconsistent 
reports.  Researcher time is ultimately required to monitor incoming data for 
completeness and accuracy (Cella & Tulsky, 1993).  Additionally, because of the rapid 
pace of change within treatment delivery, QOL information may concurrently become 
outdated as new cohorts of individuals receive variations in or altogether novel treatments 
(Rowland, 1998).  As new treatments or alterations to standard chemotherapeutic, 
radiation or medication dosages are made, QOL impacts will likely alter in tandem, 
ultimately necessitating new research needs.  As this new information is acquired from 
varying diagnostic and treatment groups, it also remains unclear what constitutes success 
relative to survivorship outcomes (Rowland, 1998).  Specifically, whether these 
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survivorship outcome markers are determined on a personal, clinician, cohort or national 
level remains variable.  Best methods of translating this acquired psychosocial data from 
descriptive to applied information that serves to improve patient care, monitoring, and 
interventions also remains a challenge within and across institutions (Rowland, 1998).  
In summary, QOL data yields invaluable information on the multidimensional 
functioning of a patient, coming from the most knowledgeable source, the patient.  This 
psychosocial information, which is influenced by numerous variables that often are 
ancillary to treatment variables, may or may not concur with the perceptions of outside 
observers or objective survivorship markers (e.g. tumor response, hemoglobin level).  
Regardless of its agreement with other sources of acquired data, QOL data provides some 
of the best opportunities for entry into the private world of the respective survivor and her 
or his acceptance of this current level of functioning.  It is fortunate, then, that QOL is 
now included in clinical trials.  
Entry of QOL into Clinical Trials 
 One of the most frequent contexts for QOL assessments is in clinical trials, during 
which patients often are randomized to treatments and a number of biological and 
psychosocial variables, including QOL, are examined over the treatment trajectory 
(McQuellon & Duckworth, 2009).  Research by Sugarbaker, Barofsky, Rosenberg, and 
Gianola (1982) serves as an early example of the entry of psychosocial assessment in a 
medical setting as well as an illustration of how the acquisition of patient-rated, 
psychosocial data can, in turn, impact subsequent treatment decision-making on the part 
of clinicians and patients.  
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In 1982, Sugarbaker et al. randomized 26 patients with soft tissue sarcoma to one 
of two groups in a clinical trial: 1) amputation plus chemotherapy or 2) limb-sparing 
surgery in conjunction with chemotherapy and radiation.   Prior to measuring the impact 
of these respective treatments on the patients‟ QOL, the researchers hypothesized that 
those patients whose limbs were spared would report improved QOL over their 
counterparts who received amputations.  Upon receipt of the QOL data, however, the 
researchers obtained a clearer understanding of the impact of treatment on these 
individuals‟ lives and quickly discovered their hypothesis was incorrect.  The limb 
sparing treatment did not lead to enhanced QOL when compared to the amputation 
treatment.  Additionally, the patients who received the limb sparing treatment with 
corresponding chemotherapy and radiation actually reported significantly reduced sexual 
functioning when compared to the individuals who received an amputation.  The authors 
speculated that these findings were likely attributable to the greater toxicity to which the 
limb-spared patients were exposed from the chemotherapy and radiation.  
Sugarbaker et al. (1982), whose hypothesis was proven incorrect, ultimately 
concluded that it is essential to assess QOL impacts post-treatment, as “an improvement 
in quality of life which seems self-evident may not really exist” (p. 22).  Measuring 
survival in isolation does not assist researchers and patients in making decisions about 
whether gains in quantifiable time are worth the morbidity and potential QOL 
impairments (American Society of Clinical Oncology, 1996).  Likewise, treatments may 
offer benefits other than increased survival time including palliation of pain from tumors 
or blockages, and these benefits may only be noticeable upon the analysis of QOL data 
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(Cella et al., 1990).  Understanding the actual psychosocial impact of treatments 
facilitates informed patient decision making, greater attention to and energy towards 
patients‟ psychosocial needs on the part of all medical and mental health parties, as well 
as improved doctor-patient relations (Sugarbaker et al., 1982).  Not surprisingly, since the 
days of these earlier clinical trials, the inclusion of QOL assessment has continuously 
become a more standardized component of clinical trial research and of cancer treatment 
and assessment in general.  Numerous governing bodies and associations, including the 
American Society of Clinical Oncology (1996) and the Food and Drug Administration 
(Johnson & Temple, 1985), have formally underscored the importance of QOL 
measurement and implications in the form of standards and practice recommendations.  
QOL of Patients Receiving CS+HIPEC 
 Although the number of investigations entailing candidates and recipients of  
 CS+HIPEC has been limited (Confuorto, Giuliano, Grimaldi, & Viviano, 2007; 
McQuellon & Duckworth, 2009), the body of literature pertaining to the procedure and 
the QOL of its recipients continues to grow.  Only ten QOL articles involving individuals 
who received this procedure were located, one of which (McQuellon, Gavazzi, Piso, 
Swain, & Levine, 2008) is a review of existing literature and recommendations for future 
practice.  It is evident, then, that many gaps remain in this literature base.  
In a recent review of these QOL studies, McQuellon and Duckworth (2009) 
offered many observations and highlighted noticeable trends across studies.  While they 
underscored the potential for successful outcome and subsequent extended life following 
the CS+HIPEC procedure, their clinical and consultation experience with members of 
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this population has deepened their respective understandings of the severe complications 
that may occur post-treatment, significantly impacting QOL.  Therefore, while it is the 
best, and often the only, treatment option for many individuals with peritoneal surface 
malignancies, CS+HIPEC poses the possibility of both short-term and long-term risks to 
the candidate‟s physical and psychological health and overall QOL (McQuellon & 
Duckworth, 2009).  
Typically, those with better performance statuses (i.e., those who are in better 
overall health) prior to surgery fare better during and post-treatment (Levine, Stewart, 
Russell, Geisinger, Loggie, & Shen, 2007; McQuellon & Duckworth, 2009), suggesting 
the importance of stringent selection criteria.  A subset of patients will die from 
complications and morbidities, and those with existing complications or poor 
performance statuses may face these risks to a greater extent.  Similarly, those with more 
physical symptoms prior to the CS+HIPEC procedure may immediately report improved 
post-treatment QOL scores, while those with fewer physical symptoms prior to the 
procedure may comparatively report more significant reductions in QOL in the acute 
recovery phase (McQuellon et al., 2001).  The subsequent post-treatment recovery pattern 
often varies, therefore, as a consequence of variations in pre-surgical performance status, 
primary tumor site, and surgical variables, among other things.  In general, however, the 
majority of candidates can anticipate returning to relatively normal functioning by three 
to six months, with some individuals needing up to 12 months to achieve recovery 
(McQuellon & Duckworth, 2009).  Few individuals return to normal functioning, and 
therefore achieve their respective baseline QOL, prior to three months, and many report 
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they experienced a more debilitating post-treatment experience than anticipated 
(McQuellon & Duckworth, 2009).  Finally, between 20-30% of patients can be expected 
to endorse depressive symptoms when monitored over the 12 months following this 
surgical and chemotherapeutic procedure (McQuellon & Duckworth, 2009).  
In summary, individual differences in both pre- and post-treatment functioning 
varies to a great extent.  Prospective candidates can generally anticipate a decline in 
physical functioning and general QOL during the acute recovery phase, with subsequent 
improvements over time.  Examining findings from each of the located QOL studies 
pertaining to this population leads to a clearer understanding of the spectrum of 
experiences as well as the general trends.  
Acute QOL. The first QOL study located of individuals following CS+HIPEC 
was published in 2001 (McQuellon et al., 2001).  In this study, all patients consecutively 
treated at Wake Forest University Baptist Medical Center (WFUBMC) between 
September 1, 1995 and December 31, 1997 were eligible.  A total of 64 patients 
consented and were interviewed prior to CS+HIPEC; 48 patients were interviewed post-
operatively (mean=13.2 days post-procedure); and 41, 39, and 31 patients were assessed 
at three, six, and 12 months, respectively.  A total of 23 patients completed the 
assessment battery at all five collection points. 
For this collective group, mean QOL scores on the Functional Assessment of 
Cancer Therapy-Colon (FACT-C) dropped significantly from the baseline to post-
procedure measurement, rebounded to levels that were better than baseline by three 
months, and subsequently showed improvement over the course of the year (i.e. six and 
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12 month time points).  A statistically significant overall effect was noted on physical 
well-being (p = 0.0025), emotional well-being (p = 0.0001), functional well-being (p = 
0.0044), colon subscale (p = 0.0229) and overall QOL scores (p = 0.0076).  The subgroup 
of patients with malignant ascites (i.e. the accumulation of fluid that contains cancer cells 
within the abdominal area; National Cancer Institute, n.d.), however, demonstrated the 
opposite trend, presenting with lower baseline QOL component scores and improved 
post-procedure QOL scores.  These findings within this subgroup likely reflect the literal 
removal of the cumbersome ascites, resulting in immediately apparent reduced physical 
symptoms and discomfort.  McQuellon et al. (2001) noted that functional status 
impairment reports resembled the collective QOL trend, with impairments increasing 
significantly from baseline to post-procedure and then demonstrating continued 
improvement throughout the year.  
Similar to McQuellon et al. (2001), other researchers reported that the physical 
health of these patients decreases for the acute time period following surgery and then 
demonstrates improvement with time.  At the 57
th
 Annual Cancer Symposium, Alexander 
et al. (2004) reported QOL findings from 73 patients with peritoneal surface 
malignancies who underwent debulking and peritonectomy, major organ resection, 
followed by continuous hyperthermic chemotherapy perfusion between February of 2000 
and July of 2003.  Specifically, they examined patients‟ generic QOL, as measured by the 
Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) (Ware & 
Sherbourne, 1992), and condition-specific QOL, as measured by the FACT-C, at 
baseline, six weeks, three, six, and nine months post-procedure.  Resembling the trend 
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reported by McQuellon et al. (2001), Alexander et al. (2004) found that the physical 
component scores of the SF-36 decreased significantly from baseline to six weeks (p < 
0.0001), yet did not differ significantly from baseline scores at three, six, and nine 
months. 
Targeting 35 patients consecutively treated with CS+HIPEC from 2001-2005 in a 
phase II study at the University of Minnesota, Tuttle, Zhang, Greeno, and Knutsen (2006) 
also examined longitudinal QOL scores. QOL scores were measured at baseline, four, 
eight, and 12 months.  The overall FACT-G (p = 0.0351) and FACT-C (p = 0.0371) 
scores as well as the emotional well being (p = 0.0026) and functional well being (p = 
0.0030) subscale scores demonstrated significant increases across time.  Specifically, the 
baseline and four month scores were not significantly different, yet scores increased to 
surpass those of baseline at eight and 12 months.  Given that Tuttle et al. (2006) did not 
assess QOL post-procedure until four months, it remains unknown if the established trend 
(i.e. a decrease in physical well-being during the acute recovery phase (McQuellon et al., 
2001; Alexander et al., 2004)) actually occurred.  It is likely that these patients 
experienced decreased physical and functional well-being during the first few months of 
recovery yet reported physical well-being levels that resembled their baseline levels by 
four months.  These findings suggest the importance of strategic timing of assessments 
post-CS+HIPEC.  Ultimately, Tuttle et al. (2006) concluded that those who live to be 
survivors often report improved and acceptable QOL because of the reduction of physical 
symptoms.  
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Finally, McQuellon (2007) published additional findings detailing post-
CS+HIPEC health outcomes.  A total of 96 individuals completed their baseline 
instrument, while 38, 32, and 24 individuals completed the three, six, and 12 month 
instruments respectively.  During the study, 31 participants died and 20 participants 
withdrew from the study or reported being too sick to complete the packet.  
With the exception of the social/family well-being subscale, all FACT QOL 
subscale scores as well as the overall QOL score demonstrated significant changes over 
time (McQuellon et al., 2007).  Those who remained in the sample across time 
demonstrated improvements in overall mean FACT scores from baseline to 12 months.  
For the 38 participants who completed the three month survey, all subscale QOL scores, 
with the exception of the physical well being subscale scores, had returned to or exceeded 
baseline levels.  Again, these findings are consistent with those of previous researchers 
(Alexander et al., 2004; McQuellon et al., 2001).  An examination of the corresponding 
SF-36 subscales further explains these findings, with the physical functioning, role 
functioning, and bodily pain subscales demonstrating a significant overall increase from 
baseline to 12 months.  Specifically, and in line with previous findings, the three 
aforementioned scales decreased significantly from baseline to three months and then 
exceeded baseline levels to achieve their highest scores by six months.  From these 
findings, one can ascertain that a significant percentage of patients continue to report 
physical limitations at the three month period, after which these symptoms begin to 
dissipate.  It is important to note, however, that all of the SF-36 scale scores, with the 
exception of the vitality subscale, remained below the general population norms, meaning 
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this collective group continued to experience less than optimal health relative to the 
general population (McQuellon et al., 2007).  
In summary, the findings of the aforementioned researchers reflect the 
fluctuations in QOL over time, primarily as a function of physical well being and 
functional status.  Specifically, with the exception of the subgroup of patients with 
malignant ascites (McQuellon et al., 2001), the patients described by these researchers 
demonstrated significant decreases in QOL and functional status from baseline to the first 
few months post-CS+HIPEC (Alexander et al., 2004; McQuellon et al., 2001; McQuellon 
et al., 2007).  While the physical and functional well being of some patients continue to 
improve over the next nine months (Tuttle et al., 2006), the physical and functional status 
of others typically returns to baseline levels (Alexander et al., 2004).  Although these 
scores demonstrate movement over time, McQuellon et al. (2007) noted that the majority 
of the scores still range below those of the general population. 
Trends in mental health also can be extracted from this longitudinal data.  
McQuellon et al. (2007) noted that the emotional well-being subscale scores of 
participants were generally the same or higher than baseline levels by three months.  
Regarding depressive symptoms, McQuellon et al. (2001) noted a progressive decrease in 
the percentage of patients endorsing clinically significant depressive symptoms across the 
first four time points, up until the 12-month assessment period.  One year post-procedure, 
the percentage of participants expressing depressive symptoms increased relative to the 
six-month assessment period yet still remained lower than the percentage of individuals 
expressing depressive symptoms at baseline (i.e. baseline (38%), post-procedure (33%), 
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three months (23%), six months (21%) and 12 months (29%)).  Although these 
depression scores are likely inflated by some of the significant physical symptoms 
experienced by members of this population, the unusually high percentages reflect the 
patients‟ continued struggles and the potential need for psychosocial interventions.  In a 
similar trend, Alexander et al. (2004) found that the mental component scores of the SF-
36 increased significantly from baseline at six weeks (p = 0.006) and three months (p = 
0.014) (indicating fewer depressive symptoms) yet did not differ significantly from 
baseline at six and nine months.  Tuttle et al. (2006) reported that the emotional and 
functional well being scores of their participants were significantly improved at eight and 
12 months relative to baseline, suggesting long-term improvement in the occurrence of 
depressive symptoms.  Interestingly Tuttle et al. (2006) also noted that the occurrence of 
an adverse event (such as an intra-abdominal abscess) correlated significantly with 
smaller increases in QOL scores.  
Overall, these findings related to the mental health of patients in the acute 
recovery period post-CS+HIPEC reveal immediate reductions (relative to baseline) in the 
percentage of patients experiencing depressive symptoms (McQuellon et al., 2001) and 
improvement in general emotional well-being in assessments following surgery 
(Alexander et al., 2004).  All researchers noted at least some positive movement in these 
mental health scores over time (McQuellon et al., 2001; Alexander et al., 2004; Tuttle et 
al., 2006), with some noting significant positive differences between baseline and 
endpoint assessments (Tuttle et al., 2006) and others noting a leveling off, with no long-
term differences (Alexander et al., 2004).  
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Long-term QOL. Researchers also have considered how long-term survivorship 
issues differ from those that are acute in nature.  McQuellon et al. (2003) examined a 
cohort of individuals not targeted in their initial study, those living three or more years 
post-CS+HIPEC.  In conducting this descriptive study, the researchers were particularly 
interested in the kind and degree of persisting deficits, that is, in the overall price of 
extended survival for the individuals who experienced peritoneal metastases.  
Considering no long-term QOL data was available for reference for this population, 
McQuellon et al. (2003) targeted overall QOL scores, psychosocial concerns and 
depressive symptoms in those living three or more years post-procedure.  All patients 
receiving this procedure at WFUBMC, treated consecutively between January 1, 1992-
December 31, 1997 and demonstrating no evidence of disease were eligible for the study.  
At the time of the study, 109 individuals had been treated at WFUBMC.  Of those, only 
29 had survived for three or more years and 12 did not want to participate.  Data from a 
total of 17 participants (mean time since procedure= 5.3 +/- 1.6 years) were therefore 
gathered.  For ten of the participants, data were compared to existing baseline QOL 
scores.  
At the time of the study, McQuellon et al. (2003) found that long-term functional 
well being (p = 0.01), physical well being (p = 0.05) and overall QOL scores (p = 0.02) 
were improved relative to baseline scores for those participants with available data and 
did not differ significantly from three, six, and 12 month QOL scores.  Likewise, mean 
scores on a general QOL measure, the SF-36, were 68.2+/-11.5 for the long-term 
survivors, compared to 67.0 +/-23.4 for the general population (McQuellon et al., 2003).  
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These findings suggest that the acute deficits that are present immediately following 
treatment dissipate with time, and the achievement of a life of quality that is comparable 
to that of the general population is possible for those who survive and recover from the 
procedure.  McQuellon et al. (2003) reported that no one who survived three or more 
years regretted having the procedure.  Alternate concerns experienced within the 30-day 
time frame of the study for greater than 15% of participants included concerns related to 
sleep quality, sex life, and fears of recurrence.  Only one individual endorsed sufficient 
depressive symptoms to be considered a probable “case” (McQuellon et al., 2003).  
Overall, these long-term survivors achieved a quality of life that resembled their general 
population peers.  
Using the European Organization for Research and Treatment of Cancer-Quality 
of Life Questionnaire-Cancer 30 (EORTC QLQ-C30), Schmidt, Dahlke, Klempnauer, 
Schlitt, and Piso (2005) also attempted to assess the QOL of 67 survivors of peritoneal 
surface malignancies from 11 different sites treated between March 1995 and February 
2003.  The overall morbidity rate in this population was 34%; the post-operative 
mortality rate was 4.5%, the median stay in the intensive care unit was 5 days (range 1-
116), and the median hospital stay was 25 days (range six-116). At the time of the study 
(mean time post-procedure=4 years), 25 individuals were still living.  Of those 
individuals, 20 returned the surveys, the largest concentration of which included 
individuals with a primary diagnosis of appendix carcinoma.  The mean QOL score 
(62.6) was measurably lower than that of the general Norwegian population (73.3). 
Patients who received a stoma (i.e. an opening from the inside to the outside of the body 
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created via surgery; National Cancer Institute, n.d.) during the procedure (n= two) 
reported significantly lower QOL estimates (mean= 16.7) than their CS+HIPEC peers.  
The most disabling symptoms reported by this group included pain, followed by 
insomnia, followed by fatigue.  The authors underscored the importance of carefully 
selecting surgical candidates and the potential existence of a better prognosis for 
individuals with peritoneal surface malignancies from specific origins (i.e. appendix 
carcinoma).  If carefully selected, the potential for extended life expectancy and the 
achievement of an acceptable QOL is attainable (Schmidt et al., 2005). 
The QOL of subgroups.  Sub-groups of patients who received CS+HIPEC also 
have been examined. For example, Jess et al. (2008) focused on a specific group of 
patients who received CS+HIPEC, individuals with pseudomyxoma peritonei (PMP) (i.e. 
peritoneal implantation metastases originating from cells that escape following a surgical 
removal or the rupture of ovarian cystadenoma, resulting in abdominal wall and intestinal 
papilla and an abdominal cavity filled with mucus-like fluid; Thomas, 1997).  
Specifically, their participants consisted of 23 patients who underwent this procedure at 
Aarhus University Hospital in Denmark.  Patients completed QOL questionnaires at 
clinic visits prior to the procedure and at three, six, 12, 18, and 24 months post-procedure. 
The relative symptom weakness for individuals with this specific diagnosis, PMP, is 
apparent, as baseline scores of patients were comparable to population norms.  The 
median hospital stay for this cohort was 18 days, although four patients were transferred 
to an alternate hospital stay for subsequent stays.  No one died within 30 days post-
procedure.  Leading morbidities post-procedure included fever of unknown etiology, 
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urinary tract infection, intraabdominal abscess, fistula to the Hartmann‟ stump, and fistula 
to the vagina.  All morbidities improved following treatment. Similar to previous studies, 
statistically significant decreases in the role physical subscale and physical dimension 
summary scale score from baseline to three months were observed.  Scores returned to 
preoperative levels by six months, and no significant differences were noted relative to 
baseline scores in subsequent measurements.  Jess et al. (2008) concluded that, despite 
the extensiveness of the procedure and the high rate or morbidity, the QOL impact of this 
procedure on individuals with PMP is relatively minor and only transitory.  
Although beyond the scope of this dissertation, numerous other researchers have 
reported their results of CS+HIPEC with various sub-populations, including those with 
malignant ascites (Garofalo, Valle, Garcia, & Sugarbaker, 2006), appendiceal neoplasms 
(Stewart et al., 2006; Sugarbaker et al., 2006), malignant peritoneal mesothelioma 
(Feldman et al., 2003; Yan, Edwards, Alderman, Marquardt, & Sugarbaker, 2007), 
sarcomatosis (Lim et al., 2007), and dissemination from the colon/rectum (Verwaal et al., 
2003).  
Case study.  Finally, McQuellon and Duckworth (2009) attempted to highlight 
the QOL impact of this specific surgical oncology procedure by means of an alternate 
methodology, a case study.  Specifically, these researchers and clinicians wanted to offer 
a descriptive picture of the QOL impacts on one survivor and additionally illustrate how 
QOL data collection and monitoring can be used to enhance clinical care.  McQuellon 
and Duckworth (2009) described the case of a 50-year-old, married female whose 
symptoms preceded her actual diagnosis of mesothelioma with peritoneal metastases by 
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several months.  Her baseline FACT score, acquired prior to CS+HIPEC, of 49 reflects 
an array of symptoms and significantly impaired QOL.  Likewise, she reported 
significant depressive symptoms on the CES-D, therefore warranting a pre-surgical 
phone call.  The patient described experiencing numerous physical symptoms and 
fatigue, which prevented her from working.  She also described ruminating about her 
condition worsening.  No further psychological care was recommended at that time. 
The patient proceeded to enter the hospital for CS+HIPEC.  In addition to the 
debulking and peritonectomy, she had multiple organs resected.  She was hospitalized for 
numerous months in her regional hospital as a consequence of nausea, inadequate 
nutrition and substantial weight loss.  Again, the acquisition of QOL questionnaires at 
three months that revealed impairments in QOL (score of 58) due to physical and 
functional deficits, trouble meeting the needs of her family, fears of recurrence, as well as 
depressive symptoms warranted a follow-up phone call.  At a post-procedure surgical 
consult, the physician recommended a consultation with a mental health professional.  In 
a mental health consultation, the patient noted she was improving physically and 
emotionally, so no further counseling was arranged at that time. 
At six months, the patient again returned the QOL questionnaires with a FACT 
score of 62.  Despite the continual improvement over time (i.e. 49, 58, 62), this most 
recent score continued to reflect significant QOL impairments, including many chronic 
impairments and frustration over her QOL.  At a nine month surgical consult, the 
physician was troubled by her flat affect and lack of excitement when he revealed that 
she was doing extremely well.  From a medical standpoint, she was doing very well; from 
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a psychosocial standpoint she was not.  She was exhibiting some mild depressive 
symptoms, had only attained roughly 50% of her normal energy levels, suffered from 
many chronic problems, and was unable to return to work.  She was not pleased with the 
quality of her life and was frustrated when she was told everything looked good from a 
medical standpoint based on a lack of residual disease.  She resumed meeting with the 
mental health professional for counseling and survivorship care planning that entailed 
strategies for meeting her biopsychosocial needs.  
This case illustrates the complexities of the recovery trajectory for many 
individuals following CS+HIPEC. Her QOL scores, as measured by the FACT, continued 
to improve significantly over time (49, 58, and 62), yet the post-procedure complications, 
the slow recovery process, the lingering physical symptoms and the overall impact on the 
quality of her life displease her. Although no residual disease was present, she continued 
to face many challenges.  A biopsychosocial approach considers the multidimensional 
impact of such a procedure, ensuring all patient needs and concerns are considered and 
addressed. From this, it seems clear that focusing exclusively on the medical results of 
such a traumatic and impactful procedure is insufficient.    
Based on this review of the results of all CS+HIPEC QOL studies located within 
the literature, some observations can be made.  First, CS+HIPEC patients have been 
insufficiently studied.  Much remains to be investigated.  Of the results that are available, 
one can conclude that patients experience decreases in QOL during the acute recovery 
phase (i.e. the first months post-procedure) due to impairments in physical and functional 
status.  QOL scores typically approach baseline levels by three to six months, and many 
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experience prolonged life expectancies that would not have possible without this 
procedure.  On the other hand, many experience significant morbidities and are likely not 
represented in existing studies.  Datasets likely capture the optimal cases, excluding many 
cases full of extreme suffering.  Reducing the sample size down to a single case study, 
McQuellon and Duckworth (2009) captured some of the intricacies and unexpected 
hurdles of the recovery process and the frequent incongruence relative to achievement of 
a medical recovery and the achievement of a desired quality of life.  Additionally, this 
case illustrated the importance of attending to the biological, psychological and social 
needs of every patient.  QOL assessment and its respective clinical application is one way 
of accomplishing this task in a medical environment.  One limitation, however, is that 
QOL researchers often insufficiently investigate the construct of sleep quality. 
Sleep Quality 
Throughout history, cultures of the world have offered unique, often mystical, 
interpretations of both the precipitating causes and subsequent meanings of sleeping and 
dreaming.  The ancient Greek culture gave us Nyx, the primordial goddess of night, who 
burrows in the Underworld by day and predictably emerges at dusk to unfold night across 
the earth‟s sky (Naiman, 2006).  Inevitably following behind in her ephemeral dusk is her 
son, Hypnos, inducing sleeping and dreaming in those below.  In addition to this 
picturesque offering provided by the Greeks, sleep has been creatively conceptualized as 
a time for the soul to occupy an alternate world; the result of blood-filled vessels forcing 
the brain into an alternate state; the brain‟s response to vapors released following 
digestion; even the result of the brain‟s exposure to a large amount of “hypnotoxins” 
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(Moorcroft, 2003, p. 15).  In the middle of the 20
th
 century, however, alongside 
technological advances in sleep measurement methods, many of these notions faded 
away, like the evanescent dusk.  
The development and utilization of polysomnography prompted changes in the 
comprehension of the process and implications of sleep, ultimately leading to a valid 
understanding of the intricacies of both sleep and wakefulness (Moorcroft, 2003).  
Polysomnography entails the measuring and recording of electrical energy released from 
bodily organs.  Recordings from brain waves (electroencephalogram, EEG), neck muscle 
tension (electromyogram, EMG), and eye movements (electrooculogram, EOG) have 
solidified our understanding of the respective stages of sleep and the fairly predictable 
pattern of sleep stage cycling (Moorcroft, 2003).  The stages (alert wakefulness, drowsy 
wakefulness, sleep stages one, two, three, four and rapid eye movement (REM) sleep) are 
differentiated by unique features in polysomnographic readings and are more accurately 
conceptualized as qualitatively different, rather than progressively deeper (Moorcroft, 
2003).  Stages one, two, three and four are collectively known as non-REMs (NREM) 
sleep, while stages three and four also are referred to as slow wave sleep (SWS) 
(Moorcroft, 2003).  
Defined as “a reversible behavioral state of low attention to the environment 
typically accompanied by a relaxed posture and minimal movement” (Moorcroft, 2003, p. 
24), sleep is an essential, rejuvenating component of all human existence of which we 
have gradually become more informed.  Certain areas of the brain (working in an 
integrated fashion), along with neurotransmitters and various substances found in the 
78 
 
cerebrospinal fluid and blood, have influential roles in both wakefulness and sleep 
(Moorcroft, 2003).  Rather than a simple and passive process, then, sleep is the product of 
active processes within the brain (Moorcroft, 2003). 
Of interest to researchers is often the reported quality of this sleep.  Defined as the 
“quantitative aspects of sleep, such as sleep duration, sleep latency, or number of 
arousals, as well as the more purely subjective aspects, such as „depth‟ or „restfulness‟ of 
sleep” (p. 194), Buysse et al. (1989) stated that this construct and its respective 
measurement are important for numerous reasons.  First, complaints and concerns related 
to sleep quality are common in the population, suggesting large numbers of individuals in 
need of intervention.  Secondly, these sleep-related concerns may, in fact, be symptoms 
of actual medical or sleep disorders, therefore warranting attention (Buysse et al., 1989). 
Buysse et al. (1989) underscored the continued disagreement within the field relative to 
the specific components that define sleep quality and their relative importance.  Often, 
the needs of the population under examination and the research goals of the respective 
study may define which aspects of sleep quality are most salient for a respective 
investigation (Buysse et al., 1989).  With that stated, however, the multidimensional 
nature of sleep quality cannot be understated.  Assessing overall sleep quality by means 
of one question or one component is insufficient.  
 Although QOL is a construct that is multidimensional in nature, many additional 
constructs of importance are not routinely included in general QOL assessments.  If these 
constructs are of interest to the researcher or are of significance to the survivorship of a 
particular diagnostic or treatment group, additional assessment of those respective 
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constructs may be necessary.  Sleep quality is one such example that may warrant 
supplemental investigation in some populations, including survivors who have had 
CS+HIPEC.  McQuellon et al. (2003) and Schmidt et al. (2005) reported that sleep 
quality and insomnia, respectively, are commonplace concerns among survivors of 
CS+HIPEC.  These findings suggest the need for further investigation of and attention to 
the sleep quality of CS+HIPEC survivors by means of multidimensional assessments 
designed specifically for the assessment of this construct.  
Buysse et al. (1989) included the following seven components in their assessment 
of sleep quality: sleep latency (i.e., the time it takes to fall asleep; Moorcroft, 2003), sleep 
duration, habitual sleep efficiency (i.e., the proportion of that respective sleep period 
actually spent asleep, rather than awake; Moorcroft, 2003), sleep disturbances, use of 
sleeping medications, daytime dysfunction, and subjective sleep quality.  The 
aforementioned components of sleep quality utilized by Buysse et al. (1989) in their 
research are likewise those areas that are routinely assessed in the clinical interviews of 
patients who present with sleep-related disturbances. Despite our advanced understanding 
of this construct, the development of tools that sufficiently measure its quality, and the 
prevalence and potential severity of sleep disturbance and impaired sleep quality, many 
cite the overall paucity of studies in which investigators have examined the multi-
component nature of sleep quality and argue that we have made insufficient progress in 
measuring and attending to certain sub-populations‟ sleep-related concerns over the 
years. 
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Prior to researching sleep quality, one must acquire at least a basic understanding 
of the sleep process and the plethora of factors potentially influencing this process.  The 
brief overview of some of the factors influencing the sleeping and waking states that 
follows will permit the reader to acquire a crude understanding of the bodily processes 
during sleep.  
The Body During Sleep 
To remain awake and responsive to stimuli, a person needs activation in the 
cerebral cortex and forebrain (Moorcroft, 2003).  The ascending reticular activating 
system (ARAS; a portion of the reticular formation) receives information transmitted 
from the forebrain and alternate sensory systems and, in turn, utilizes neurotransmitters 
(e.g. acetylcholine, norepinephrine, glutamate) to activate the cerebral cortex in various 
ways (Moorcroft, 2003).  Other portions of the brain, including the raphe (located in the 
middle of the brainstem) and the locus coeruleus (on top of the pons) also utilize 
neurotransmitters to activate the forebrain, thus promoting wakefulness.  Additionally, 
within the suprachiasmatic nucleus (SCN), the circadian clock serves to regulate an 
individual‟s bodily rhythm and subjective sense of day and night (Moorcroft, 2003; 
Schenck, 2008).  Although influenced by zeitgebers (or time givers), such as light, the 
cells within the SCN work together to create this individualized bodily rhythm and to 
impact additional hormonal and physiological activities within the body (Moorcroft, 
2003).  This rhythm enables us to have an “internal biological (subjective) day and night 
that usually enables us to mirror and prepare for the forthcoming change between 
external (objective) day and night” (p. 48). 
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As subjective night begins approaching, a person does not simply fall into sleep 
instantaneously.  Rather, gradual and successive changes occur, and a person may 
transition in and out of sleep numerous times prior to maintaining sleep (Moorcroft, 
2003).  Throughout wakefulness, a byproduct (i.e., adenosine) of certain 
molecules progressively builds up in the system, contributing strongly to the intensity of 
sleepiness while waking and subsequently impacting the amount of time spent in certain 
sleep stages while sleeping (Moorcroft, 2003). Additionally, the basal forebrain, thalamus 
and anterior hypothalamus, along with other areas of the brainstem and forebrain, utilize 
neurotransmitters to reduce activity in parts of the brain when sleep onset arrives.  Other 
factors that concurrently serve to impact sleepiness include prior amounts of sleep, the 
point in the circadian phase, the amount of time spent waking, age, health status, context, 
and recent drug use (Moorcroft, 2003).  
As a person begins transitioning into stage I sleep, certain polysomnographic 
signs are notable.  For instance, EOG readings of slow eye movements, along with EEG 
readings of alpha waves (i.e. moderate intensity, intermediate frequency brain waves that 
occur in persons who are awake yet drowsy) and then theta waves (i.e., moderate to low 
intensity, intermediate frequency brain waves occurring in sleeping individuals) indicate 
entry into this initial sleep stage (Moorcroft, 2003).  The presence of K-complexes (i.e., 
waves lasting approximately ½ second, exhibited on polysomnography as large peaks 
followed by small valleys) or spindles (i.e., moderately fast and intense oscillations 
lasting approximately ½ to 1 ½ seconds) on EEG readings, along with the absence of eye 
movements indicates a movement into stage II sleep. Once the large and slow delta 
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waves (i.e., brain waves that are intense and of low frequency) are noted in the EEG, 
stage III sleep, or the beginning of SWS, has commenced.  After approximately 30 
minutes of SWS, an individual typically will drift back into stage II sleep, exhibiting the 
characteristic stage II K-complexes, spindles, and theta waves for 20 minutes or so, and 
then re-enter SWS (Moorcroft, 2003; Schenck, 2008).  
As an individual enters this NREM sleep (i.e. stages I-IV sleep), neurons are 
operating at a lower activity and metabolic rate relative to waking levels (Moorcroft, 
2003).  Brain feedback systems continue to interact and maintain bodily stability, yet at a 
lower level as well.  These effects are partially a consequence of the actions of certain 
parts of the brain (e.g., basal forebrain and thalamus) using inhibitory neurotransmitters 
and neuromodulators to reduce forebrain activity (Moorcroft, 2003).  The 
parasympathetic nervous system (PNS) is predominant during NREM sleep, maintaining 
the body‟s resources and conserving energy in a restful manner (Moorcroft, 2003).  The 
heart rate is slower and blood pressure is lower.  With the exception of those areas 
responsible for NREM sleep, most brain areas are receiving less blood flow than during 
the waking state (Moorcroft, 2003).  Rather than behaviorally controlled, breathing is 
automatic and serves to regulate oxygen and carbon dioxide levels in the blood, albeit at 
levels that deviate somewhat from the waking state (i.e., less oxygen and more carbon 
dioxide in the blood).  Less air is leaving and entering the lungs each minute, and airflow 
resistance increases. Breathing, therefore, requires extra effort relative to waking, yet is 
deeper overall (Moorcroft, 2003).  The body temperature drops during sleep onset, with 
the body temperature reaching its nadir approximately six hours following sleep onset.  
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The body continues to regulate its temperature by means of blood flow in the same 
manner as during the waking period.  Overall, the NREM state might best be described as 
restorative and calm, with systems continuing to function but on a lower and slower level 
(Moorcroft, 2003). 
Approximately 80 minutes following sleep onset, however, signs of the first REM 
sleep appear, and the aforementioned patterns and system functioning changes.  
Specifically, during REM sleep, (i.e., the stage during which dreaming predominantly 
occurs), EEG readings denote sawtooth-appearing brain waves (i.e. mixed frequency, low 
intensity waves having a notched appearance); EOG readings demonstrate bursts of eye 
movements; and EMG readings denote a low degree of muscle contraction and tension 
(Moorcroft, 2003).  Both tonic (i.e., constant) and phasic (i.e., short-lived) aspects of 
REM sleep can be noted.  As opposed to the slower, yet regular, functioning of the bodily 
systems in NREMS, irregularity characterizes REM sleep (Moorcroft, 2003; Schenck 
2008).  
Certain parts of the brain, including the back of the pons, midbrain, thalamus, 
temporal and occipital cortical lobes, and parts of the limbic system, are activated to a 
greater extent in REMS than during waking states, and specific neuronal activity patterns 
occur that do not otherwise occur in waking (Moorcroft, 2003).  The pons is the section 
of the brain that is essential for REMS.  Specifically, the REM-on cells within the pons 
interact with midbrain, medulla, and hypothalamus cells by means of specific 
neurotransmitters (i.e., acetylcholine, GABA, glycine, and glutamate) to produce both the 
tonic and phasic aspects of REM sleep. An example of one of the primary tonic aspects 
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of REMS is muscle paralysis.  Although motor impulses from the forebrain continue, 
actual muscle movements are blocked by means of glycine originating from neurons in 
the medulla (Moorcroft, 2003).  This temporary muscle paralysis prevents individuals 
from acting on or responding to their vivid, seemingly real dreams.  In a similar manner, 
lower sections of the brain (i.e., the brainstem) override local reflexes that are operating 
the bodily systems, ultimately not taking into account or acting on the sensory 
information received from these systems throughout this stage (Moorcroft, 2003).  
This irregularity and lack of responsiveness to sensory stimuli is underscored 
further with an examination of the functioning of many of the major organ systems 
during the REM sleep. Many central nervous system neurons are more metabolically 
active in the tonic phase of REM sleep than during waking, highlighting the large amount 
of mental activity that is truly occurring during this time.  Blood flow increases 
substantially in some portions of the brain (especially during phasic stages), with some 
areas receiving 50-200% more blood flow than during waking. Similar to NREM sleep, 
the PNS is dominant during tonic aspects of REM sleep.  The PNS remains active into 
the phasic stages of REM as well, yet the sympathetic nervous system (SNS) (i.e. the 
“fight or flight” response that dominates during threats to bodily integrity) sporadically 
activates certain organ systems in an intense manner as well (Moorcroft, 2003).  During 
the phasic components, neurons exhibit bursts of sporadic activity in certain brain areas, 
including the visual areas (Moorcroft, 2003).  Heart rate and blood pressure during tonic 
REMS are slow and low, respectively, and are much less responsive to the blood flow 
demands of the various organs (Moorcroft, 2003).  In phasic REMS, both the heart rate 
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and blood pressure are highly variable, with increases and pauses.  In general, an 
individual‟s blood pressure is much higher during phasic REMS, sometimes 30% higher 
than baseline (Moorcroft, 2003).  Breathing in REMS is fast, variable, and irregular 
(Moorcroft, 2003).  Input and output levels of oxygen and carbon dioxide are largely 
disregarded, and breathing is predominantly behavioral (rather than automatic).  Finally, 
rather than making slight adjustments to regulate the internal body temperature during 
REMS, the body simply adjusts to its surrounding context. The temperature of the brain 
increases due to the higher levels of brain activity (Moorcroft, 2003).  
In summary, the majority of the bodily systems are not strictly regulated during 
REM sleep, and there is a general disregard of or reaction to feedback relative to bodily 
fluctuations (Moorcroft, 2003).  Unlike the previous sleep stages, REM sleep is not 
restful and restorative, nor are bodily systems operating in a routine fashion.  Rather, 
variability and irregularity are the temporary norm.  As a consequence, some argue that 
the body‟s welfare is somewhat jeopardized during this sleep phase (Moorcroft, 2003).  
Aside from rest and restoration, however, some of the many hypothesized benefits gained 
from this unique sleep stage include memory consolidation, the stimulation and 
maintenance of synaptic connections, and emotional regulation following the processing 
of dream content (Moorcroft, 2003). 
Throughout the night, the sleep stages will continue to cycle in a lawful pattern, 
yet the time allocations for each vary.  For instance, more SWS occurs in the beginning 
of the night relative to REM sleep (Moorcroft, 2003).  As the sleep period extends, the 
REM periods increase progressively, from approximately one to two minutes early in the 
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sleep cycle to about 30 minutes towards the end of the night.  Cutting sleep periods short 
will, then, reduce the amount of REM sleep (Moorcroft, 2003).  Reducing sleep periods 
significantly and habitually may also result in other adverse effects on the body and 
performance, highlighting the strong relationship between sleep and health.  
Effects of sleep on the body.  Naiman (2006) argued that deep sleep attainment 
is one of the most important investments in our strivings toward optimal health.  Much of 
our knowledge relative to the essential functions of sleep comes from investigations in 
which sleep has been restricted or altogether deprived in subjects.  The effects of such 
deprivation include impacts on immune functioning, metabolism, psychological states, 
and central nervous system regulation (Weinhouse & Schwab, 2006), thereby 
underscoring the multidimensional impact and importance of sleep. 
Although some evidence exists that contradicts the notion that rest and restoration 
are primary functions of sleep, one of the longstanding notions is that sleep is “a time of 
quiescence when the body appears to be able to generally reverse the wear and tear 
accumulated when awake” (Moorcroft, 2003, p. 268).  A certain amount of continuous 
sleep containing both SWS and REM sleep must occur, however, in order to acquire 
these proposed beneficial effects (Moorcroft, 2003).  This concept that sleep has a 
restorative function is supported by level of hormone release.  Many hormones, including 
human growth hormone (GH) and the anabolic hormones prolactin, leutenizing hormone, 
and testosterone, reach their highest levels during sleep (Moorcroft, 2003).  GH, released 
largely in SWS, plays a key role in many biological processes, including immune system 
functioning, the cellular absorption of nutrients, as well as healthy weight and lean 
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muscle mass maintenance (Naiman, 2006).  Melatonin, which also reaches its peak 
during sleep, enhances immunity and offers antiviral and anti-cancerous protection as 
well (Naiman, 2006).  The reduced activity levels, energy use and body temperature 
experienced during sleep also contribute to the restorative effect of sleep on the body 
(Moorcroft, 2003).  
Sufficient amounts of sleep may be necessary for the maintenance of mental 
health as well.  In their research with rodents, Novati et al. (2008) found that chronic 
sleep deprivation may contribute to the development of symptomology that is 
characteristic of psychiatric disorders, including depressive symptoms.  Specifically, 
Novati et al. (2008) employed an animal model of sleep restriction and investigated the 
subsequent impacts on the neuroendocrine and neurobiological systems believed to have 
a contributory role in the development of depressive systems (i.e., the serotonergic 
system and the hypothalamic-pituitary-adrenal (HPA) axis).  Blood samples were drawn 
from the rodents who were permitted only four hours of sleep per nychthemeron, and 
special attention was paid to the adrenocorticotropin (ACTH) and corticosterone 
responses (Novati et al., 2008).  The researchers found no significant impact on HPA axis 
stress reactivity after one day of sleep deprivation.  Following a week of chronic 
deprivation, however, Novati et al. (2008) noted a diminished pituitary ACTH response 
in a fear paradigm, potentially due to lowered sensitivity of serotonin-IA receptors and 
corticotropin-releasing hormone receptors.  Novati et al. (2008) concluded that habitual 
sleep deprivation may precipitate alterations in neurotransmitter receptor systems and 
neuroendocrine reactivity, as seen in individuals exhibiting depressive symptoms.  In 
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summary, although commonly conceptualized as a symptom of a psychiatric disorder, 
disrupted or habitually diminished sleep also may serve as a precipitating factor in the 
development of subsequent problems (Novati et al., 2008). 
In addition to recuperation and the maintenance of mental health, numerous other 
major functions of sleep have been proposed.  Researchers have offered evidence 
suggestive of specific benefits to the brain and local cells, memory consolidation, and 
even emotional benefits afforded by the act of dreaming (Moorcroft, 2003).  The 
exploration of each of the aforementioned benefits as it applies to the general population 
is beyond the scope of this dissertation.  It is important to realize their relationship to 
sleep and the fact that certain populations may experience fewer of these benefits, as their 
sleep periods are more frequently interrupted and their sleep quality is reduced. 
Effects of the body on sleep.  While sleep impacts human functioning, many 
aspects of human functioning, whether endogenous, self-induced, or contextual, also have 
the ability to impact sleep quality.  That is, the relationship between the body and sleep is 
mutually influential.  The list of potential variables impacting sleep is extensive, yet a 
few that are particularly salient to cancer populations include age, stress, pain, medication 
intake and health status.  
Age is an example of an endogenous variable that has relevant implications for 
sleep. From newborns and small children, to teenagers, to young adults, to middle-aged 
and elderly adults, noteworthy sleep changes are typical with age (Moorcroft, 2003).  
Although individual variation abounds relative to these changes, many individuals who 
are diagnosed with cancer in middle- to late-age already may have noticed changes in 
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their sleep irrespective of their cancer diagnoses.  Common age-related sleep changes 
experienced by those in later stages of life include difficulty with sleep onset and both 
longer and more common nighttime awakenings (Moorcroft, 2003).  Sleep tends to be 
lighter and more parceled.  Likewise, sleep disorders and many illnesses become more 
common with age, increasing the likelihood of interrupted sleep due to the disorder itself 
or the prescribed medication (Moorcroft, 2003).  Circadian rhythms tend to phase 
advance as well, with the desire to sleep and rise both coming earlier (Moorcroft, 2003).  
The sum of total nighttime sleeping hours is typically reduced to six or seven hours, 
although the inclusion of daytime naps might make sleeping more evenly spaced 
throughout the nychthemeron and leave the total sum of sleeping hours in a given time 
period the same (Moorcroft, 2003).  Finally, the examination of polysomnography 
readings reveals a reduction in SWS, a reduced intensity of delta waves, and a reduction 
in the total number of REMS in a sleep period (although the same amount of total REM 
time) (Moorcroft, 2003).  Age range alone, then, irrespective of health status, is 
associated with significant changes in sleep across the lifetime. 
Stress and recurrent nightmares also have the potential to impair sleep. Whether 
transitory or chronic, stress is disruptive to sleep, causing sleep fragmentation and altered 
amounts of time spent in the various sleep stages (Moorcroft, 2003).  Racing thoughts 
characteristic of anxiety may prevent or greatly postpone sleep until the underlying issues 
are worked through or dissipate on their own (Naiman, 2006).  The increase in numerous 
stress-related hormones, including adrenal cortical tropic hormone and cortisol, as well as 
the negative impacts of stress on the immune system can lead to further sleep 
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fragmentation.  Additionally, high levels of stress and troubling experiences often prove 
inescapable during sleeping hours, symbolically presenting themselves, either 
thematically or in full, in recurrent dreams (Moorcroft, 2003).  Following traumatic 
situations, individuals may continue to re-experience their respective trauma in 
nightmares that are even more invasive or panic-inducing than more banal nightmares 
(Moorcroft, 2003).  Associated with such dreams or nightmares are augmented levels of 
stress, anxiety or depression, traumatic nighttime awakenings, and even phobias related 
to sleep (Moorcroft, 2003). 
Individuals experiencing pain or taking non sleep-related medications also may 
experience impaired sleep.  In a cyclical fashion, sleep affects one‟s subjective 
experience of pain, while pain, in turn, impacts sleep quality (Moorcroft, 2003).  
Specifically, high levels of pain may make sleep disruption and impairment more 
probable, while reductions in sleep are associated with higher subjective ratings of pain. 
Similarly, bodily inflammation, a common condition in many diseases and disorders 
(e.g., digestive reflux, breathing and limb disorders), frequently prevents the host‟s body 
from cooling and resting sufficiently to sustain deep sleep (Naiman, 2006).  Individuals 
who are in pain also commonly find themselves in a hospital environment where they 
encounter nightly disturbances, noises and bright lights that serve to further impair sleep 
quality (Moorcroft, 2003).  
Further, prescription medications taken for non-sleep related conditions, including 
pain, often impact the brain in ways that effect the sleeping and waking cycle as well 
(Moorcroft, 2003).  Common culprits that impact the sleep/wake cycle include 
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medications frequently prescribed for depression, anxiety, cardiovascular concerns, 
breathing disorders, schizophrenia, allergies (i.e. antihistamines), pain relief and nasal 
congestion (Moorcroft, 2003).  Often, these medications are effective at relieving 
symptoms of the conditions for which they were prescribed, yet side effects may include 
impacts on the sleep/wake cycle.  Often, concomitant with this reduced sleep quality is an 
awareness of more pain or discomfort, thus creating a negative cycle.  
Sedative-hypnotics, or sleeping pills, also may affect the sleep cycles.  In hopes of 
being able to fall sleep faster or maintain sleep periods without disruption, many 
individuals who experience pain, stress or interrupted sleep turn to sleeping pills to 
compensate for any lost sleep or sleep that they feel they are unable to acquire naturally. 
Three classes of drugs currently are approved for treatment of insomnia, including the 
non-benzodiazepines (e.g., zolpidem), the benzodiazepines (e.g., temazepam), and a 
melatonin receptor agonist (i.e., ramelteon) (Schenck, 2008).  In addition, dietary 
supplements and herbal remedies (e.g., kava and valerian) are commonly utilized, yet 
their lack of regulation by the Food and Drug Administration (FDA) indicates a general 
lack of standardization relative to dosages and manufacturing.  Schenck (2008) noted that 
the FDA-approved classes of drugs approved for the treatment of insomnia are a helpful 
component of sleep therapy treatment, given that patients are appropriately diagnosed and 
are followed routinely.  For instance, Schenck (2008) listed the rapid absorption, the 
dearth of active metabolites, the relatively low potential for abuse or side effects, the 
extensive research basis and his personal clinical experience with the non-
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benzodiazepines in support of their use, alongside talk therapy, in the treatment of 
individuals with insomnia.  
Acknowledging their utility in a short-term context with certain populations, 
Naiman (2006), on the other hand, underscored the many factors that contribute to the 
overuse and abuse of sleeping pills within society.  Among others, the misinformed belief 
that sleep is synonymous to unconsciousness augments the desire of individuals to knock 
themselves out with what Naiman (2006) referred to as magic bullet pills (i.e., sleeping 
pills).  Disregarding the intricacies of the sleep/wake cycle, the benefits gained from 
cycling through each of the respective sleep stages in a natural way, as well as the 
lifestyle factors, cognitions and underlying anxieties that are sustaining sleeping 
problems, humans in need of fast fixes are quick to undermine their own autonomy.  
Rather than follow their own circadian cycle or make the effort to discern which lifestyle 
factors are hindering their sleep, they seek these sleeping aides.  Unfortunately, “most 
[sleeping pills] are more like the scatter of shotgun pellets that take broad aim at 
wakefulness but simultaneously hit and damage deep sleep and dreaming in the process” 
(Naiman, 2006, p. 85).  In addition to the residual drowsiness and cognitive impairments 
often experienced in the next waking period, many sleeping pills increase time spent in 
the lighter, stage II sleep and reduce time spent in SWS and REM sleep (Naiman, 2006).  
Natural sleep with the appropriate allocation of time spent in each stage is therefore not 
restored with these pills; a state of unconsciousness is simply induced (Naiman, 2006).  
Awakenings may still occur, yet patrons often feel like they awakened less on account of 
their amnesia for the events.  Dependency, habituation, and rebound effects are all 
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common as well (Naiman, 2006).  Further, Naiman (2006) eloquently argued that the 
overarching problem with sleeping pills is their attempt to cure sleeping ills without due 
consideration of the individual‟s holistic life context.  Biological and psychological 
factors, internal rhythms, and lifestyle choices are disregarded.  
In summary, sedative-hypnotics may be appropriately or inappropriately utilized 
by individuals desiring to acquire more sleep.  Either way, the body on sedative-
hypnotics during sleep is different from the same body free of sedative-hypnotic 
metabolites during sleep.  
Illness also affects sleep patterns.  When illness is looming, the desire to sleep 
increases, often serving as an advanced warning that the body is combating an infection 
(Moorcroft, 2003).  Depending on the type of bacteria, the nature of the host‟s current 
immune system, and the point of entry of the respective bacteria, many changes in sleep 
may be anticipated during a bacterial infection.  As bacteria enter the host, white blood 
cells (i.e., macrophages) assail and engulf the bacteria then subsequently excrete certain 
chemical components (i.e., muramyl peptides) that were actually part of the cell walls of 
the bacteria (Moorcroft, 2003).  The release of these peptides initiates biochemical 
processes that precipitate fever, immune responses, and increased levels of cytokines 
(e.g., interleukin-1B) (Moorcroft, 2003).  These cytokine levels constantly play a role in 
sleep, as the body is always combating bacteria that is present in the gastrointestinal tract, 
yet they are simply elevated when more bacteria enters the host (Moorcroft, 2003).  As 
these cytokine levels increase, feelings of sleepiness and levels of NREM sleep increase, 
while the amount of REM sleep decreases.  Specifically, levels of SWS and delta waves 
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increase around the height of, and immediately following, the infection, followed by 
significantly lower levels a few days later (Moorcroft, 2003).  Infections caused by fungi, 
viruses or protozoans precipitate similar effects.  Although more research is warranted as 
to the specific function of these sleep changes surrounding illness, Moorcroft (2003) 
stated it is probable that the additional amounts of SWS permit the allocation of more 
resources to healing and the febrile state and to the reduction of the swell of infection.  
Sleep deprivation.  Regardless of the specific etiology, depriving subjects of a 
sleep state has ramifications.  Constant, sustained deprivation of deep sleep in animals 
leads to illness and ultimately death (Naiman, 2006), further underscoring the strong 
relationship between sleep and health.  Unfortunately, even multiple nights of partial 
sleep deprivation will lead to effects that resemble total sleep period deprivation and a 
subsequent vengeful rebound of sleep.  Although recovery from sleep deprivation can be 
achieved in a fairly fast and efficient manner, the characteristics of sleep in nights 
following such deprivation will be altered (e.g., higher sleep efficiency and more REMS 
earlier in the night (Moorcroft, 2003).  Those who continue to struggle to achieve 
restorative sleep may experience a plethora of side effects.  The salience of these sleep 
deprivation effects may ebb and flow, depending on numerous factors, such as 
environmental stimuli, reinforcement, and ingestion of substances that attenuate the 
effects, yet the intensity of the numerous impacts of sleep deprivation will continue to 
increase as the level of sleep deprivation rises (Moorcroft, 2003).  Moorcroft (2003) 
described these widespread effects and categorized them as behavioral, biological, 
cognitive, and subjective. 
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Among others, the biological impacts of sleep deprivation may include itchy eyes, 
tremors, weight gain, a decrease in body temperature, droopy eyelids, heart palpitations, 
alterations in hormone levels, and a significant impact on immune system functioning 
(Moorcroft, 2003).  Haack, Sanchez, and Mullington (2007) investigated the relationship 
between sleep deprivation, pain, and inflammation in a randomized, 16-day controlled in-
laboratory study.  By randomizing 18 volunteers to either 12 consecutive days of sleeping 
eight or four hours per night, Haack et al. (2007) were able to examine the effects of 
reduced sleep duration on peripherally circulating inflammatory mediators and the 
relationship between the degree of inflammation and the increase in level of pain 
following reductions in sleep periods.  Throughout the experiment, participants 
completed measures related to their mood, tiredness-fatigue, and pain symptoms, while 
the experimenters collected periodic blood and urine samples to assess levels of plasma 
interleukin (IL)-6, serum C-reactive protein (CRP), metabolites D2 and E2, plasma 
soluble tumor necrosis factor receptor p55 (sTNF-R p55), and urinary levels of 
prostaglandin (PG).  Haack et al. (2006) found IL-6 levels were significantly elevated in 
the four hour sleep condition group relative to the eight hour condition (p < 0.05), and 
these elevated IL-6 levels were strongly associated (r = 0.67; p < 0.01) with greater pain 
ratings following sleep period reductions.  Tiredness or fatigue did not better account for 
these findings. The researchers concluded that significant reductions in sleep cause 
elevations in IL-6 levels that, in turn, facilitate or augment pain levels.  In individuals 
with existing diagnoses or disorders, these reductions in sleep alone may maintain 
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increased pain and inflammation levels (Haack et al., 2007), therefore making sleep an 
appropriate area to target for symptom reduction interventions. 
Additionally, sleep deprivation may lead to a subjective sense of lethargy, 
anhedonia, irritability, paranoia, negative mood and a sense of loss of control (Moorcroft, 
2003).  Cognitive impacts of sleep deprivation also are apparent, and examinations of 
functional imaging of the brain demonstrate differences in patterns of brain activity 
following deprivation (Moorcroft, 2003).  Relative to mental impacts of sleep reduction, 
the following may be prevalent: impairments in concentration, reductions in reaction 
times, short term memory capacity, mental flexibility, integrative ability and originality, 
increased indecisiveness, perceptual distortions or hallucinations, impairments in logical 
reasoning in the context of complicated problem solving, and blunders in consciousness 
(Moorcroft, 2003; Schenck, 2008).  Likewise, Caplette-Gingras, Savard, Ivers, and 
Savard (2009) reported significant impairments in episodic memory in breast cancer 
patients with insomnia treated with chemotherapy, radiation therapy or surgery and 
actively receiving hormone replacement therapy relative to breast cancer patients with 
similar treatments yet who are considered good sleepers (F(1,64) = 7.68, p < 0.01).  Sleep 
deprivation appears to impact to a greater extent tasks requiring mental effort, rather than 
those demanding strictly physical effort (Moorcroft, 2003), yet physical tasks may seem 
more difficult and demanding with sleep deprivation.  Behaviorally, sleep deprivation 
may lead to clumsiness, reduced psychomotor abilities, reduced vigilance and 
spontaneity, less of a drive to socialize and microsleeps (i.e., brief lapses of attention that 
occur more frequently as level of sleep deprivation increases) (Moorcroft, 2003).  
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Without external reinforcement or stimulation, these microsleeps occur more frequently, 
leading to brief lapses during the respective activity that is occurring at the time.  If these 
microsleeps occur during high risk activities (e.g., driving), the ramifications can be 
severe. 
This brief review of the potential implications of sleep deprivation highlights its 
potentially severe and far-reaching implications.  In a population whose members are 
already struggling with numerous life and physical hurdles (such as cancer patients), 
more challenges may be confronted when trying to enter and maintain the sleeping state, 
and the impacts of such sleep deprivation may be even more devastating.  A review of the 
sleep quality of cancer survivors will highlight what is known about the sleep of these 
individuals. 
Sleep Quality of Cancer Survivors 
Many medical conditions are associated with irregularities in sleep that may, in 
turn, heighten the perceived severity of the symptoms of the medical condition (Parish, 
2009).  Numerous researchers have examined the prevalence of disruptions in the 
sleep/wake cycle in cancer patients in particular.  In a systematic assessment, Berger et 
al. (2007) reported that 30-50% of adults with cancer have sleep disorders- a prevalence 
that is two times that of the general population.  Kozachik and Bandeen-Roche (2008) 
reported that pain, fatigue and insomnia are some of the most widespread, distressing, 
and undermanaged symptoms that cancer patients experience.  In an investigation of 752 
cancer patients from three states who had been given a diagnosis of one of the ten most 
common cancers, Baker et al. (2005) found that 47.9% of participants reported 
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experiencing sleep difficulties, while 67.1% reported reductions in strength and fatigue 
(more noticeable in those who received chemotherapies).  Parish (2009) noted that those 
who are currently receiving or recently completed therapies for cancer treatment often 
experience numerous nighttime awakenings, insomnia, extreme fatigue and 
hypersomnolence.  Weinhouse and Schwab (2006) described the sleep of critically ill 
patients as severely fragmented, riddled with more awakenings, and consistent of more 
stage I sleep, rather than stages II, III, IV and REM sleep.  Likewise, the total hours of 
sleep per nychthemeron may approach that of healthy individuals, yet these hours are 
typically more parceled throughout the day and night by means of periodic napping 
(Weinhouse et al., 2006).  Numerous factors, including their medical illnesses, 
psychological stress, immediate surroundings (e.g., the lights, noises, and constant 
tending characteristic of the intensive care unit), medications and treatments may have 
contributory roles in this reduced sleep quality.  
Similarly, Kvale and Shuster (2006) noted that a cancer diagnosis and treatment 
place survivors at an increased risk for disruption of the sleep/wake cycle.  Specifically, 
behavioral disruptions of one‟s normal routine (e.g., more time in bed or in the hospital, 
less daytime activity) increase the odds of disruption in the sleeping cycle; discomfort, 
physical symptoms and pain often combine to impact sleep onset and maintenance; 
reduced lung capacity or neoplasms may impact respiratory functioning; symptoms of 
depression or anxiety may serve as additional psychosocial concerns and sources of 
stress; and individuals who are immune-suppressed as a consequence of advanced disease 
or treatment may have organic disruptions of their sleep/wake cycles as well (Kvale & 
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Shuster, 2006).  As more individuals survive cancer and live with pathologic and 
treatment effects, the importance of pinpointing, targeting and even preventing all 
lingering effects, including sleep disruptions, becomes all-the-more important (Baker, 
Denniston, Smith, & West, 2005).  With a primary focus of quality of any remaining life 
in palliative medicine (Kvale & Shuster, 2006), sleep disruptions have implications that 
are too vast to be ignored. 
In a recent study, Fernandes, Stone, Andrews, Morgan, and Sharma (2006) 
compared the sleep disturbances, fatigue, and circadian rhythms in 25 female cancer 
patients with those of 25 healthy controls by means of subjective (i.e., self report 
instruments) and objective (i.e. wrist actigraphs, or “small piezoelectric accelerometers 
that are worn on the wrist…[to] detect movement of the limb and then summarize the 
data in 1-minute epochs” (p. 247)) measures.  Compared to the healthy controls, cancer 
patients tended to be less active during the day, more active at night, have less marked 
circadian rhythms, more fatigue, poorer sleep quality and overall lower quality of life 
(Fernandes, 2006).  All actigraphic parameters (i.e., mean activity levels, sleep periods, 
sleep efficiency, sleep latency, and awakenings after onset), with the exception of sleep 
latency, were significantly different between the patients and controls as well. Within the 
cancer group, estimates of fatigue were associated with reductions in QOL, self-reported 
physical functioning, constipation and depression.  In their small sample, Fernandes et al. 
(2006) concluded that, relative to controls, many cancer patients have both verifiable 
impairments in sleep and changes in circadian rhythms that can potentially lead to QOL 
impairments.  
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Savard and Morin (2001) underscored the prevalence and general neglect of one 
sleeping problem in particular, insomnia, within the cancer population.  Finding that 
symptoms of insomnia are prevalent in the two to five years following treatment, Savard 
and Morin (2001) concluded that symptoms of insomnia develop a chronic course in a 
large percentage of cancer survivors.  The etiology of these symptoms may be classified 
as predisposing factors (i.e., existing traits that increase an individual‟s likelihood of 
developing insomnia, such as aging, the presence of a psychiatric disorder or a familial 
history of insomnia), precipitating factors (i.e., contextual conditions that lead to the 
onset of insomnia), and perpetuating factors (i.e., variables that contribute to the 
maintenance of symptoms) (Savard & Morin, 2001).  When reviewing many studies, it is 
difficult to discern whether symptoms of insomnia are the manifestation of variables that 
were already in existence prior to the cancer diagnosis or treatment (i.e., predisposing 
factors), or whether the sleep/wake disturbances truly originated following the cancer 
diagnosis or treatment (i.e., precipitating factors).  Such precipitating factors that may be 
associated with insomnia in a cancer-context include psychological reactions to the 
diagnosis itself, physical effects of the various oncologic treatments, hospitalization, pain, 
effects of medications, and delirium, among others (Savard & Morin, 2001). The 
presence or absence of perpetuating factors within this population (e.g., chronic pain, 
maladaptive beliefs about sleep or poor sleep hygiene) will then determine if this 
insomnia becomes a chronic problem. Of those who experience chronic insomnia, many 
report that their inability to sleep negatively impacts their ability to cope with stress, 
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emotionality, concentration, sense of physical wellness, and their daily functioning 
(Parish, 2009).  
It is apparent, then, that vast numbers of cancer patients struggle with sleep 
disturbances and disorders.  Yet these disruptions often are not the focus of targeted 
interventions (Berger et al., 2007).  Interestingly, Homsi et al., (2006) reported that 
patient reports and patient assessments do not always yield comparable results.  
Specifically, while controlling for race, gender and age, Homsi et al. (2006) found that 
the median number of symptoms indentified via the systematic assessment of patients 
was ten times higher than the number of symptoms volunteered by the same patients (p < 
0.001). Specifically, within a sample of 265 patients who were referred to the palliative 
medicine department, 322 symptoms were volunteered, while an additional 2075 
symptoms were pinpointed via systematic assessment.  While pain was volunteered the 
most, fatigue was the symptom most commonly identified by systematic assessment 
(Homsi et al., 2006), suggesting an underreporting of specific types of symptoms. 
Overall, insomnia was one of the ten most common symptoms within this sample. 
Interestingly, only 2.5% of the participants readily volunteered concerns related to 
insomnia.  When systematically assessed, 40.5% revealed that they were struggling with 
insomnia (Homsi et al., 2006).  Relative to bad dreams, 1.0% voluntarily revealed that 
they were experiencing bad dreams, while 6.0% revealed this problem when assessed 
systematically.  Homsi et al. (2006) concluded that some symptoms are more likely to be 
volunteered than others, and a thorough assessment is necessary for a detailed 
understanding of the patient‟s status.  It seems, then, that concerns related to sleeping are 
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prevalent within the cancer population, yet patients may not readily volunteer these 
concerns.  It is possible that patients believe that other concerns are more salient or 
pressing relative to their medical health.  Accordingly, systematic assessment of sleep-
related concerns may be needed (Homsi et al., 2006). 
This adequate assessment of sleep disturbances and sleep quality does not occur, 
however, with only one question or one sleep parameter (Berger et al., 2007).  In other 
words, while measurement may take many forms, including those that are objective (e.g., 
wrist actigraphs or polysomnography) or subjective (e.g., self report, sleep 
questionnaires, sleep scales on QOL questionnaires or sleep diaries) in nature, accurate 
measurement of sleep disturbance and sleep quality must be multidimensional (Berger et 
al., 2007).  Although disagreement exists as to what these parameters should definitively 
be (Berger et al., 2007), professionals concur that there should be many holistic 
dimensions accounted for in this assessment.  
Unfortunately, in a systematic review of current methodological approaches 
utilized to study sleep disturbances in adults with cancer, Berger et al. (2007) did not find 
many studies in which the researchers were compliant with these suggestions.  
Specifically, Berger et al. (2007) systematically searched for studies (descriptive or 
interventional in nature) written in English between January 1, 1995- January 30, 2005 in 
which the longitudinal collection of both sleep and QOL data (a minimum of two time 
points) in adult cancer patients by means of psychometrically sound instruments were 
detailed.  Of the 40 studies that met their inclusion criteria, only four utilized a multi-item 
sleep-specific instrument, and only six employed more than a single item to assess sleep.  
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Many studies considered sleep to be a secondary or ancillary analysis.  These findings 
elucidate the low methodological quality of many sleep studies and the general infantile 
state of this collective body of research in general (Berger et al., 2007).  Single item 
questions related to sleep insufficiently assess and capture the quality of this intricate 
process or its associated effects (Berger et al., 2007; Fernandes et al., 2006). 
Many other variables in combination may serve to keep sleep disturbances from 
being assessed and included in interventions.  Many patients may not believe that sleep-
related concerns are true medical conditions or worth the precious discussion time at a 
doctor visit.  Likewise, many medical doctors may feel ill equipped to broach the subject 
or may lack sufficient time to comprehensively assess the nature of their patients‟ sleep.  
Sleep-related concerns and their vast implications may then go untreated, further 
complicating the healing process.  Collectively, the aforementioned reviewed findings 
reveal that sleep disturbances and the connected impediments are among the most 
common symptoms experienced by cancer patients during all phases of care, yet they 
have traditionally received minimal attention and few efforts at targeted improvement 
from clinicians and researchers within the oncology community (Berger et al., 2006; 
Savard & Morin, 2001).  
Sleep quality of CS+HIPEC recipients.  The sleep quality of CS+HIPEC 
recipients has received even less attention from researchers. In a review of the literature 
regarding members of this population, only one article was located that focused on a 
concern potentially related to sleep impairment.  Anderson and Hacker (2008) explored 
the literature and hypothesized potential contributing factors to fatigue within women 
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with stage III or IV ovarian cancer who are receiving intraperitoneal (IP) chemotherapy.  
In addition to surgical variables, the effects of the IP chemotherapy, pain, anemia, 
gastrointestinal disturbances and emotional distress, Anderson and Hacker (2008) stated 
that sleep disturbances may be precipitating factors for fatigue.  It is important to note, 
however, that no empirical studies of sleep quality among CS+HIPEC patients were 
located.  To better understand the true sleep disturbances and their ancillary effects within 
this population of CS+HIPEC recipients, more assessment and data collection needs to 
occur. 
 In conclusion, sleep is an essential process that provides important biological and 
psychological benefits to its host.  Unfortunately, individuals with chronic illnesses, 
including cancer patients, remain sleep deprived on account of the combination of 
biological, physiological, medicinal, environmental or psychological factors.  A paucity 
of investigators have examined the multidimensional construct of sleep quality in cancer 
patients, and even fewer have examined sleep quality in survivors of CS+HIPEC.  
Without such descriptive data, it remains unknown what components of sleep quality are 
most affected in those who had CS+HIPEC, and without this understanding, targeted 
sleep-related interventions are not possible.  Without such psychosocial interventions or 
adjustments, sleep disturbances may become chronic, and other diagnosis- or treatment-
related concerns may be exacerbated.  
 In summary, patients post-CS+HIPEC may be confronting treatment-related 
toxicities, sleep quality impairments, and/or adjustments in any number of dimensions of 
QOL.  A better understanding of how the aforementioned variables are interrelated can be 
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acquired with the support of a suitable biopsychosocial conceptual model of patient 
outcomes, such as the Wilson and Cleary model (Wilson & Cleary, 1995).  In this model, 
variables from a traditional biomedical model and those from a social science paradigm 
are combined so as to integrate these differing models of health and offer causal 
relationships between biological, psychological, and social variables (Wilson & Cleary, 
1995).  
The Wilson and Cleary Model 
Patient outcome measures may take a plethora of forms in the weeks, months, and 
years post-CS+HIPEC.  For example, a CS+HIPEC survivor‟s health team will likely be 
interested in outcome measures pertaining to white blood cell counts, hemoglobin levels, 
and surgical wound appearance (i.e., biological and physiological outcomes), the number 
of bowel movements or episodes of emesis and the presence of any depressive or anxious 
symptoms (i.e., symptom status), the patient‟s ability to ambulate and shower (i.e., 
functional status),  and even her or his own perception of how he or she is faring (general 
health perception), among many others.  By training, individual members of a patient‟s 
multidisciplinary health team often focus on and prioritize one particular category of 
these outcome measures, yet each category of measure has important implications for the 
CS+HIPEC survivor and her or his current health and quality of life.  Likewise, these 
underlying variables represented by outcome measures have causal and bidirectional 
influences on one another, underscoring the need to be cognizant of the impact that 
variables in one category may have on those of another (Wilson & Cleary, 1995).  Mental 
health professionals in any setting are trained to think systemically, looking for 
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relationships, patterns, and activating events in their patients‟ lives. Arguably, such 
interrelationships between levels of patient outcomes are highlighted optimally in patients 
within a medical setting when changes in biological or physiological variables all-too-
often result in symptom reports, impairments in functional status, the development of 
mood disorders, and ultimately a reduced rating of one‟s quality of life.  The positive side 
of these interrelationships between levels of patient variables is revealed, however, when 
interventions designed to target one level of patient outcomes results in a contagion of 
improvement across the remaining levels.  Not surprisingly, mental health professionals 
transitioning into medical settings initially may find this need to broaden their clinical 
conceptualizations and research investigations to include biological or physiological 
variables in addition to the staple psychological and social variables quite challenging. If 
the primary goal of clinical care is to improve the overall outcomes and QOL of patients, 
however, diagnoses and interventions designed to improve these outcomes optimally 
should be built upon a solid conceptual understanding of the causal conduits that network 
the various classifications of patient outcomes (Wilson & Cleary, 1995).  In this 
investigation, consideration is given to the impact of an array of variables, from those that 
are biological and physiological to those psychosocial in nature, on survivors‟ long-term 
QOL.  
Given the numerous relationships that exist between traditional clinical (i.e., 
biomedical) variables and measures of health status (e.g., QOL measures), it is interesting 
that these associations are not well articulated in the existing integrative models and 
theories of patient outcomes (Wilson & Cleary, 1995).  In response, Wilson and Cleary 
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(1995) created a conceptual model that illustrates the relationships of levels of clinical 
variables to such end measures of health-related QOL.  Specifically, these researchers 
combined variables from a traditional biomedical model with those from a social science 
(QOL) model in order to create an integrative model that classifies patient outcome 
measures by means of the basic health concepts they represent. Concurrently, Wilson and 
Cleary (1995) illustrated suggested causal relationships between these levels of measures.  
The measures of health are conceptualized as existing on a hierarchical continuum, with 
biological and physiological measures on one end and increasingly integrated and 
compound measures, such as general health perceptions, on the other end.  If one is going 
to gather QOL information with the end goal of understanding the population and 
creating interventions to target problematic areas, a solid understanding of the 
relationships between the many levels of patient outcome variables is essential so that the 
interventional efforts are appropriately targeted.  The Wilson and Cleary Model (1995) 
provides a framework for understanding these relationships between patient outcome 
measures that assess concepts that are relatively easy to define and appraise (e.g. 
hemoglobin level) and those that are inherently more difficult to define and compute (e.g. 
overall QOL).  This taxonomy of patient outcome measures commences with measures 
pertaining to cell counts or single organ function and continues on to those examining an 
individual in a systemic context.  
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Figure 1. Wilson and Cleary‟s conceptual model (1995) of patient outcomes.  
Copyright circa (1995) American Medical Association 
 
 
Prior to examining the Wilson and Cleary Model (1995) in depth, an examination 
of the two models that were integrated into this one conceptual model serves to 
underscore respective strengths as well as the divergent foci and principles of each.  With 
its foundation in biology, physiology and biochemistry, the traditional biomedical model 
was created in order to investigate the underlying cellular, genetic and molecular disease 
mechanisms (Wilson & Cleary, 1995).  Etiologic agents, processes of pathogenesis, as 
well as physiological, clinical and biological outcomes are the foci (Wilson & Cleary, 
1995).  Primarily via controlled experiments, the predominant goal of those espousing 
this model is to better comprehend causation in order to direct both diagnosis and 
treatment.  On the contrary, with its roots in psychology, sociology and economics, the 
social science (QOL) model focuses on dimensions of functioning, overall well-being, 
and the ways that institutions and social systems impact individuals (Wilson & Cleary, 
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1995).  Researchers utilizing this model attempt to find ways to precisely measure 
composite feelings and behaviors, and genuine experimental designs are much more 
difficult to implement comparatively (Wilson & Cleary, 1995).   
When combining the biomedical and social science models, Wilson and Cleary 
(1995) had many aims, the first being the inclusion and categorization of measures of 
patient outcomes representing variables from both of the aforementioned models.  
Secondly, by illustrating the relationships between these outcome measures that target 
different classes of variables, the researchers hoped to elucidate causal pathways between 
variables, thereby informing conceptualization, diagnosis, treatment, and interventions.  
If social science researchers are gathering QOL data, for instance, the numerous 
pathways of patient variables impacting these QOL scores should be understood.  Finally, 
Wilson and Cleary (1995) desired to create an empirically testable model that is sensible 
and user-friendly for clinicians and researchers alike.   
In the model, the measures of health are depicted on a continuum of increasing 
complexity.  Patient outcome measures representing each of the five categories within the 
model will be collected in this dissertation.  On the far left side are the biological 
measures, while the increasingly integrated measures, such as general health perceptions 
and QOL, are represented on the right (Wilson & Cleary, 1995).  Arrows represent the 
dominant causal associations, yet the absence of an arrow between outcome measure 
categories does not denote an overall lack of a relationship nor does it denote that the 
relationship is strictly unidirectional.  Rather, bidirectional and additional relationships 
beside those depicted pictographically exist as well (Wilson & Cleary, 1995).  A total of 
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five levels of patient outcome measures are portrayed in the model.  Additionally, 
characteristics of both the individual and the environment have the potential to impact 
measures from each level of the model.  These factors are therefore discussed separately.  
Level one consists of biological and physiological variables (Wilson & Cleary, 
1995).  Although the model developers noted that molecular and genetic factors are the 
most basic health status determinants, they decided to make biological and physiological 
variables the initial level of the model, as these are the variables most routinely 
considered and measured in daily clinical work.  Measures pertaining to this category 
provide evidence of the current functioning of the cells, organs, and organ systems within 
an individual (Wilson & Cleary, 1995).  Examples from this level that are pertinent to 
CS+HIPEC survivors include laboratory results (e.g., complete blood cell counts, blood 
gas levels, microbial levels), measures of physiological function (e.g., blood pressure 
readings), or diagnoses (e.g., ovarian cancer with peritoneal metastases).  Specific 
variables from this category that will be used in the analyses for this dissertation include 
age at CS+HIPEC, primary diagnosis, and surgical resection status.  In terms of 
measurement, these patient outcomes are the most straightforward and the easiest to 
measure without the impact of intervening variables.  
In level two, symptom status, the focus broadens from the cells or specific organ 
systems to the holistic individual (Wilson & Cleary, 1995).  Given that many categories 
of symptoms exist (including psychological, physical, and even bio-psychological 
symptoms), Wilson and Cleary (1995) broadly defined a symptom as “a patient‟s 
perception of an abnormal physical, emotional, or cognitive state” (p. 61).  By the time an 
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individual visits a clinician to report a symptom, numerous processes heavily influenced 
by social, cultural, familial, and personal factors, have already occurred, including 
perception of and judgment about the symptom. “Symptom reports, therefore, are 
expressions of subjective experiences that summarize and integrate data from a variety of 
disparate sources,” (p. 61) noted Wilson and Cleary (1995). Inherent complexity 
therefore exists between level one (i.e., biological and physiological) and level two 
(symptom status) variables.  For instance, some severely atypical level one variables may 
go unreported by some people, while others present with intense symptom reports with 
no notable level one variables (Wilson & Cleary, 1995).  Given this complex, often 
inconsistent, relationship between biological or physiological variables and symptom 
reports as well as the additional non-clinical factors likely impacting this relationship, 
Wilson and Cleary (1995) suggested that targeting presumed underlying level one 
variables will not always reduce or altogether remove symptom reports.  Clinicians and 
researchers must examine the other variables potentially impacting these level two 
reports. Some examples of outcome measures of interest in this dissertation in the 
symptom status category include sleep quality and the bodily pain (BP) subscale scores.  
Level three in the model is functional status. Measures pertaining to this level 
capture the ability of an individual to perform a specified task (Wilson & Cleary, 1995).  
Typically, numerous facets of functional status are assessed in these measures, including 
physical, role, social, and psychological functioning (Wilson & Cleary, 1995).  Not 
surprisingly, level one and level two variables are usually associated with level three 
variables.  Likewise, the impact of biological and physiological (level one) variables on 
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functional status (level three) is often mediated by symptom status (level two).  However, 
these relationships are not exclusively explained by these three categories of variables 
(Wilson & Cleary, 1995).  Personal and environmental variables also have contributory 
roles to this functional status.  Further research is needed to elucidate alternate mediating 
variables (Wilson & Cleary, 1995). Pertinent functional status outcome measures in this 
dissertation include scores on the role emotional (RE), role physical (RP), and social 
functioning (SF) subscales as well as the ECOG performance status scores assigned to 
patients by the surgeons. 
The next level in the Wilson and Cleary Model (1995) is general health 
perceptions.  General health perceptions are, by nature, subjective and represent a general 
integration of all of the preceding levels of health concepts, in addition to many others 
(Wilson & Cleary, 1995).  Because of the numerous variables that contribute to one‟s 
health perceptions, a gamut of health perceptions often are noticeable among individuals 
with the same general symptoms, functioning, and overall health status. The general 
health (GH) QOL subscale score utilized in this dissertation is an outcome measure that 
falls neatly within this category. 
Finally, level five of the model consists of patient outcome measures examining 
overall QOL, such as the overall QOL scores obtained from participants by means of the 
SF-36 in this dissertation.  Similar to general health perceptions, QOL measures are 
increasingly complex and difficult to dissect, given the large number of variables 
impacting one‟s perception of her or his QOL.  Additionally, given the adaptability of 
individuals and their tendency to alter both expectations and goals based on changing life 
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circumstances, QOL outcomes may vary over time simply as a consequence of a shift in 
perception (Wilson & Cleary, 1995).  In summary, although associations exist between 
variables represented by the five levels of this model, numerous other intervening or 
confounding variables that cannot be controlled by the clinician or system must be 
considered as one transitions further to the right of the model (Wilson & Cleary, 1995). 
In addition to the five levels of patient outcomes, characteristics of both the 
individual and the environment also are depicted in the model (Wilson & Cleary, 1995).  
Characteristics of the environment that purportedly impact variables at certain levels of 
the model are psychological, economic, and social supports.  Characteristics of the 
individual delineated by Wilson and Cleary (1995) include symptom amplification, 
personality, motivation, values, and preferences.  To illustrate the role of patient 
preferences, Wilson and Cleary (1995) noted that certain symptoms may be preferable 
relative to others for any given individual, and their presence may largely impact general 
health perceptions or QOL (Wilson & Cleary, 1995).  
Finally, not only do psychological and emotional factors have an important role in 
each level of the model (Wilson & Cleary, 1995), but, based on the conceptualization of 
the researcher or clinician and the measure selected to assess the respective psychological 
factor, psychological or emotional variables can be categorized under numerous levels of 
this five-level model.  For instance, a psychological symptom may be considered a 
biological or physiological variable (level one); if a researcher is utilizing a symptom 
measure to assess symptoms of a psychological concern, symptom status (level two) 
might be a more appropriate categorization; or if the researcher is administering a scale 
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that assesses functioning as a consequence of the psychological concern, the measure 
may be considered one of psychological functioning (level three) (Wilson & Cleary, 
1995).  It is this fluid and overarching impact of psychological factors that convinced 
Wilson and Cleary (1995) not to house these factors in one discrete level within the 
model.  In conclusion, even though they are not represented with their own level in this 
model, psychological and emotional factors have the potential to have strong, 
bidirectional associations and causal relationships with variables at each of the five levels 
of the model (Wilson & Cleary, 1995).  
The Wilson and Cleary Model (1995) is useful in both research and clinical work 
involving CS+HIPEC patients. From a research standpoint, the Wilson and Cleary (1995) 
conceptual model informed the design of this investigation and the selection of the 
variables, constructs, and instruments. Specifically, by using the model as a framework to 
unpack the contributions of and causal relationships between the many levels of patient 
outcomes in the context of QOL reports, the investigator was able to make informed 
selections relative to important variables of measurement.  The specific variables of 
interest within the study can be classified into numerous levels across the taxonomy, from 
level one to level five, and the model may have explanatory value relative to the end 
results.  
This integration of outcome measures from varying model categories is illustrated 
in various research questions within the dissertation. For example, the researcher is 
interested in the respective contributions of age at CS+HIPEC and surgical resection 
status (biological or physiological variables) in predicting QOL (the level five, integrative 
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variable) within each of the primary diagnostic groups (biological variable). Relying on 
the model, one can comprehend how variables from intervening levels of patient 
outcomes (i.e. symptoms, functional status, and the patient‟s perception of her or his 
health) may mediate this relationship and how characteristics of the patient or the 
patient‟s environment may augment or diminish the strength of these hypothesized 
relationships.  As an additional example within the proposed study, sleep quality will be 
examined in relation to QOL.  From the model, one can extrapolate that (if categorized as 
an outcome measure pertaining to symptom status), not only should they be related, but 
variables pertaining to functional status (e.g., impaired daytime functioning) and general 
health perceptions may mediate this relationship (Wilson and Cleary, 1995).  Likewise, 
characteristics of the respective patient and the patient‟s environment likely influence 
these relationships.   
In the clinical context with CS+HIPEC survivors, reliance on the conceptual 
model informs systemic thinking and multidisciplinary collaboration, as variables in each 
level of the taxonomy have implications for those in alternate levels and ultimately 
impact overall QOL scores.  Likewise, the model highlights the ways that specific 
characteristics of the individual and the individual‟s environment impact variables in 
each category, encouraging the clinician to include unique patient variables into the 
conceptualization.  A personally-suited, in-hospital psychosocial intervention, for 
example, may serve as the impetus for change across the taxonomy of patient variables. 
Following individual counseling, a CS+HIPEC patient may report improved mood, fewer 
depressive symptoms and a lower perception of pain.  Subsequently, he may begin 
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ambulating and showering, thereby using his muscles, experiencing fewer back sores 
from remaining sedentary, and even socializing occasionally while walking the halls.  As 
he slowly begins using his body, he achieves more restorative sleep at night, during 
which his body is able to devote more energy to healing.  As these subtle improvements 
accumulate, the patient begins reporting enhanced health perceptions and ultimately 
improved quality of life.  By relying on this conceptual framework, the clinician adopts a 
systemic viewpoint to consider how various levels of patient outcomes impact her or his 
targeted variable of interest and may ultimately provide enhanced, holistic clinical care. If 
supported by empirical data, such interventions could serve as the applied end of this line 
research. 
In conclusion, the Wilson and Cleary Model (1995) is an important 
biopsychosocial addition to clinical work and research within a setting in which health 
related QOL is of importance.  It is conceptually suitable to research and clinical work 
with CS+HIPEC survivors, accounting for the many levels of variables potentially 
contributing to overall QOL (as measured by the SF-36 in this dissertation).  
Incorporation of this conceptual model can inform diagnosis, treatment, and 
interventions, as outcome measures pertaining to numerous levels of variables from both 
the traditional biomedical model and the social science, QOL, model are integrated.  
Likewise, the suggested relationships between these variables permit practitioners to 
better understand the overall QOL impact of interventions designed to target variables at 
one of the lower levels in the model (Wilson & Cleary, 2005).    
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Limitations of Research on QOL in Survivors of CS+HIPEC 
 It is evident that reliance upon a conceptual model such as the Wilson and Cleary 
(1995) Model can serve to enhance a practitioner‟s interpretation of information retrieved 
from patient outcome measures.  An additional means of capitalizing upon any retrieved 
patient outcome information is to ensure the methodological integrity of the research.  
Following a review of the QOL studies pertaining to CS+HIPEC survivors, some 
thematic limitations are apparent.  In their recent review of studies pertaining to HRQOL 
and CS+HIPEC, McQuellon and Duckworth (2009) underscored many of these 
limitations in hopes that they will be considered in future studies.  
For starters, only nine studies in which QOL data of CS+HIPEC survivors were 
gathered were retrieved in the literature search for this dissertation.  Within these studies, 
sample sizes were small, thereby limiting generalizations (McQuellon & Duckworth, 
2009).  For example, a total of three cross-sectional studies performed with long-term 
survivors were located.  McQuellon et al. (2003) reported a sample size of 17 out of a 
potential 109 patients treated between January of 1992 and December of 1997, while 
Schmidt et al. (2005) had a sample size of 20 out of a possible 67 patients treated 
between March of 1995 and February of 2003.  With such small numbers, the power of 
analyses performed is weakened, thereby warranting caution upon the interpretation of 
any results.  In the third, and most recent, cross-sectional study located, Zenasni et al 
(2009) reported a sample size of 68, reflecting significant improvement relative to sample 
size.  Within the description of their inclusion and exclusion criteria, however, Zenasni et 
al. (2009) stated that all individuals with recurrent disease or comorbidities were 
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excluded from participation.  The participants in the Zenasni et al. (2009) study, then, 
represent strictly the healthy individuals and the best-case scenarios.  These inclusion 
criteria must be considered upon the interpretation of their results.  
Similarly, sample sizes from the longitudinal studies are relatively small as well.  
McQuellon et al. (2001) commenced their study with 64 participants (baseline), reducing 
to 48 (post-procedure), 41 (three months), 39 (six months), and 31 (12 months).  A total 
of 23 individuals completed all instrument batteries across the time series (McQuellon et 
al., 2001).  In 2007, McQuellon et al. retrieved baseline assessments from 96 persons and 
had 12-month data from only 24 persons.  In alternate longitudinal studies, Tuttle et al. 
(2006) reported a sample size of 35, while Jess et al. (2008) maintained a sample size of 
23.  These small sample sizes reflect high mortality rates, high attrition rates (presumably 
due to recurrence or other complications), and a plethora of missing data, again limiting 
generalization and the power of any analyses.  
The missing data from these studies are likely not missing at random (McQuellon 
et al., 2007).  It is probable that those with the most significant illnesses and debilitating 
symptoms drop out of the research studies.  Of these dropouts, a significant percentage is 
likely experiencing significant psychosocial symptoms (McQuellon et al., 2007).  
Additionally, individuals who die prior to discharge from the hospital or before the first 
post-procedure assessment likely do not contribute their experiences to the data pool.  
This lack of randomness likely associated with missing data suggests that existing 
datasets represent the best-case scenarios.  Those who share their stories are those who 
are living and living without symptoms that prevent them from completing a packet of 
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questionnaires.  McQuellon et al. (2007) suggested the need for CS+HIPEC researchers 
to design studies that permit the investigation of those patients who drop out or who have 
significant psychosocial stressors or QOL impairments associated with the treatment or 
recurrent disease.  In other words, these researchers reminded colleagues of the 
importance of studying those who do not fare well post-CS+HIPEC. 
Next, the timing of both baseline and post-procedure instrument administration 
varies between the studies located (McQuellon & Duckworth, 2009), introducing a 
possible source of variance between the sets of data.  On the front end of the longitudinal 
studies retrieved, baseline data acquired one week versus one day pre-CS+HIPEC may 
vary markedly in nature.  Relative to post-procedure administrations, McQuellon et al. 
(2007) administered surveys at baseline and three, six, and 12 months post-procedure; 
Alexander et al. (2003) administered surveys at baseline and six weeks, three, six, and 
nine months post-procedure; while Tuttle et al. (2006) retrieved data at baseline and four, 
eight, and 12 months post-procedure.  Data collected at differing time post-CS+HIPEC 
limits comparisons across studies. 
 McQuellon and Duckworth (2009) noted the considerable morbidity experienced 
in the acute recovery phase following surgery yet the few incidences when data have 
been collected during this sensitive time period when patients are experiencing so many 
hardships.  For example, both McQuellon et al. (2001) and Alexander et al. (2003) 
gathered data within the six weeks post-procedure, and both noted significant QOL 
reductions relative to baseline.  In contrast, Tuttle et al. (2006) refrained from gathering 
post-surgery data until four months post-procedure.  Their baseline and four month 
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assessment results were very similar, not reflecting the acute recovery reductions.  These 
findings reflect the need for more consideration relative to the timing of instrument 
administration and the recovery experiences of members of this population.  The true 
path of recovery may not be captured in its entirety if administrations do not occur in the 
months following CS+HIPEC.  Without this information, patients‟ needs may remain 
unknown and unmet.  Likewise, until recommendations are made relative to the 
appropriate timing of administrations, comparisons between datasets remain difficult.  
Also making comparisons of findings across studies difficult is the use of 
numerous QOL instruments as well as the numerous variables that often are unreported 
or uncontrolled in the studies (McQuellon & Duckworth, 2009).  In the located studies, 
various QOL instruments were utilized, including the FACT-C (colon) or FACT-G 
(general) (Cella et al., 1993), the SF-36, as well as both English and French versions of 
the European Organization for Research and Treatment of Cancer (EORTC) Quality of 
Life Questionnaire (QLQ)-C30 (Aaronson, et al., 1993) and the QLQ-CR38 (colorectal 
module) (Sprangers, te Velde, & Aaronson, 1999).  These instruments vary in terms of 
number of items, sensitivity, and question wording, complicating direct comparison 
between studies.  
Additionally, alternate variables that likely impacted individuals‟ experiences and 
QOL reports, including social support, counseling assistance throughout the process, 
previous psychiatric history, and diagnosis often go unreported or are not controlled.  
Numerous primary diagnoses may result in peritoneal carcinomatosis, and individuals 
with differing primary diagnoses often are aggregated within these small samples.  For 
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instance, of 67 potential study participants available to Schmidt et al. (2005), the 
following primary diagnoses were represented: appendix, ovary, colon, peritoneum, 
stomach, pancreas, liver, small bowel, retroperitoneal, sarcoma, uterus, and other. As the 
body of QOL research from these individuals is enhanced, more attention to some of the 
aforementioned variables and their impact on QOL data is needed.  
It is apparent, then, that numerous limitations exist relative to the existing body of 
literature on long-term CS+HIPEC survivors.  First, relatively few QOL studies of 
CS+HIPEC have been performed.  Within these studies, numbers traditionally have been 
small, thereby limiting generalizations and reducing the power of statistical analyses.  
Likewise, by nature of the study designs, those who die or are experiencing the most 
significant symptomology often are not represented.  Stringent inclusion and exclusion 
criteria in some studies limit potential participants to those who have no recurrent disease 
(e.g., Zenasni et al., 2009), further homogenizing the data to that provided by the 
healthier participants.  Additionally, both instrument selection and the timing of 
instrument administration often vary, making across-study comparisons of results 
challenging.  Finally, there is a dearth of phase III trials with individuals receiving 
CS+HIPEC.  In the event that future national or international, multi-institutional trials are 
established, matched control groups could serve as true points of comparison relative to 
those receiving CS+HIPEC. 
 The current study will attempt to improve upon some of the existing limitations in 
previous QOL studies of survivors of CS+HIPEC.  In attempt to acquire a more accurate 
and descriptive picture of the QOL and sleep quality of long-term survivors, the 
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investigator first located a large number of prospective participants.  Undeniably, and 
similar to previous studies, those who did not live to be long-term survivors will not be 
represented in this study as well; yet alternate strategies will be implemented in order to 
acquire more representative data that depicts the range of current life conditions of those 
who have survived for 12 or more months post-CS+HIPEC.  Specifically, the investigator 
will loosen study exclusion criteria, permitting all survivors (and not strictly those with 
no evidence of disease), to participate.  Additionally, targeted strategies for avoiding 
missing data and achieving a high participation rate (i.e., personal phone calls and 
incentives) will be implemented.  Utilizing these strategies, the researcher hopes to 
achieve not only more participants than did the investigators of past studies but also 
participants who represent a variety of potential outcomes.  In addition to the inclusion of 
more participants and more diversity, larger numbers of participants will permit more 
complex analyses and the possibility of generalizing the findings.  The use of a QOL 
instrument that has been utilized in previous studies also will facilitate the comparison of 
findings across studies.  Finally, the addition of a measure assessing an under-studied 
construct, sleep quality, will serve to enhance this body of research by increasing 
awareness of an alternate life aspect potentially in need of additional attention. 
 Despite these improvements upon existing study designs, McQuellon et al. (2003) 
highlighted an obstacle confronted by QOL researchers when investigating long-term 
survivors.   
“One vexing problem facing QOL researchers conducting long-term follow-up studies is 
to what extent a disease process and subsequent treatment have affected the patient‟s 
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overall well-being compared with what changes in QOL would have occurred during the 
normal process of aging” (p. 161).  An array of ancillary variables may be impacting the 
QOL and sleep quality of long-term survivors, and it is difficult to separate the effect of 
these ancillary variables from that of the procedure and disease process.  Means of 
separating the impact of normal aging from that of the disease process and treatment do 
exist, however, and will be implemented in this study.  First of all, the long-term QOL 
scores will be compared to standardized general population norms in order to acquire 
group comparisons.  Secondly, (when available) the long-term QOL scores of survivors 
will be compared to personal baseline, pre-procedure scores to assess change within 
participants over time.  These strategies should yield within-participant comparisons as 
well as comparisons between these survivors and members of the general population 
(McQuellon et al., 2003).  
Conclusion 
In conclusion, over the last few decades, CS+HIPEC has, over the last few 
decades, become a promising option for long-term survival in many patients with 
peritoneal carcinomatosis (al-Sammaa et al., 2008; Stewart et al., 2008) and may become 
even more so as surgeons continue to hone their skills, knowledge and selection criteria 
relative to the procedure.  Simply because the invasive treatment has concluded for these 
individuals, however, their lives may be impacted by associated disease- and treatment-
related variables.  A biopsychosocial conceptual model, such as the Wilson and Cleary 
Model (1995), enhances researchers‟ and clinicians‟ understanding of how variables from 
differing domains may interact to impact the life quality of survivors.  A need for more 
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methodologically sound studies with sufficient numbers of participants exists so that 
individuals can be truly informed decision makers pre-treatment and professionals remain 
informed of the QOL of these survivors.  Ideally, such rich, descriptive psychosocial data 
can serve as the foundation of future interventions designed to improve survivors‟ QOL 
and sleep quality complications.  In the realm of peritoneal carcinomatosis, 
considerations pertaining to quality must not be overshadowed by those pertaining to 
quantity. 
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CHAPTER III 
METHODOLOGY 
 
 
In Chapters I and II, the rationale and literature basis for the study of QOL and 
sleep quality in patients who received an aggressive treatment procedure were presented.  
The review of the literature demonstrated the dearth of current knowledge relative to the 
QOL and sleep quality of individuals who live at least 12 months following the CS+ 
HIPEC.  These findings support the need for additional psychosocial studies with these 
survivors.  In this chapter, the methodology for conducting such a study is explained.  
Research questions and hypotheses are included.  Also, participants and instrumentation 
are described, and data collection and statistical procedures are delineated. 
Research Questions and Hypotheses 
The aim of the present study was to acquire a better understanding of the QOL 
and sleep quality of cancer survivors who had CS+HIPEC a minimum of 12 months prior 
to the study date.  Special attention was paid to both their mental and physical quality of 
life scores, how these scores compared to their own respective (baseline) scores prior to 
having the CS+HIPEC procedures (for the subset of patients on whom pre-surgery data 
was collected), and how their overall and component QOL scores compared to those of 
the general population.  Sleep quality, a commonly reported concern and variable 
impacting QOL, also was examined among individuals in this population.  Special 
attention was paid to the interrelations between sleep quality, quality of life, number of 
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months since procedure, and age at procedure.  Finally, the contributions of selected 
surgical and physiological variables were examined in relation to their predictive power 
of QOL scores 12 (or more) months following CS+HIPEC in these survivors. 
 
Research Question 1: What are the QOL subscale scores (i.e. Physical Functioning, 
Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Mental Health, 
Role Emotional) and component scores (i.e. Physical Component Score and Mental 
Component Score) of participants, as measured by the Medical Outcomes Study 36-Item 
Short-Form Health Survey (SF-36) instrument, and how do they compare to those of 
general population norms? 
Hypothesis 1a: The QOL subscale scores of participants will be lower than the 
standardized population norms. 
 
Research Question 2: Regarding those participants for whom pre-surgical data is 
available, what differences exist between pre-surgical QOL subscale scores and 12 or 
more-month QOL scores for participants who received CS+HIPEC and have survived? 
Hypothesis 2a: Post-surgical, 12-month Physical Functioning (PF), Role Physical 
(RP) and Bodily Pain (BP) subscale scores will be significantly higher than those 
acquired from Participants pre-surgery. 
 
Research Question 3: What is the sleep quality of participants, as defined by one‟s 
global and component scores on the Pittsburgh Sleep Quality Index (PSQI)? 
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Hypothesis 3a: Global PSQI scores of the majority of CS+HIPEC patients will be 
above the recommended clinical threshold of eight, indicating poor sleep quality. 
 
Research Question 4: What relationship exists between sleep quality, age at CS+HIPEC, 
months since surgery, and QOL subscale scores?  
Hypothesis 4a: A significant positive relationship will exist between global sleep 
quality scores and the QOL subscale scores. 
 
Research Question 5: What are the respective contributions of resection status (RO/R1, 
R2a, R2b, and R2c) and primary tumor site in predicting QOL subscale scores at 12 or 
more months? 
Hypothesis 5a: Patients who achieved a better resection status will demonstrate 
higher QOL scores at 12 or more months. 
Hypothesis 5b: Patients with appendiceal tumors and pseudomyxoma peritonei 
will demonstrate higher QOL scores at 12 or more months. 
Participants 
Participants were individuals who received CS+HIPEC at Wake Forest University 
Baptist Medical Center 12 or more months prior to the initiation of this study.  
Participants‟ names were originally selected from a hospital database containing 
demographic information on all individuals who received CS+HIPEC at WFUBMC.  
Participants‟ primary diagnoses varied, yet all had localized peritoneal carcinomatosis 
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that surgeons believed was amenable to complete resection and all were deemed 
sufficiently healthy to undergo this extensive procedure. 
A subset of these individuals previously consented to participate in longitudinal 
QOL assessments via an alternate protocol prior to their hospital admission for 
CS+HIPEC.  These individuals‟ pre-treatment QOL data also was available, therefore, for 
comparison purposes. The remaining participants were patients who had never been 
actively enrolled in a WFUBMC QOL study following CS+HIPEC, either because they 
were not offered the opportunity to participate in the ongoing assessments or were 
disinterested at the original time of consent.  
All participants were English-speaking and had accurate contact information on 
file at the hospital.  All participants provided both verbal and written consent prior to 
participating in this study.  A summary of demographic characteristics of the sample is 
provided in Chapter 4.  
Instrumentation 
Participants completed two standardized instruments, a brief informational 
questionnaire, and a socio-demographic form.  Instruments (Demographic Questionnaire, 
SF-36, PSQI and Patient Information Questionnaire) were randomly sequenced between 
participants in an effort to avoid differential impacts of fatigue on the concluding 
questionnaire(s).  What follows is a description of the development and psychometric 
properties of the respective instruments. 
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Medical Outcomes Study 36-item Short-Form Health Survey (SF-36) 
Cognizant that an insufficient quantity of information on patients‟ disease and 
treatment experiences had been collected from the optimal sources (i.e., the patients 
themselves), a group of researchers developed the Medical Outcomes Study (MOS) in 
order to both gather this health-related information and examine the feasibility of 
utilizing self-administered, generic health surveys with populations with chronic medical 
and psychiatric conditions (Ware, Snow, Kosinski, & Gandek, 1993).  The MOS surveys 
were based on a multidimensional model of health, including 40 mental and physical 
health concepts.  This multidimensionality is integral in health assessments, as mental 
and physical conditions are not mutually exclusive.  In fact, they often coexist in various 
severities in patient populations (McHorney et al., 1993). 
Following the successful completion of the MOS, Ware and Sherbourne (1992) 
grew increasingly aware of the potential for participant burden in populations of the 
chronically ill and the associated costs of data collection with lengthy instruments.  Ware 
and Sherbourne (1992) therefore desired to create a more feasible and practical 
instrument, without compromised psychometric characteristics or content coverage, for 
use in general population surveys, clinical practice and research, and health policy 
evaluation.  Aware of the need to achieve standards of comprehensiveness across an array 
of health concepts yet concurrently keep patient burden considerations in mind, the 
developers attempted to balance depth and breadth considerations.  In other words, they 
included in their measure the most frequently assessed concepts in existing 
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questionnaires and ensured they included a sufficient number of comprehensive items in 
order to measure each of the respective concepts accurately (Ware & Sherbourne, 1992).  
The subsequent product, following previous versions (i.e., SF-18, SF-20), was the 
Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36; Ware et al., 1992), 
a self- or interviewer-administered (self administration will be used in this study), generic 
health survey yielding data that ultimately allows researchers to determine how 
individuals suffering from chronic medical or psychiatric conditions differ both from one 
another and the general population as a whole.  Two versions of the SF-36 have been 
developed.  Given that the subset of individuals who contributed baseline data (that will 
be analyzed for the purpose of assessing change over time in this study) completed 
version one of the SF-36, version one will be administered to all survivors in order to 
maintain this continuity between versions. The SF-36 is considered a “generic” health 
measure, as it assesses health concepts that are collectively valued. It is not disease, 
treatment or age-specific, but rather examines outcomes that are directly impacted by 
treatment and disease (Ware et al., 1993).  It is precisely this “generic”, non-disease-
specific, status that permits norm comparisons. 
 The SF-36 was designed for individuals age 14 or older and consists of one multi-
item scale that measures eight health-related concepts (i.e. physical functioning (PF), 
role-physical (RP), bodily pain (BP), general health perception (GH), vitality (VT), social 
functioning (SF), role-emotional (RE) and mental health (MH)) (Ware et al., 1993).  
McHorney, Ware, and Raczek (1993) noted it is insufficient to measure strictly mental 
and physical health in a comprehensive health assessment.  Rather, information on the 
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limitations individuals experience as a consequence of their respective mental and 
physical health problems when attempting to engage in their usual life roles needs to be 
included as well.  Role and social functioning scales were therefore included for this 
purpose (McHorney et al., 1993) as were additional operational definitions of the primary 
health concepts (i.e. functioning, well-being, disability and personal evaluation) 
throughout the scales (Ware et al., 1993).  
 For years, researchers examined the component structure of the SF-36 when used 
with the relatively healthy, general population and those with chronic conditions (Ware & 
Kosinski, 2001).  If scales with the same component content are likely to lead to the same 
health conclusions, then researchers reasoned these scales are good candidates for 
aggregation (Ware & Kosinski, 2001).  After repeated study, it became clear that the 
mental and physical components account for 80-85% of the reliable variance in the eight 
SF-36 scales across differing populations (Ware & Kosinski, 2001).  Derived from the 
eight SF-36 scales, The Mental Component Summary (MCS) and Physical Component 
Summary (PCS) are the two comprehensive, distinct components measured in the survey.  
Researchers and practitioners can therefore examine the eight scales individually or the 
two component scores for scoring and interpretation purposes.  The SF-36 measurement 
model is therefore predicated on three levels: 1) items; 2) scales that cluster these items; 
and 3) summary measures that aggregate the scales (MCS, PCS) (Ware & Kosinski, 
2001).  The eight subscales will comprise the unit of analysis for this study. A brief 
description of these eight scales follows. 
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Physical Functioning (PF) scale.  Wanting to capture a range of physical 
limitations, the full, ten-item MOS Physical Functioning (PF) scale was incorporated into 
the short-form without adaptations (Ware et al., 1993).  Participants are provided with an 
array of physical activities ranging from those vigorous in nature (e.g., participating in 
strenuous sports) to those less demanding (e.g., bathing or dressing oneself) and asked to 
rate the extent of limitation with each activity on a three-level continuum.  The one self-
care item included in this scale represents the “floor” of the scale (Ware et al., 2000).  
Those who achieve low scores on this scale are limited in performing all physical 
activities, from those mild to vigorous in nature, while those who achieve high scores are 
able to perform the range of physical activities without health-related limitations (Ware et 
al., 1993).  
Role Emotional (RE) and Role Physical (RP) scales.  The role functioning 
scales (RE (n = three items), RP (n = four items)) assess limitations in functioning due to 
emotional and physical problems, respectively.  Specifically, these scales examine 
limitations in work or other typical activities, reductions in the amount of time spent in 
the aforementioned activities, and the difficulties experienced when performing these 
activities (Ware et al., 1993).  A variety of roles are represented among the items, making 
the scales more responsive to those who have multiple roles.  Low scores indicate 
substantial functional impairments in life roles due to mental and/or emotional problems 
(respectively), while higher scores indicate few role impairments due to mental or 
physical health-related problems.  Response choices are dichotomized.  
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Bodily Pain (BP) scale.  The BP questions (n = two items) measure both the 
intensity of pain (on a six-point Likert scale) over the past four weeks as well as the level 
of interference with daily activities (on a five-point Likert-type scale).  A low score 
indicates the individual experiences intense pain that interferes with daily activities, while 
a high score indicates minimal pain and minimal life interference due to pain (Ware et al., 
1993). 
General Health Perception (GH) scale.  The GH scale is comprised of five 
questions that assess the participant‟s perception of her or his current health, health 
outlook and resistance to illness. Specifically, a single-item rating of health (i.e., poor to 
excellent) and four items from the Health Perceptions Questionnaire (Davies & Ware, 
1981) were included (Ware et al., 2000).  The inclusion of favorably and unfavorably 
worded items helps control for response set effects (Ware et al., 2000).  This scale is also 
one of three dual-sided scales that yield a wider range of negative and positive health 
scores (Ware et al., 1993).  In these scales, the absence of negative symptoms will not 
yield a high score.  A respondent must report positive states or evaluate her or his 
respective health positively in order to receive a high score.  A middle-range score is 
acquired when the respondent reports no symptoms or limitations but also no positive 
states (Ware et al., 1993).  
Vitality (VT) scale.  The VT scale consists of four items that measure the 
participant‟s energy and fatigue levels.  The combination of favorably and unfavorably 
worded items is present in this scale as well.  The VT scale is another of the three dual-
sided scales (Ware et al., 1993).  Low scores on the VT scale reveal the presence of 
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substantial energy deficits and fatigue; middle-range scores indicate minimal 
impairments or symptoms but no positive states or favorable ratings; high scores reveal 
minimal fatigue and high energy levels. 
Social Functioning (SF) scale.  The SF scale (n= two items) assesses both the 
extent and frequency with which physical or emotional problems have interfered with 
social activities.  Low scores indicate physical or emotional problems have greatly 
interfered with social activities on a frequent basis, while high scores indicate the 
respondent has had minimal interruptions of typical social functioning due to physical or 
emotional problems. 
Mental Health (MH) scale.  The MH scale consists of five questions, one from 
each of the major mental health dimensions, including anxiety, depression, psychological 
well-being, loss of behavioral control and loss of emotional control (Ware et al., 1993).  
These five items are those that most accurately predict the 38-item summary score on the 
Mental Health Inventory (Ware et al., 1993).  The MH is the last of the three dual-sided 
scales.  Lower scores on the MH scale reveal the presence of problems in many of the 
major mental health dimensions; middle range scores reveal no mental health problems 
but no positive states or ratings either; high scores reveal the absence of psychological 
concerns and the presence of positive, healthy mental health states (Ware et al., 1993). 
Reported Health Transition (RHT).  Finally, the single reported health 
transition (RHT) question asks participants to rate the extent of change in their health 
over the past year.  Although not included in the tabulated final score, the authors believe 
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this question yields useful information about individuals‟ perceptions of their health 
changes (Ware et al., 1993).  
 Various researchers have examined the psychometric properties of the SF-36, and 
numerous studies have provided evidence of instrument validity.  Ware and Kosinski 
(2001) presented the correlations between the SF-36 scales and these principal Mental 
and Physical components in the MOS data (n = 3,445).  As hypothesized, the PF (.88), 
RP (0.78) and BP (0.77) scales demonstrated the strongest correlations with the physical 
dimension, while the MH (0.12) and RE (0.19) scales were weakly correlated with the 
physical dimension.  Alternately, the MH (.90), RE (.81) and SF (0.71) scales correlated 
most highly with the mental health component, while the PF (0.04), RP (0.30) and BP 
(0.24) scales correlated weakly with the mental health component.  Of these scales, the 
MH and PF were the purest measures of the mental and physical health dimensions, 
respectively.  McHorney et al. (1993) found similar results in their analyses and 
concluded that the interpretations of the MH and PF scales are unambiguous in their 
measure of clinical manifestations of mental and physical conditions, respectively 
(McHorney et al., 1993).  The other mental and physical health scales measure alternate 
aspects of their respective dimension of health (Ware et al., 1993). 
Not surprisingly, the three scales estimated to measure both the mental and 
physical health dimension (i.e., GH, VT, SF) demonstrated correlations with both 
dimensions of interest, making their interpretations more complex (Ware & Kosnski, 
2001).  Although correlated with both dimensions to some extent, some of these scales 
were more closely associated with one dimension over the other.  For instance, the 
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researchers found that the GH scale was more strongly correlated with the physical 
dimension (0.68 vs. 0.32); the SF scale was more strongly associated with the mental 
health dimension (0.71 vs. 0.44); and the VT scale was virtually equally associated with 
both (0.57 vs. 0.59).  Unlike the interpretation of the MH and PF scales, the interpretation 
of these three scales that measure components of both primary dimensions is more 
complex, and differences cannot be unequivocally related to one dimension or the other 
(McHorney et al., 1993).  Their inclusion in the overall scale, however, remains vital so 
that clinicians and researchers can better understand the manifestations and impacts of 
both physical and mental health problems on daily functioning (McHorney et al., 1993).  
 In addition to the statistical validity, McHorney et al. (1993) also examined the 
clinical validity of the SF-36 scale in order to better understand its applicability and 
utility in a clinical setting.  Specifically, the researchers examined the score profiles of 
four mutually exclusive adult patient groups (i.e. those with minor medical conditions, 
those with major medical conditions, those with solely psychiatric conditions and those 
co-morbid medical and psychiatric conditions) in order to examine the scale‟s ability to 
detect declines in health status associated with psychiatric and/or medical conditions. 
McHorney et al. (1993) found that the score profiles of SF-36 accurately differentiated 
between those with varying severities of medical and psychiatric conditions, suggesting 
strong clinical validity.  
 Also interested in the validity of the SF-36, McHorney, Ware, Lu, and Sherbourne 
(1994) examined the item discriminant validity.  After completing 280 item-discriminant 
validity tests with 24 subgroups of individuals, they found that the correlations between 
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an item and its respective scale was higher than the correlation between the respective 
item and alternate scales 99.5% of the time.  The correlations between each item and its 
respective scale exceeded correlations with all other scales by an excess of two errors 
92.5% of the time (McHorney et al., 1994), suggesting strong item discriminant validity.  
Of the eight subscales, the GH scale demonstrated the most scaling variability across the 
diverse groups. 
 Researchers also have provided evidence for the reliability of the SF-36.  
McHorney et al. (1994) examined the reliability of the SF-36 across 24 patient subgroups 
differing in diagnoses, disease severity and sociodemographic characteristics.  Internal-
consistency reliability (Cronbach‟s alpha) for the combined sample ranged from 0.78 
(GH) to 0.93 (PF).  This lower reliability coefficient for GH can be attributed to the 
multidimensional nature of the items included to comprehensively assess the general 
health perceptions construct (McHorney et al., 1994). Some variability in internal-
consistency reliability was noted across scales when administered to the 24 diverse 
subgroups (range: 0.65-0.94).  Across all subscales among all tested subgroups, minimal 
Cronbach‟s alpha expectations were not meet (i.e. 0.70) at solely one time point: the GH 
subscale for participants with comorbid psychiatric and complicated medical conditions.  
In fact, McHorney et al. (1994) reported that this group of patients with co-morbid 
psychiatric and complicated medical conditions had the lowest reliability estimates on 
three of the scales (GH, SF, and RP).  For the remainder of the patient subgroups as well 
as the combined sample, minimal standards for internal-consistency reliability were met 
or exceeded. 
138 
 
In addition to validity and reliability considerations, McHorney et al. (1994) 
examined other characteristics of the data dispersion, including potential floor and ceiling 
effects.  In a combined sample of diverse patient subgroups (n = 3,445), McHorney et al. 
(1994) noted that floor effects occurred less than 5% of the time in six of the eight scales 
but were fairly common in the RP and RE scales.  Likewise, ceiling effects often 
occurred in the RP and RE scales as well as in the SF scale.  They attributed these floor 
and ceiling findings in the role-scales to the fact that these are the “coarsest” of the eight 
scales, with only four (RE) and five (RP) levels each.  Modest ceiling effects were also 
noted for the PF and BP scales (McHorney et al., 1994).  Three of the SF-36 scales (i.e. 
GH, MH, and VT) are dual sided, balanced scales, meaning the absence of symptoms is 
insufficient to obtain a high score.  To receive a high score on these scales, the 
respondent must endorse the absence of symptoms as well as the presence of positive 
symptoms. McHorney et al. (1994) found that these three dual-sided, balanced scales did 
not demonstrate floor and ceiling effects.  
Finally, McHorney et al. (1994) examined the data completeness profiles across 
their 24 diverse subgroups.  They noted a range of 75%-98% completeness, with a 
median completeness percentage of 91.5.  Strictly the PF items had overall item-
completeness rates of less than 80%, occurring predominantly among the 
sociodemographic groups that were most disadvantaged.  Differences in item 
completeness were not better accounted for by subgroup membership. Rather, poverty, 
age and education were the best predictors, with those who were oldest, less educated and 
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more economically disadvantaged completing the least percentage of items (McHorney et 
al., 1994).  
With the incorporation of norm-based scoring, results interpretation is relatively 
easy across subscales (Ware, n.d.).  Specifically, linear transformations were used to 
transform scores on all scales (which had vastly different means when utilizing the 0-100 
summative scoring) to a mean of 50 and a standard deviation of 10 (Ware, n.d.).  The 
results from the general U.S. population census were utilized as the norm anchors, 
thereby adding an inherently meaningful anchor to each score (Ware, n.d.).  For instance, 
any score below 50 is below that of the average person in the U.S., and every point below 
this norm of 50 signifies one-tenth of a standard deviation.  With this basic knowledge, a 
reviewer of results can quickly gauge how many scores are below what would be 
expected in the general population.  On the contrary, when utilizing the previous 0-100 
summative scoring, a layperson would have no idea relative to the mean for each scale or 
how to deduce the relativity of scores on varying scales (Ware, n.d.).  In conclusion, the 
use of norm-based scoring provides ease of results interpretation with the SF-36 scores. 
Pittsburgh Sleep Quality Index (PSQI) 
Designed by Buysse et al. (1989) for use with clinical populations, the Pittsburgh 
Sleep Quality Index (PSQI) is a client-rated instrument that assesses both sleep quality 
and sleep disturbances over the course of the four weeks prior to instrument 
administration.  Although brief and simple, this instrument offers a comprehensive 
picture of one‟s sleep quality over the past month, making possible applications 
numerous.  Among a plethora of additional uses noted by Buysse et al. (1989), the PSQI 
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facilitates clinicians‟ and researchers‟ identification of different groups of individuals 
within psychological and general medical settings, allows for a quick screening of sleep-
wake disturbances and “good”/”poor” sleepers among patients, and assists in longitudinal 
research and clinical work by means of highlighting the course, nature and severity of 
sleep disturbances within and between populations over time. 
During the early development stages of the PSQI, Buysse et al. (1989) agreed 
their specific aims included 1) creating a standardized measure of sleep quality that was 
both valid and reliable; 2) developing an instrument capable of differentiating poor from 
good sleepers; 3) introducing an instrument that was brief yet concurrently capable of 
detecting numerous sleep disturbances impacting one‟s quality of sleep; and 4) 
introducing an instrument that was both user-friendly and interpretable for clients, 
clinicians and researchers (Buysse et al., 1989).  Three primary sources informed PSQI 
item derivation during this development period, including the authors‟ clinical 
experiences with patients struggling with impaired sleep quality, a literature review of 
existing sleep quality questionnaires, and the knowledge gained as a consequence of 18 
months of field testing the instrument with various populations (Buysse et al., 1989).  
During the 18-month field testing period, Buysse et al. (1989) administered the 
original items to three groups of individuals: controls (n = 52) without professed sleep-
wake disturbances, “poor” sleepers diagnosed with Major Depressive Disorder (MDD; n 
= 34) and receiving outpatient or inpatient clinical interventions via the Western 
Psychiatric Institute and Clinic, and “poor” sleepers referred by their physicians to the 
Sleep Evaluation Center (n = 62) at the Western Psychiatric Institute and Clinic for a 
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myriad of sleeping and waking disturbances (Buysse, et al., 1989).  All of the 
aforementioned 148 individuals completed the PSQI at least once, while a subgroup of 91 
individuals (43 “good” sleepers, 22 individuals diagnosed with MDD and 26 individuals 
with sleep-wake disturbances) completed the PSQI a second time, an average of 28.2 
days later (Buysse et al., 1989).  By administering the PSQI to diverse populations, the 
authors were not only able to gain narrative feedback from diverse sources about their 
experiences while completing the instrument but were also able to compile global and 
component score profiles for each of the respective populations for comparison purposes. 
The final version of the PSQI includes 24 items, 19 of which are client-rated and 
five of which are completed by either a bed partner or roommate, if applicable.  The five 
items completed by a sleep observer are used strictly for clinical purposes and are not 
included in the scoring tabulation (Buysse et al., 1989).  Instructions delineate the need 
for the participant to reflect upon her or his sleep quality over the past month.  This 
targeted four-week time interval prior to instrument administration was intentionally 
selected by the authors in hopes of bypassing some of the concerns relative to alternate 
existing sleep measures (Buysse et al., 1989), noting that sleep instruments that broaden 
their focus to the previous year may not highlight the sleep concerns that are most 
pressing and pertinent to the current time.  Conversely, sleep instruments that narrow the 
time frame of interest to strictly the previous night may not highlight themes and patterns 
of sleep disturbances relevant to the course of an individual‟s sleep (Buysse et al., 1989).  
By targeting the past four weeks, the authors of the PSQI believe the instrument detects 
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currently relevant sleep-wake disturbances that have become more than transient 
problems. 
For each of the 19 items, the scorer assigns an ordinal score, ultimately deriving a 
global PSQI score as well as seven component scores (i.e., sleep quality (n = one item), 
sleep latency (n = two items), sleep duration (n = one item), habitual sleep efficiency (n = 
four items), sleep disturbance (n = eight items), use of sleeping medication (n = one item) 
and daytime dysfunction (n = two items)).  Component scores, ranging from zero to 
three, are given equal value upon tabulation of the global PSQI score, indicating a 
possible global PSQI score of zero to 21 (Buysse et al., 1989).  The global PSQI score 
will serve as the unit of analysis in the current study.  Lower PSQI scores reflect better 
sleep quality, with a score of “zero” in a component score indicating no difficulty and a 
score of “three” reflecting severe difficulties.  Buysse et al. (1989) established a global 
clinical cutoff score of five, meaning anyone scoring above this threshold is experiencing 
either severe problems in a minimum of two areas or moderate-intensity problems in 
more than areas.  Scores, therefore, inherently reflect both the number and severity of 
sleep-wake disturbances (Buysse et al., 1989). 
Various researchers have provided validity evidence for the PSQI.  From a 
possible score range of zero to 21, scores derived from all three field-tested participant 
groups ranged from zero to 20.  The global PSQI score was 2.67 +/- 1.70 for the “good” 
sleepers, 11.09 +/- 4.31 for those diagnosed with MDD, and 10.38 +/- 4.57 for those with 
a Disorder of Initiating and Maintaining Sleep (DIMS).  The global scores for the 
diagnostic groups (MDD and DIMS) resembled one another yet differed significantly 
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from that of the controls (using sex and age as covariates in an ANCOVA).  This 
similarity in profiles between those with MDD and DIMS makes sense, as individuals 
with depression typically have sleep initiation and maintenance disturbances similar to 
those with DIMS (Buysse et al., 1989).  Based on these findings, the authors noted the 
existence of distinguishing global and component score profiles for the varying 
diagnostic groups (Buysse et al., 1989).  
Beck, Schwartz, Towsley, Dudley, and Barsevick (2004) also reported support for 
the construct validity of the PSQI after finding statistically and clinically significant 
differences in the global sleep quality scores of heterogeneous groups of cancer patients 
with high and low fatigue, respectively.  The validity of the instrument is further 
supported by the high rates of sensitivity (89.6%) and specificity (86.5%) maintained by 
the established cut-off score of five (Buysse et al., 1989).  Together, these findings 
indicate the PSQI successfully differentiates the “poor” from the “good” sleepers and the 
individuals with varying diagnoses with characteristic sleep-wake disturbance features 
from controls.  
Further evidence suggests that the PSQI may be valid for use with cancer 
survivors.  Carpenter and Andrykowski (1998) examined the psychometrics of the PSQI 
with a heterogeneous group of cancer survivors, including bone marrow transplant 
survivors (n = 155), women with breast cancer (n = 102) at least three months following 
their primary treatment and women with benign breast problems (n = 159).  Paying 
special attention to convergent and discriminant validity considerations, the authors 
examined correlations between global PSQI scores and other constructs.  The correlations 
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between global PSQI scores and related constructs, such as sleep restlessness (as 
measured via the Center for Epidemiologic Studies-Depression), all exceeded 0.69, while 
correlations between global PSQI scores and unrelated constructs, such as nausea and 
vomiting, did not exceed 0.37 (Carpenter & Andrykowski, 1998), providing evidence of 
good convergent and discriminant validity.  
Buysse et al. (1989) also examined the relationship between the PSQI and other 
measures of sleep quality.  Specifically, Buysse, et al. (1989) examined the relationship 
between subjective PSQI scores and objective reports of sleep quality, as measured by 
polysomnography.  With the exception of sleep latency, the authors found that PSQI 
scores did not correlate significantly with polysomnographic results.  This finding is not 
surprising, however, given the differing time intervals of interest between the two tests 
(Buysse et al., 1989).  While polysomnography provides a detailed, objective picture of 
the sleep quality of the participant‟s previous night‟s sleep, the PSQI instructions ask the 
participant to reflect upon his sleep quality over the course of the past four weeks.  It is 
not unexpected, then, that these results are not significantly correlated to those from 
strictly the previous night‟s sleep.  The objective polysomnographic results did, however, 
confirm group differences in the sleep quality of those belonging to the various field-
tested groups (Buysse et al., 1989), thereby corroborating the PSQI findings that 
categorical differences exist in the sleep quality of controls versus those with MDD or 
DIMS. 
Evidence for the reliability of the PSQI is also available.  Buysse et al. (1989) 
reported a high degree of internal consistency among the seven component scores, with 
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an overall reliability coefficient (Cronbach‟s alpha) of 0.83 for the full scale, and 
concluded that the respective components are measuring a certain aspect of the same 
unifying construct (i.e., sleep quality), thus supporting the use of the use of the full scale 
score.  Carpenter and Andrykowski (1998) also calculated the Cronbach‟s alpha 
coefficient for the global PSQI scores and the 8-item sleep disturbances component 
scores of various groups of cancer survivors.  These researchers reported that the 
Cronbach‟s alphas remained stable across participant groups for the global scores (0.80) 
and ranged from 0.70-0.78 for the sleep disturbances component scores.  Additional 
authors (Beck et al., 2004) have corroborated the contributions of the seven component 
scores to the overall measurement of the sleep quality construct.  
Test-retest reliability also was examined for the global and component scores of a 
subset of the field-tested participants (n = 91; n = 43 controls, 22 with MDD, 26 with 
sleep disorders) by means of paired t-tests and Pearson product-moment correlations 
(Buysse et al., 1989). Participants were administered the second instrument a mean of 
28.2 days following the initial administration.  Paired t-tests for the combined global and 
component scores showed no significant differences between T1 and T2, suggesting 
stability in scores across time.  The Pearson product moment correlations also 
demonstrated the reliability in scores across time for the combined group.  The T1-T2 
correlation coefficient for the entire group was 0.85 (p < 0.001), while component scores 
ranged from 0.84 (sleep latency) to 0.65 (medication use), with variability in patterns and 
amounts medicine use not expected.  When examining the various patient groups, Buysse 
et al. (1989) noted that the scores of the patients with MDD demonstrated two significant 
146 
 
differences across the two administrations: a reduction in sleep disturbances and reduced 
daytime dysfunction (changes which may be accounted for by exterior factors).  
Although demonstrating more variability, both the global and component scores within 
the respective subgroups were significantly correlated across the two administrations, 
with the sole exception being the medication use subscale (Buysse et al., 1989).  Overall, 
test-retest reliability estimates are strong. 
In addition to validity and reliability considerations, researchers have examined 
additional PSQI-related issues in the cancer care arena, including the frequency of 
missing data. Missing data among self-administered PSQI instruments is especially 
worrisome, as missing items can cumulatively result in missing component scores and 
ultimately missing global PSQI scores (Beck et al., 2004).  Cognizant of the high levels 
of fatigue and additional co-morbid symptoms in cancer patients and survivors, Carpenter 
and Andrykowski (1998) examined the PSQI instruments completed by a heterogeneous 
group of cancer survivors for missing data.   Upon analysis of the frequency distributions, 
the authors found <4% of the individual item data was missing for the cancer survivor 
responders.  The items most commonly left incomplete included those seeking 
information as to the reason behind the troubled sleep on the sleep disturbances 
component of the instrument (Carpenter & Andrykowski, 1998).  The authors 
extrapolated that individuals who leave these items blank may experience disturbed sleep 
for alternate reasons not adequately represented and suggested clinical follow-up 
interviews may successfully reduce this problem further.  
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Beck et al. (2004) reported a much higher preponderance of missing data among 
their participants, with an inability to calculate 21% of their first study participants‟ 
global PSQI scores.  These authors found higher rates of missing data for the “usual bed 
time” questions.  Instead of providing a numerical time, many participants provided a 
“yes/no” answer, ultimately preventing the researchers from calculating the sleep 
efficiency component score and therefore the global sleep quality score as well.  
Enhancing their second study with a follow-up phone call in the event of missing data, 
Beck et al. (2004) managed to reduce this percentage from 21% to 4.2%.  
Buysse et al. (1989), Carpenter and Andrykowski (1998) and Beck et al. (2004), all 
concluded the psychometric characteristics of the PSQI are strong.  Beck et al. (2004) 
encouraged its continued use with cancer patients exhibiting a wider range of both racial 
and ethnic characteristics.  Disagreement remains between the developers of the 
instrument and Carpenter and Andrykowski (1998) as to the optimal clinical cut-off score 
for those with significant sleep-wake disturbances.  While Buysse et al. (1989) maintain 
five is the optimal cut-off score for a “case”, Carpenter and Andrykowski (1998) found 
the mean PSQI scores were greater than eight (rather than five) in all groups with sleep 
problems.  They recommended using eight, rather than five, as a clinical cut-off score 
with cancer patients to signify the presence of poor sleep quality and reduce the 
possibility of false positives.  The original instrument developers continue to suggest the 
use of five as a clinical cutoff score.  Because of this discrepancy in the literature as to 
what constitutes a clinical cutoff, the more conservative cutoff of eight will be used.
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Patient Information Questionnaire 
 A description of the full Patient Information Questionnaire given to participants is 
beyond the scope of this dissertation, as much of the data collected on this instrument will 
be analyzed for research being conducted by faculty at the hospital at which the study is 
being conducted.  Essentially, this questionnaire contains a total of 19 questions that 
represent the collective suggestions of the primary mental health practitioners and 
surgical oncologists who work with this population at this hospital.  The contributors felt 
that the topics addressed by these questions (a mixture of Likert-type, dichotomized, and 
open-ended response formats) are insufficiently covered in the included questionnaires 
yet very important to the holistic care of this population.  They were therefore included 
for the purpose of enhancing the team‟s understanding of the population‟s recovery post-
treatment.  The findings associated with these questions could potentially lead to 
subsequent research investigations but the majority were not analyzed as part of this 
dissertation.  
For the purposes of this study, only responses to question number two (My sleep 
quality prior to surgery + heated chemotherapy (IPHC) was poor) were examined.  
Respondents answered on a five-point Likert-type scale that ranges from “not at all” to 
“very much”.  This question was added because the selected sleep quality questionnaire 
(PSQI; Buysse et al., 1989) strictly assesses sleep quality over a four-week period 
following CS+HIPEC.  Without this research question, the researcher has no way of 
knowing who struggled with poor sleep quality prior to the procedure (i.e., who has 
chronic sleep quality problems).  
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Demographic Questionnaire 
Participants completed a Demographic Questionnaire containing questions about 
the following information: name, gender, address, phone number, age, date of birth, 
diagnosis, date of diagnosis, physician, race, ethnicity, marital status, housemates, annual 
salary, highest grade in school completed, current employment status, occupation, 
partner‟s occupation, type of insurance, any active medical treatments, date of most 
recent treatment, and most troubling symptoms. 
Procedures 
Prior to its development, the prospective study was discussed with behavioral 
researchers as well as surgical oncologists who routinely work with and study patients 
who receive CS+HIPEC at WFUBMC.  The team decided to expand the study, making 
this dissertation a component of a larger study.  In addition to the instruments described 
above, two additional instruments were included: the Functional Assessment of Cancer 
Therapy Colorectal (FACT-C) (Ward et al., 1999) and the FACIT Treatment Satisfaction 
scale (FACIT-TS) (Hahn et al., 2000). 
After gaining permission from the Hospital Institutional Review Board (IRB) to 
proceed with data collection, potential participants‟ names were located in the hospital 
database containing the demographic and surgical information of all of the individuals 
who have received CS+HIPEC at WFUBMC.  The names of all individuals who received 
treatment 12 months prior to the initiation of the study were retrieved.  
Next, a telephone script pre-approved by the hospital IRB was used to make 
contact phone calls to potential participants.  The purpose of the telephone call was to 
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explain the purpose of the study and receive verbal consent from the prospective 
participant to mail: 1) a cover letter detailing the study, 2) a formal written consent, and 
3) a battery of instruments to her or his address.  Two researchers, including the primary 
investigator of this dissertation and a post-doctoral member of the hospital CS+HIPEC 
research team, conducted the telephone calls over a two week period.  Three rounds of 
calls were completed, with messages and return phone numbers left only once.  The 
utilization of telephone scripts permitted relative uniformity during these calls.  
Two slightly different versions of the phone script were created, one for 
individuals who previously opted to participate in the existing CS+HIPEC QOL study 
and the other for the individuals who have not participated in a CS+HIPEC-related QOL 
study at WFUBMC.  The script for previous participants differed from the other version 
only in that it thanked them for their previous contributions and delved into slightly less 
depth about the nature of QOL studies. All participants were told that the researchers are 
interested in acquiring information about the quality of life and sleep quality of 
individuals living one or more years post-treatment.  Prospective participants were told 
that their contributions will inform the team‟s comprehensive understanding of and future 
work with this population.  Additionally, they were given instructions related to 
completion of the consent form and how to contact the principal researcher, informed of 
the approximated completion time, and offered a $25 gas card, provided by the hospital, 
as a token of appreciation for their contributions.  Individuals were told that they would 
be mailed the gas card along with their copy of the signed consent form upon receipt of 
their completed instruments.  They also were informed of the possibility of receiving a 
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follow-up phone call if: a) they neglected to return the packet, b) missing data was 
evident, or c) the researcher was interested in inquiring further about certain responses. 
The individuals who verbally agreed to the mailing were mailed a packet 
containing a brief cover letter, written consent form, the instrument packet and a self-
addressed, postage-stamped return envelope for their convenience.  The consent form 
included a statement regarding the possibility of researchers making follow-up phone 
calls with the participants.  While not explained further to participants, the researcher 
introduced this possibility in the event of missing data or the presence of clinically 
alarming QOL scores, as defined by two or more standard deviations below the 
population norms.  
Upon receipt of returned packets, the primary researcher examined the packet for 
completeness.  If complete, the data was entered into the established database, and both 
the gas card and a copy of the signed consent form were mailed to that respective 
individual.  If incomplete, a follow-up phone call was performed to retrieve any missing 
data.  Occasionally, blank instruments, or single pages within instruments, were returned 
in hopes of obtaining complete datasets from participants.  Individuals who did not return 
packets were called approximately two weeks from the day of the initial mailing.  
Numerous participants neglected to return the written consent form with their data, 
requiring the primary investigator to resend the consent form and a return envelope.  If no 
consent form was received, the data were lost.   
The data was compiled and scored as it was received.  Statistical analyses were 
performed when data retrieval and scoring were complete.  
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Data Analysis 
Each research question yielded information about this respective group of surgical 
oncology patients.  Descriptive statistics of demographic information were calculated in 
order to provide a profile of the sample.  Additionally, estimates of internal consistency 
(Cronbach‟s alpha) were calculated for all study variables.  Descriptive statistics also 
were calculated for the component and subscale QOL scores of participants, and z-
statistics were calculated by comparing these sample scores with population parameters.  
A subset of the sample has both pre-surgical QOL data on file as well as the data 
acquired in the current cross-sectional study.  For this subset of the sample, paired t-tests 
with all eight subscale scores and the two component scores were performed to assess 
whether significant change occurred between the pre-surgery and 12 or more month QOL 
scores.  Additionally, the respective contributions of resection status and primary tumor 
site to 12 or more month QOL scores were examined with two separate two-way 
ANOVAs.  Through a t-test, the means of these primary tumor site groups were 
compared as well.  Descriptive statistics also were utilized to better understand the global 
and component sleep quality scores of participants.  A t-test also was performed in order 
to examine whether the mean sleep quality scores of this sample significantly differed 
from scores of other cancer populations that were used in order to determine the 
recommended clinical cutoff score.  Finally, Pearson correlation coefficients  
demonstrated the magnitude of relationships between each of the QOL subscale and 
component scores, the global PSQI scores, age at CS+HIPEC, and months since 
procedure.   
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Table 1 
Research Questions, Hypotheses, Variables, and Analyses 
Research Question 1: What are the QOL subscale scores (i.e. Physical Functioning, 
Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Mental Health, 
Role Emotional) and component scores (i.e. Physical Component Score and Mental 
Component Score) of participants, as measured by the Medical Outcomes Study 36-Item 
Short-Form Health Survey (SF-36) instrument, and how do they compare to those of 
general population norms? 
Hypothesis Variables Analysis 
 
 
Hypothesis 1a: The QOL 
subscale scores of 
Participants will be lower 
than the standardized 
population norms. 
-PF, RP, RE, BP, GH, VT, 
SF, and MH subscale scores 
(continuous) 
-Component QOL scores 
(continuous) 
-Standardized population 
norms for the QOL 
component & subscale 
(n=10) scores (continuous) 
 
 
 
Descriptive statistics 
z-statistics 
Research Question 2: Regarding those participants for whom pre-surgical data is 
available, do differences exist between pre-surgical QOL subscale scores and 12 or more-
month QOL scores for participants who received CS+HIPEC and have survived? 
Hypothesis Variables Analysis 
Hypothesis 2a:Post-
surgical, 12-month Physical 
Functioning (PF), Role 
Physical (RP) and Bodily 
Pain (BP) subscale scores 
will be significantly higher 
than those acquired from 
Participants pre-surgery. 
 
-Pre-surgical QOL subscale 
and component scores 
(n=10) (continuous) 
-Post-surgical QOL 
subscale scores and 
component scores (n=10)  
(continuous) 
 
 
Paired t-tests 
 
 
Research Question 3: What is the sleep quality of participants, as defined by one‟s 
global and component scores on the Pittsburgh Sleep Quality Index (PSQI)? 
Hypothesis Variables Analysis 
 
Hypothesis 3a: Global PSQI 
scores of the majority of 
CS+HIPEC patients will be 
above the recommended 
clinical threshold of 8, 
indicating poor sleep 
quality. 
-global PSQI score 
(continuous) 
-component scores (n=7): 
sleep quality, sleep latency, 
sleep duration, habitual 
sleep efficiency, sleep 
disturbance, use of sleeping 
medication, daytime 
dysfunction (continuous) 
 
 
Descriptive statistics 
t-test 
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Research Question 4: What relationship exists between sleep quality, age at CS+HIPEC, 
months since surgery, and QOL subscale scores? 
Hypothesis Variables Analysis 
 
Hypothesis 4a: A significant 
positive relationship will 
exist between global sleep 
quality scores and the QOL 
subscale scores. 
 
 
Post-surgical, 12-month 
QOL subscale and 
component scores (n=10) 
(continuous) 
-global PSQI score 
(continuous) 
-age at CS+HIPEC 
(continuous) 
-months since procedure 
(continuous) 
 
 
Correlation Matrix 
 
 
 
Research Question 5: What are the respective contributions of resection status (RO/R1, 
R2a, R2b, and R2c) and primary tumor site in predicting QOL subscale scores at 12 or 
more months? 
Hypothesis Variables Analysis 
 
Hypothesis 5a: Patients who 
achieved a better resection 
status will demonstrate 
higher QOL scores at 12 or 
more months. 
Hypothesis 5b: Patients 
with appendiceal tumors 
and pseudomyxoma 
peritonei will demonstrate 
higher QOL scores at 12 or 
more months. 
 
-Primary tumor site 
(categorical data) 
-Resection status 
(categorical, independent 
variable) 
-Component QOL scores 
(continuous; dependent 
variable) 
 
 
 
 
Two-way ANOVAs 
t-test 
 
 
 
Pilot Study 
A pilot study was conducted to field test the instrumentation and instructions, to 
gauge the time requirements relative to the verbal consent phone calls and the data 
collection process, and to acquire estimations of both the projected response rate for the 
full study and the percentage of survivors in the existing database for whom phone 
contact was not possible.  The main purpose of the pilot study, then, was to assess the 
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ease of participant recruitment and uncover any procedural adjustments that needed to be 
made to fortify the full study.  Detailed pilot study methodology and results are provided 
in Appendix C.  An overview of what was gleaned from pilot study participants and how 
this information has been incorporated into the full study follows.  
When conversing with prospective participants over the phone in order to obtain 
their verbal consent to mail the packet of instruments to their home address, patients were 
invited to share any feedback related to the length of time needed to complete the packet 
and any items that appeared confusing.  Additionally, participant packets were analyzed 
to assess for any apparent trends in terms of missing, incomplete, or misunderstood items.  
Some of this direct and indirect feedback has been incorporated, while other feedback 
was not. What follows is a summary of the direct and indirect feedback and the rationale 
for its inclusion or exclusion, respectively.  
Feedback 
All individuals who completed the instruments followed the written instructions 
provided with the mailed packet.  Specifically, they signed and dated the written consent 
and returned it along with their completed packets.  Additionally, all but one prospective 
pilot participant returned the contents in a one-week period from their reception of the 
packet.  During the initial phone contact, patients were asked to indicate on the packet if 
it took an excess of 20 minutes to complete the pilot instruments.  No one made any 
indications suggesting the completion time exceeded this specified time frame.  One 
prospective pilot participant did, however, call the investigator to state that the 
completion of the battery in its entirety was too much given her current state of health.  
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Rather than complete, or partially complete, select instruments, the prospective 
participant returned the entire battery without any data.  This incident suggests that those 
who are experiencing significant health complications may find the idea of completing a 
battery of instruments requiring approximately 20 minutes of time to be a daunting 
endeavor.  Consequently, if prospective participants indicated such concerns over the 
initial verbal consent phone call in the full study, they were given the non-pressured 
option of completing select instruments, as their health and mindset allowed, so that it 
was possible to acquire some data from any individuals with similar concerns. 
  Other indirect feedback was obtained while reviewing the returned instruments.  
Given the importance of obtaining participants‟ primary diagnosis for certain analyses, 
the accuracy of this diagnostic information that they were asked to provide on the 
sociodemographic form is essential.  While some participants provided accurate primary 
diagnoses, others simply indicated they had peritoneal dissemination.  For the purposes of 
accuracy and consistency, the primary diagnosis of each participant was pulled from the 
existing CS+HIPEC database of WFUBMC for the full study.  
 Additionally, in numerous instances, participants selected more than one response 
choice on the SF-36 and PSQI items.  Although scoring strategies are in place for such 
occurrences, the cleanest conclusions can be drawn from analyses of the one best 
response provided by the respective participants.  On the PSQI, these numerous responses 
often took the form of a range of bed times, waking times, or typical hours of sleep.  In 
an attempt to acquire the most suitable or representative response for each question in the 
full study, interested prospective participants were asked in the initial phone contact to 
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select or offer the one response choice that was most representative or typical for each 
item. 
 Finally, the completion of all of the requisite steps of the pilot study informed the 
investigator‟s understanding of the procedural aspects of the study.  First, the estimated 
time allocation for each of the initial telephone contacts in order to obtain verbal consent 
for the mailing was insufficient.  In general, patients appreciated the phone contact and 
often took the opportunity to update the investigator on her or his health status, QOL, and 
upcoming appointments, thereby lengthening the estimated call duration.  Additionally, 
many patients requested certain hospital triage numbers in order to reach someone who 
could answer their medical questions or check appointment dates.  These numbers were 
acquired and available when additional questions arose in the full study.  Finally, of the 
prospective pilot participants who were randomly pulled from the database, those who 
were contacted were more frequently retired and not working or disabled.  This is likely 
because the phone calls predominantly occurred during normal business hours.  Messages 
were left on many answering machines, and numerous working individuals returned the 
message expressing interest in participating in the study.  In addition to having some 
form of voicemail, these working individuals who returned the calls demonstrated some 
initiative on their parts.  Together, these findings related to the results of the initial verbal 
consent pilot phone calls suggested that the time allocated for each phone call needed to 
be increased, appropriate telephone triage numbers of WFUBMC needed to be on hand, 
and phone call times needed to be extended to after hours in order to target working 
individuals.  
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Summary 
 Additional descriptive information is needed on the survivors of CS+HIPEC.  In 
this study, the researcher examined the quality of life and sleep quality of these survivors 
and investigated the role of certain demographic and clinical variables in predicting long-
term QOL within these individuals.  In this chapter, the research questions and 
hypotheses were outlined, a description of participant recruitment was provided, the 
instrumentation and procedures were expressed, and the intended data analyses were 
offered.  Lastly, direct and indirect feedback obtained via the pilot study was described, 
and changes implemented to enhance the integrity of the full study were listed.
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CHAPTER IV 
RESULTS 
 
 
In this chapter, the results of the study are presented by means of both descriptive and 
inferential statistics.  First, the sample characteristics are described.  Next, the 
psychometric characteristics of the instruments are reported.  Finally, the results of the 
analyses performed to test the respective hypotheses are described.  
Sample Characteristics 
Following a database search for all WFUBMC patients living 12 or more months 
post CS+HIPEC, 205 individuals were located in addition to the 17 who were invited to 
participate in the pilot study.  Of these prospective 205 individuals, the investigator 
learned that two individuals died during the phone call time frame, leaving 203 potential 
participants.  Of these 203 remaining individuals, 35 persons had numbers that were 
disconnected or inaccurate.  Removing those who did not have accurate contact 
information, the investigator counted a total of 168 potential participants.  At the 
conclusion of the calling period, 124 of the 168 individuals had given verbal consent for 
the mailing and only two individuals declined participation.  The remaining 42 qualifying 
individuals were not reached via telephone and did not return the voice messages.  Of 
note, the investigator learned, through loved ones and caregivers, that some of these 42 
individuals with whom she did not converse directly were sick, in hospitals with 
complications, or at home with hospice care.  Of the 124 individuals who gave verbal
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consent to the mailing, 63 participated previously in a longitudinal research study in 
which they provided baseline, pre-surgical QOL information.  The other 61 individuals 
did not participate and therefore did not have baseline data available for comparison 
purposes. 
The final sample consisted of 82 CS+HIPEC survivors (55.56% female (n = 45) 
and 44.44% male (n = 36)) ranging from 13 months to 180.2 months post-procedure (m = 
48.9 months, sd = 39.6 months).  This number reflects a 49% overall response rate (i.e. 
82/168) and a 66% response rate from those who gave verbal consent for the mailing (i.e. 
82/124).  Age at the time of study completion ranged from 23 to 87 (m = 58.4, sd = 12.4), 
while age at CS+HIPEC ranged from 21 to 80.0 (m = 54.9, sd = 11.8).  Relative to race, 
79.27% of the sample self-identified as White (n = 65), 12.20% as Black (n = 10), 4.88% 
as both White and Native American (n = 4), 2.44% as Asian (n = 2), and 1.22% as Native 
American (n = 1).  All but 1.25% of the sample self-identified as Non-Hispanic.  Post-
surgery, 60% (n = 48) were classified as receiving a R0/R1 resection status, 30% (n = 24) 
were classified as receiving an R2a resection status, and 10% (n = 8) received an R2b 
resection status.  Finally, primary tumor sites most commonly represented among final 
sample participants included appendix (60.49% (n = 49)), colon (14.81% (n = 12)), ovary 
(7.41% (n = 6)), and mesothelioma (6.17% (n = 5)), among others.  For these, and other, 
descriptive statistics, please refer to Tables 2-8.                                                                                                                     
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Table 2 
Descriptive Statistics: Current Age, Age at CS+HIPEC, Months since Surgery 
Variable Mean Std Dev. Median  Minimum Maximum 
Age (current) 58.4 12.4 61.0 23.0 87.0 
HIPEC age 54.9 11.8 56.0 21.0 80.0 
Time_since_surgery (mo.) 48.9 39.6 33.9 13.0 180.2 
 
 
 
Table 3 
Descriptive Statistics: Resection Status 
Resection Status Frequency Percent Cumulative Frequency Cumulative Percent 
R0/R1 48 60 48 60.00 
R2a 24 30 72 90.00 
R2b 8 10 80 100.00 
Note: Frequency Missing = 2  
 
 
 
Table 4 
Descriptive Statistics: Gender 
Gender Frequency Percent Cumulative 
Frequency 
Cumulative 
Percent 
Female 45 55.56 45 55.56 
Male 36 44.44 81 100.00 
Note: Frequency Missing = 1 
 
 
 
Table 5 
Descriptive Statistics: Ethnicity 
Ethnicity Frequency Percent Cumulative 
Frequency 
Cumulative 
Percent 
H 1 1.25 1 1.25 
NH 79 98.75 80 100.00 
Note: Frequency Missing = 2 
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Table 6 
Descriptive Statistics: Race 
Race Frequency Percent Cumulative 
Frequency 
Cumulative 
Percent 
Asian 2 2.44 2 2.44 
Black 10 12.20 12 14.63 
Native American 1 1.22 13 15.85 
White 65 79.27 78 95.12 
White & Native 
American 
4 4.88 82 100.00 
 
 
 
Table 7 
Descriptive Statistics: Primary Cancer Site 
Site Frequency Percent Cumulative 
Frequency 
Cumulative 
Percent 
GIST  2 2.47 2 2.47 
PMP-disseminated 
peritoneal mucinous 
1 1.23 3 3.70 
Appendix 49 60.49 52 64.20 
Appendix & colon 1 1.23 53 65.43 
Appendix; DPAM 1 1.23 54 66.67 
Colon 12 14.81 66 81.48 
Mesothelioma 5 6.17 71 87.65 
Ovary 6 7.41 77 95.06 
Rectal 2 2.47 79 97.53 
Sarcoma 1 1.23 80 98.77 
unknown 1 1.23 81 100.00 
*Frequency Missing = 1 
Note: GIST= Gastrointestinal Stromal Tumor; PMP= Pseudomyxoma Peritonei; DPAM= Disseminated Peritoneal 
Adenomucinous 
 
 
 
Table 8 
Descriptive Statistics: Marital Status 
Marital Status Frequency Percent Cumulative Frequency Cumulative Percent 
Single 5 6.10 5 6.10 
Married 57 69.51 62 75.61 
Separated 2 2.44 64 78.05 
Divorced 9 10.98 73 89.02 
Widowed 9 10.98 82 100.00 
 
163 
 
Instrument Psychometrics 
 
Within the SF-36 subscales, measures of internal consistency ranged from 0.76 
(MH) to 0.93 (PF) with a median alpha of .85, while the Cronbach‟s alpha estimate for 
the global PSQI measure was 0.75.  These estimates of internal consistency support the 
reliability of these measures with this sample (see Table 9). 
 
 
Table: 9 
Internal Consistency of Measures 
Measure Cronbach‟s  
Alpha 
SF36: PF 0.932 
SF36: RP 0.907 
SF36: BP 0.875 
SF36: GH 0.820 
SF36: VT 0.870 
SF36: SF 0.830 
SF36: RE 0.815 
SF36: MH 0.758 
PSQI Global 0.753 
 
Note: PF = Physical Functioning; RP = Role Physical; BP = Bodily Pain; GH = General Health; VT = 
Vitality; SF = Social Functioning; RE = Role Emotional; MH = Mental Health; PSQI = Pittsburgh Sleep 
Quality Index 
 
 
 
 
Hypothesis Testing 
  
The results of analyses to test the following research questions are delineated 
below.  
 
1. What are the QOL subscale scores (i.e. Physical Functioning, Role Physical, Bodily 
Pain, General Health, Vitality, Social Functioning, Mental Health, Role Emotional) and 
component scores (i.e. Physical Component Score and Mental Component Score) of 
participants, as measured by the Medical Outcomes Study 36-Item Short-Form Health 
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Survey (SF-36) instrument, and how do they compare to those of general population 
norms? 
 
2. Regarding those participants for whom pre-surgical data is available, what differences 
exist between pre-surgical QOL subscale scores and 12 or more-month QOL scores for 
participants who received CS+HIPEC and have survived? 
 
3. What is the sleep quality of participants, as defined by one‟s global and component 
scores on the Pittsburgh Sleep Quality Index (PSQI)? 
 
4. What relationship exists between sleep quality, age at CS+HIPEC, months since 
surgery, and QOL subscale scores?  
 
5. What are the respective contributions of resection status (RO/R1, R2a, R2b, and R2c) 
and primary tumor site in predicting QOL subscale scores at 12 or more months? 
 
 
Research Question 1 
 
Research question one pertained to the QOL scores of CS+HIPEC survivors.  In 
Tables 10-11, the QOL means, standard deviations, confidence intervals, and z-statistics 
are delineated for the subscale and component scores.  Figure 2 offers a graphical display 
of the QOL mean scores. 
 
 
165 
 
Table 10 
Quality of Life: Norm-based Scores and Confidence Intervals for Mean Scores 
Variable N Mean Std. 
Dev. 
Median 25
th
 
Pctl 
75
th
 
Pctl 
Minimum Maximum Lower 
95% 
CL 
for 
Mean 
Upper 
95% 
CL 
for 
Mean 
PF_NBS 82 45.9 11.1 49.8 38.3 55.1 15.2 57.1 43.5 48.3 
RP_NBS 81 46.9 11.7 56.2 35.0 56.2 28.0 56.2 44.3 49.5 
BP_NBS 82 52.7 10.3 55.9 42.2 62.8 28.9 62.8 50.4 54.9 
GH_NBS 82 49.4 10.2 50.9 43.9 57.0 24.2 64.0 47.2 51.7 
VT_NBS 82 52.4 10.4 53.8 44.3 60.9 23.0 70.4 50.1 54.7 
SF_NBS 82 51.1 9.3 57.1 46.3 57.1 13.7 57.1 49.1 53.2 
RE_NBS 82 49.9 10.2 55.3 44.8 55.3 23.7 55.3 47.7 52.2 
MH_NBS 82 54.0 8.2 57.3 50.4 59.5 32.3 64.1 52.2 55.8 
PCS 82 47.0 10.7 51.2 37.2 55.5 19.8 60.3 44.6 49.3 
MCS 82 53.9 8.3 56.0 50.8 59.2 25.9 68.9 52.1 55.7 
Note: PF_NBS = Physical Functioning Norm-based Score; RP_NBS = Role Physical Norm-based Score; 
BP_NBS = Bodily Pain Norm-based Score; GH_NBS = General Health Norm-based Score; VT_NBS = 
Vitality Norm-based Score; SF_NBS = Social Functioning Norm-based Score; RE_NBS = Role Emotional 
Norm-based Score; MH_NBS = Mental Health Norm-based Score; PCS = Physical Component Score; 
MCS = Mental Component Score 
 
 
The norm-based QOL scores, standard deviations, and ranges are listed for each 
scale and component score.  First, percentiles and 95% confidence intervals were 
established around the observed mean scores in order to demonstrate score ranges.  If a 
confidence interval did not include 50 (i.e. the norm-based mean), it was possible to 
gauge, at an alpha level of 0.05, if a respective mean was either lower or higher than that 
of the standardization sample.  In Table 11, z-statistics that were calculated with general 
population parameters are displayed.  The scores that differed significantly from 50 at the 
.05 level are bolded.  Because there were a large number of analyses being conducted, 
Bonferroni corrections were used to control Type I error, and a more conservative 
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significance level of p = 0.005 was used.  In Table 11, those scores that differed 
significantly from 50 at the p = 0.005 level are marked with an asterisk. 
 
 
Figure 2: Norm-based QOL Subscale and Component Scores 
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Table: 11 
Quality of Life: z-statistics and p-values 
Scale z-statistic p-value 
PF* -3.373 <0.001 
RP -2.354 0.019 
BP 2.352 0.019 
GH -0.497 0.619 
VT 2.086 0.037 
SF 1.085 0.278 
RE -0.049 0.961 
MH* 4.422 <0.001 
PCS -2.540 0.011 
MCS* 4.228 <0.001 
 
Note: PF = Physical Functioning; RP = Role Physical; BP = Bodily Pain; GH = General Health; VT = 
Vitality; SF = Social Functioning; RE = Role Emotional; MH = Mental Health; PCS = Physical 
Component Score; MCS = Mental Component Score 
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Contrary to what was hypothesized, all QOL scores of participants were not 
significantly lower than the population norms.  Rather, in this sample, the PF (z =-3.373, 
p = <0.001) scores were significantly lower than those of the general population, while 
the MH (z = 4.422, p < 0.001) scores and the MCS (z = 4.228, p = < 0.001) were 
significantly higher than those of the general population.   
Although the Bonferroni correction p = 0.005 was utilized to determine the actual 
significance of the scores, it is important to take note of those scores that were not 
significant at the p = 0.005 level yet differed from the population parameters at the p = 
0.05 level.  Scores with p values less than 0.05 but greater than 0.005 included those 
associated with the RP (z = - 2.354, p = 0.019) scale and PCS (z = -2.540, p = 0.011), as 
well as the BP (z = 2.352, p = 0.019) and VT (z = 2.086, p = 0.037) scores.  Utilizing this 
conservative cut point, these scores were not considered significantly different from the 
population means, unlike the Physical Functioning, Mental Health, and Mental 
Component scores.  If a less conservative test of significance was utilized or if a larger 
sample was attained, however, it is possible that these scores would be considered 
significantly different from the population norms as well. 
In conclusion, one is able to conclude from these scores that these survivors 
continue to fare significantly worse than their general population counterparts in a 
physical capacity.  Their mental health, however, was significantly better.  The 
hypothesis that all QOL scores would be lower than those of the population norms was 
not supported.  
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Research Question 2 
 The purpose of research question two was to examine the significance of changes 
between baseline and follow-up QOL scores in each of the mean scale and component 
scores.  Each person served as a control for her- or himself, and alpha levels were 
adjusted prior to the analyses.  The results of these analyses are reported below (see 
Tables 12-21) for the 41 participants for whom baseline data were available.  Again, a 
Bonferroni correction (p = 0.005) was utilized to determine the actual significance of the 
scores.  For reference, those scores that were not significant at the p = 0.005 level yet 
differed at the p = 0.05 level are bolded as well.  In Figure 3, a graphical display of these 
changes is depicted. 
 
Table: 12 
Paired t-test: Change at Follow-up, Physical Functioning 
Variable N Mean Std Dev Median Minimum Maximum P-value 
PF_NBS_BL 41 47.5 9.3 48.8 19.4 57.1  
PF_NBS 41 47.7 10.1 50.9 23.6 57.1  
PF change 41 .2     0.8857 
PF_NBS_BL: Physical Functioning Norm-based Score Baseline; PF_NBS: Physical Functioning-Norm-
based Score 
 
 
 
Table: 13 
Paired t-test: Change at Follow-up, Role Physical 
Variable N Mean Std Dev Median Minimum Maximum P-value 
RP_NBS_BL 41 44.9 12.8 56.2 28.0 56.2  
RP_NBS 41 48.1 10.9 56.2 28.0 56.2  
RP change 41 3.3     0.183 
 RP_NBS_BL: Role Physical Norm-based Score Baseline; RP_NBS: Role Physical-Norm-based Score 
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Table: 14 
Paired t-test: Change at Follow-up, Bodily Pain 
Variable N Mean Std Dev Median Minimum Maximum P-value 
BP_NBS_BL 41 52.8 10.0 55.9 33.2 62.8  
BP_NBS 41 53.7 9.9 55.9 37.5 62.8  
BP change 41 0.9     0.616 
  BP_NBS_BL: Bodily Pain Norm-based Score Baseline; BP_NBS: Bodily Pain-Norm-based Score 
 
 
 
Table: 15 
Paired t-test: Change at Follow-up, General Health 
Variable N Mean Std Dev Median Minimum Maximum P-value 
GH_NBS_BL 41 49.8 7.5 50.9 31.2 64.0  
GH_NBS 41 51.1 8.8 50.9 31.8 64.0  
GH change 41 1.3     0.337 
   GH_NBS_BL: General Health Norm-based Score Baseline; GH_NBS: General Health Norm-based 
Score 
 
 
 
Table: 16 
Paired t-test: Change at Follow-up, Vitality 
Variable N Mean Std Dev Median Minimum Maximum P-value 
VT_NBS_BL 41 52.4 9.3 53.8 25.4 70.4  
VT_NBS 41 54.0 8.9 56.2 37.2 70.4  
VT change 41 1.6     0.366 
   VT_NBS_BL: Vitality Norm-based Score Baseline; VT_NBS: Vitality Norm-based Score 
 
 
 
 
Table: 17 
Paired t-test: Change at Follow-up, Social Functioning 
Variable N Mean Std Dev Median Minimum Maximum P-value 
SF_NBS_BL 41 47.5 10.4 46.3 13.7 57.1  
SF_NBS 41 53.0 6.7 57.1 30.0 57.1  
SF change* 41 5.6     0.003* 
   SF_NBS_BL: Social Functioning Norm-based Score Baseline; SF_NBS: Social Functioning Norm-based 
Score 
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Table: 18 
Paired t-test: Change at Follow-up, Role Emotional 
Variable N Mean Std Dev Median Minimum Maximum P-value 
RE_NBS_BL 41 48.9 11.3 55.3 23.7 55.3  
RE_NBS 41 51.2 9.4 55.3 23.7 55.3  
RE change 41 2.3     0.298 
  RE_NBS_BL: Role Emotional Norm-based Score Baseline; RE_NBS: Role Emotional Norm-based Score 
  
 
 
Table: 19 
Paired t-test: Change at Follow-up, Mental Health 
Variable N Mean Std Dev Median Minimum Maximum P-value 
MH_NBS_BL 41 52.3 7.0 55.0 34.5 64.1  
MH_NBS 41 55.6 7.8 57.3 32.3 64.1  
MH change 41 3.3     0.008 
   MH_NBS_BL: Mental Health Norm-based Score Baseline; MH_NBS: Mental Health Norm-based Score 
 
 
 
Table: 20 
Paired t-test: Change at Follow-up, Physical Component 
Variable N Mean Std Dev Median Minimum Maximum P-value 
PCS_BL 41 47.7 10.1 51.0 21.8 63.1  
PCS 41 48.4 9.9 52.2 19.8 60.3  
PCS change 41 0.7     0.704 
   PCS_BL: Physical Component Score Baseline; PCS: Physical Component Score 
 
 
 
Table: 21 
Paired t-test: Change at Follow-up, Mental Component 
Variable N Mean Std Dev Median Minimum Maximum P-value 
MCS_BL 41 51.5 8.2 53.1 35.7 67.0  
MCS 41 55.4 8.2 57.0 27.2 68.9  
MCS change 41 3.9     0.014 
   MCS_BL: Mental Component Score Baseline; MCS: Mental Component Score 
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Figure: 3 
Changes in QOL Scores over Time 
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Note: PF = Physical Functioning; RP = Role Physical; BP = Bodily Pain; GH = General Health; VT = 
Vitality; SF = Social Functioning; RE = Role Emotional; MH = Mental Health; PCS = Physical 
Component Score; MCS = Mental Component Score 
 
 These paired t-tests were performed to assess change on all QOL subscales 
between time one (pre-procedure) and time two (follow-up).   Exactly 50% of the 
participants (n = 41) had accessible baseline QOL pre-procedure data.  Although the 
majority of the changes were not statistically significant, it is interesting to note that all 
change scores were positive (i.e., all baseline QOL mean scores were lower than 12+ 
month follow-up QOL scores).  The magnitude of the changes was statistically 
significant for the SF (p = 0.003) scale, suggesting participants reported significantly 
improved social functioning as compared to pre-procedure.  Although not significant at 
the conservative p-value established by the Bonferroni correction, the MH (p = 0.008) 
scale and the MCS (p = 0.014) differed significantly from baseline at the p = 0.05 level, 
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indicating improved mental health as compared to pre-procedure.  Contrary to what was 
hypothesized, no significant changes were noted in the mean Physical Functioning, Role 
Physical, or Bodily Pain scores.  
Research Question 3 
 Research question three was developed to examine the sleep quality of 
participants and the relativity of these sleep quality scores to the conservative cutoff score 
of eight suggested by Carpenter and Andrykowski (1998).  In Tables 22-25, descriptive 
statistics, the lower and upper 95% confidence intervals for the percentage of participants 
at or above the clinical cutoff score of eight, and the results of a t-test comparing the 
PSQI mean with that of other populations originally used to determine the cutoff score of 
eight are outlined. 
 
Table 22 
Pittsburgh Sleep Quality Index Means 
Variable N Mean Std Dev Minimum Maximum 
Sleep Quality 82 0.7 0.8 0.0 3.0 
Sleep Latency 80 1.1 1.1 0.0 3.0 
Sleep Duration 81 0.9 1.0 0.0 3.0 
Habitual Sleep Efficiency 78 0.7 1.0 0.0 3.0 
Sleep Disturbance 82 1.4 0.6 0.0 3.0 
Use of Sleeping Medication 82 0.8 1.1 0.0 3.0 
Daytime Dysfunction 82 0.7 0.7 0.0 2.0 
Total PSQI 82 6.3 4.4 0.0 19.6 
 
 
The mean PSQI score for participants was 6.3 (sd = 4.4), falling below the 
conservative cutoff score of eight.  Global PSQI scores ranged from 0.0 to 19.6, however, 
suggesting variation in sleep quality within the sample.   
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Table 23 
Pittsburgh Sleep Quality Index Frequencies 
PSQI Total Frequency Percent Cumulative  
Frequency 
Cumulative  
Percent 
0 1 1.22 1 1.22 
1 6 7.32 7 8.54 
2 9 10.98 16 19.51 
2.3333 1 1.22 17 20.73 
3 9 10.98 26 31.71 
4 8 9.76 34 41.46 
5 7 8.54 41 50.00 
6 9 10.98 50 60.98 
7 6 7.32 56 68.29 
8 3 3.66 59 71.95 
9 5 6.10 64 78.05 
10 3 3.66 67 81.71 
10.5 1 1.22 68 82.93 
11 4 4.88 72 87.80 
12 2 2.44 74 90.24 
13 1 1.22 75 91.46 
14 2 2.44 77 93.90 
15 2 2.44 79 96.34 
16 1 1.22 80 97.56 
18.6667 1 1.22 81 98.78 
19.6000 1 1.22 82 100.00 
 
Within this sample, 31.70% of participants scored at or above the clinical cutoff 
of eight, indicating the presence of significant sleep disturbances within almost one third 
of the sample.  The investigator hypothesized that the majority of the sample would have 
PSQI scores at or above the recommended clinical cutoff of eight.  Prior to Carter and 
Andrykowski‟s (1998) work, a clinical cut score of five was used for the PSQI.  It is 
interesting to note that this hypothesis would have been supported using this more liberal 
cutoff score.  Contrary to what was hypothesized, however, using the more conservative 
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cutoff, only 31.70% of participants had scores of eight or higher.  The majority of the 
participants, then, did not report significantly impaired sleep quality.  
 
 
Table: 24 
Pittsburgh Sleep Quality Index Cutoff Percentages and Confidence Intervals 
Percentage at or  
Above Cutoff of 8 
Lower 95% CI  
for Percentage 
at or Above 8 
(alpha = 0.05) 
Upper 95% CI  
for Percentage  
at or Above 8 
(alpha = 0.05) 
31.70% 21.6% 42.8% 
 
A 95% confidence interval was established around the observed percentage of 
participants who scored at or above the recommended cutoff of eight.  This 95% 
confidence interval ranged from 21.6% to 42.8%, suggesting that, if the study was 
conducted 100 times, the observed percentage of individuals scoring eight or higher 
would be expected to fall within this confidence interval at least 95 of those 100 times. 
This information also supports the rejection of the hypothesis that the majority of 
participants would have significantly impaired sleep functioning, using the clinical cut 
score of eight. 
 A t-test was completed in order to compare the mean PSQI scores of differing 
populations.  The sample means and standard deviations were referenced in the Carpenter 
and Andrykowski (1998) article and subsequently utilized in these analyses.  Carpenter 
and Andrykowski examined the psychometric characteristics of the PSQI with various 
populations and used the findings as the basis of their recommendation to move the 
clinical cut point of the PSQI to a more conservative level of eight, rather than five.  
Given that the mean scores in the Carpenter and Andrykowski (1998) samples were used 
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to establish this more conservative cutoff score, it seemed valuable to compare the 
current sample to those samples.  
 
Table 25 
T-test: Comparison of Pittsburgh Sleep Quality Index Mean Scores of Current Sample 
with Other Populations 
 Sample  N Months post Mean Std 
Dev 
p-
value 
CS+HIPEC 82 12+ 6.3 4.4 - 
Bone Marrow Transplant 155 60.0 post transplant 5.6 3.9 0.216 
Renal Transplant 56 66.6 post transplant 7.6 4.4 0.090 
Women w/ Breast Cancer 102 28.9 post Dx 
(at least 3 mo. Post 
Tx) 
7.0 4.4 0.302 
Women w/ Benign Breast 
Problems 
159 - 6.4 4.2 0.905 
Controls*  - 2.7 1.7 <0.001 
Sample means and standard deviations published by Carpenter and Andrykowski (1998) 
 
 
 An examination of the p-values revealed that the sleep quality of CS+HIPEC 
survivors did not differ significantly from that of bone marrow transplant recipients, renal 
transplant recipients, women treated for breast cancer, or women with benign breast 
problems. The mean sleep quality was, however, significantly worse than that of healthy 
controls (p = <0.001). 
Research Question 4 
 
 The purpose of research question four was to examine the relationships between 
global sleep quality scores, the QOL subscale and component scores, age at CS+HIPEC, 
and months since procedure (all continuous variables).  The correlation matrix is 
presented in Table 26.  
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Table 26 
Pearson Correlation Coefficients: Sleep Quality and Quality of Life 
 HIPEC_age time_since_surgery PF_NBS RP_NBS BP_NBS GH_NBS 
HIPEC_age 
 
1.000 
 
81 
-0.020 
0.859 
81 
-0.270 
0.015 
81 
-0.290 
0.009 
80 
-0.098 
0.387 
81 
-0.109 
0.335 
81 
time_since_surgery 
 
-0.020 
0.859 
81 
1.000 
 
81 
-0.032 
0.779 
81 
-0.058 
0.612 
80 
-0.005 
0.966 
81 
-0.017 
0.880 
81 
PF_NBS 
 
-0.270 
0.015 
81 
-0.032 
0.779 
81 
1.000 
 
82 
0.747 
<.001 
81 
0.556 
<.001 
82 
0.603 
<.001 
82 
RP_NBS 
 
-0.290 
0.009 
80 
-0.058 
0.612 
80 
0.747 
<.001 
81 
1.000 
 
81 
0.642 
<.001 
81 
0.628 
<.001 
81 
BP_NBS 
 
-0.098 
0.387 
81 
-0.005 
0.966 
81 
0.556 
<.001 
82 
0.642 
<.001 
81 
1.000 
 
82 
0.564 
<.001 
82 
GH_NBS 
 
-0.109 
0.335 
81 
-0.017 
0.880 
81 
0.603 
<.001 
82 
0.628 
<.001 
81 
0.564 
<.001 
82 
1.000 
 
82 
VT_NBS 
 
-0.183 
0.102 
81 
0.050 
0.657 
81 
0.628 
<.001 
82 
0.751 
<.001 
81 
0.601 
<.001 
82 
0.731 
<.001 
82 
SF_NBS 
 
-0.174 
0.121 
81 
-0.059 
0.600 
81 
0.640 
<.001 
82 
0.668 
<.001 
81 
0.603 
<.001 
82 
0.634 
<.001 
82 
RE_NBS 
 
-0.153 
0.173 
81 
-0.039 
0.731 
81 
0.572 
<.001 
82 
0.633 
<.001 
81 
0.530 
<.001 
82 
0.619 
<.001 
82 
MH_NBS 
 
-0.101 
0.369 
81 
-0.078 
0.490 
81 
0.360 
0.009 
82 
0.554 
<.001 
81 
0.376 
0.001 
82 
0.521 
<.001 
82 
PCS 
 
-0.248 
0.026 
81 
-0.013 
0.907 
81 
0.890 
<.001 
82 
0.866 
<.001 
81 
0.778 
<.001 
82 
0.736 
<.001 
82 
MCS 
 
-0.090 
0.422 
81 
-0.044 
0.698 
81 
0.340 
0.002 
82 
0.516 
<.0001 
81 
0.410 
0.000 
82 
0.603 
<.001 
82 
psqi_tot 
Total PSQI 
0.133 
0.238 
81 
-0.052 
0.648 
81 
-0.417 
<.001 
82 
-0.485 
<.001 
81 
-0.453 
<.001 
82 
-0.340 
0.000 
82 
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 VT_NBS SF_NBS RE_NBS MH_NBS PCS MCS psqi_tot 
HIPEC_age 
HIPEC_age 
-0.183 
0.102 
81 
-0.174 
0.121 
81 
-0.153 
0.173 
81 
-0.101 
0.369 
81 
-0.248 
0.026 
81 
-0.090 
0.422 
81 
0.133 
0.238 
81 
time_since_surgery 
 
0.050 
0.657 
81 
-0.059 
0.600 
81 
-0.039 
0.731 
81 
-0.078 
0.490 
81 
-0.013 
0.907 
81 
-0.044 
0.698 
81 
-0.052 
0.648 
81 
PF_NBS 
 
0.628 
<.001 
82 
0.640 
<.001 
82 
0.572 
<.001 
82 
0.360 
0.001 
82 
0.890 
<.001 
82 
0.340 
0.002 
82 
-0.417 
<.001 
82 
RP_NBS 
 
0.751 
<.001 
81 
0.668 
<.001 
81 
0.633 
<.001 
81 
0.554 
<.001 
81 
0.866 
<.001 
81 
0.516 
<.001 
81 
-0.485 
<.001 
81 
BP_NBS 
 
0.601 
<.001 
82 
0.603 
<.001 
82 
0.530 
<.001 
82 
0.376 
0.001 
82 
0.778 
<.001 
82 
0.410 
0.000 
82 
-0.453 
<.001 
82 
GH_NBS 
 
0.731 
<.001 
82 
0.634 
<.001 
82 
0.619 
<.001 
82 
0.521 
<.001 
82 
0.736 
<.001 
82 
0.603 
<.001 
82 
-0.400 
0.000 
82 
VT_NBS 
 
1.000 
 
82 
0.709 
<.001 
82 
0.598 
<.001 
82 
0.592 
<.001 
82 
0.739 
<.001 
82 
0.700 
<.001 
82 
-0.521 
<.001 
82 
SF_NBS 
 
0.709 
<.001 
82 
1.000 
 
82 
0.662 
<.001 
82 
0.434 
<.001 
82 
0.688 
<.001 
82 
0.675 
<.001 
82 
-0.270 
0.014 
82 
RE_NBS 
 
0.598 
<.001 
82 
0.662 
<.001 
82 
1.000 
 
82 
0.597 
<.001 
82 
0.536 
<.001 
82 
0.832 
<.001 
82 
-0.425 
<.001 
82 
MH_NBS 
 
0.592 
<.001 
82 
0.434 
<.001 
82 
0.597 
<.001 
82 
1.000 
 
82 
0.338 
0.002 
82 
0.843 
<.001 
82 
-0.456 
<.001 
82 
PCS 
 
0.739 
<.001 
82 
0.688 
<.001 
82 
0.536 
<.001 
82 
0.338 
0.002 
82 
1.000 
 
82 
0.341 
0.002 
82 
-0.452 
<.001 
82 
MCS 
 
0.700 
<.001 
82 
0.675 
<.001 
82 
0.832 
<.001 
82 
0.843 
<.001 
82 
0.341 
0.002 
82 
1.000 
 
82 
-0.410 
0.000 
82 
psqi_tot 
Total PSQI 
-0.521 
<.001 
82 
-0.270 
0.014 
82 
-0.425 
<.001 
82 
-0.456 
<.001 
82 
-0.452 
<.001 
82 
-0.410 
0.000 
82 
1.000 
 
82 
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Abbreviations: PF_NBS = Physical Functioning Norm-based Score; RP_NBS = Role Physical Norm-based 
Score; BP_NBS = Bodily Pain Norm-based Score; GH_NBS = General Health Norm-based Score; 
VT_NBS = Vitality Norm-based Score; SF_NBS = Social Functioning Norm-based Score; RE_NBS = Role 
Emotional Norm-based Score; MH_NBS = Mental Health Norm-based Score; PCS = Physical Component 
Score; MCS = Mental Component Score 
 
 
In Table 26, the Pearson Correlation Coefficients between the global sleep quality 
scores, QOL subscale and component scores, CS+HIPEC age, and months since 
procedure for the entire sample are presented.  Given that a higher score on the PSQI 
indicates the presence of more sleep quality problems (not desirable), while a higher 
QOL score indicates better QOL (desirable), a negative correlation in this analysis 
actually signified the expected relationship between the variables.  As hypothesized, all 
of the QOL subscales were related significantly to PSQI scores.  Among these 
correlations, the strongest relationship existed between sleep quality and the Vitality 
subscale (r = -0.52, p < .001).  This relationship of moderate strength indicated that as 
sleep quality improved, vitality also improved (i.e. energy levels increased and signs of 
fatigue diminished).  In conclusion, hypothesis four was accepted. 
Also of note in these interrelationships were the significant negative relationships 
between age at CS+HIPEC and the Physical Functioning (r = -0.27, p = 0.02), Role 
Physical (r = -0.29, p = 0.01), and Physical Component (r = -0.25, p = 0.03) scores.  
These findings suggest that as age increased, physical functioning decreased.  Similar 
findings would be anticipated in the general population.  The number of months since 
surgery was not related significantly to the QOL scores. 
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Research Question 5 
  
Hypothesis one. 
 
 In research question five, the investigator examined the respective contributions 
of resection status and primary tumor site to the overall Mental and Physical Component 
scores.  Two separate two-way ANOVAs were run in order to examine the effects of 
these categorical variables on the component quality of life scores.  Based on the 
demographics of the sample, some adjustments were made for the intended analyses.  
Specifically, R0 and R1 resection statuses were combined on account of inconsistent 
ratings and recordings by various surgeons within the database.  Additionally, no 
individuals with R2c were represented within the sample.  This was not surprising given 
that all participants had to be at least 12 months post-procedure, and R2c is the worst 
resection status ranking.  Resection status categories, then, were R0/R1, R2a, and R2b.  
Additionally, individuals with an R2b resection status were present only in those with a 
primary diagnosis of appendiceal cancer.  Finally, over sixty percent of the sample was 
composed of individuals with a primary diagnosis of appendiceal cancer, while the 
remainder of the primary diagnostic categories were much smaller.  Therefore, 
participants who did not have a primary diagnosis of appendix cancer were grouped 
collectively as “other”.   
Ultimately, two separate two-way ANOVAs were run in order to examine the 
contributions of the two independent, categorical variables (i.e. resection status and 
primary tumor site) to the respective QOL Physical and Mental Component scores.  
Specifically, the full models (with the main effects and interaction) were run first.  
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Results for both were not significant, so the models were rerun without the interactions.  
The results of the analyses for research question five are presented in Tables 27-28.  
Specifically, the models without interactions are presented.  Parameters for these models 
without interactions are in Appendix D (Tables M-N). 
The first hypothesis for research question five was that patients who achieved a 
better resection status would have higher QOL scores at 12 or more months.  There was 
no significant main effect of resection status on the Physical Component F(2, 76) = 0.48, 
p = 0.619 (Table 27) or Mental F(2, 76) = 0.41, p = 0.667 (Table 28) scores.  This 
hypothesis, therefore, was not accepted. 
Although resection status did not produce significant main effects in this model, 
primary tumor site produced a significant main effect on the Physical Component Scores 
of the participants F(1, 76) = 4.00, p = 0.049.  
 
Table 27 
Analysis of Variance: Physical Component Scores, No Interaction 
Source DF 
Sum of 
Squares Mean Square F Value Pr > F 
Model 3 468.018 156.006 1.41 0.245 
Error 76 8382.521 110.296   
Corrected Total 79 8850.539    
 
 
R-Square Coeff Var Root MSE PCS Mean 
0.053 22.292 10.502 47.111 
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Source DF Type III SS Mean Square F Value Pr > F 
site 1 441.329 441.329 4.00 0.049 
resect 2 106.356 53.178 0.48 0.619 
 
 
 
 
Table 28 
Analysis of Variance: Mental Component Scores, No Interaction 
Source DF 
Sum of 
Squares Mean Square F Value Pr > F 
Model 3 61.549 20.516 0.28 0.837 
Error 76 5490.672 72.246   
Corrected Total 79 5552.221    
 
 
R-Square Coeff Var Root MSE MCS Mean 
0.011 15.810 8.500 53.763 
 
 
Source DF Type III SS Mean Square F Value Pr > F 
site 1 0.034 0.034 0.00 0.983 
resect 2 58.895 29.448 0.41 0.667 
 
 
 
Hypothesis two. 
The second hypothesis for research question five was that patients with a primary 
diagnosis of cancer of the appendix or pseudomyxoma peritonei (PMP) would 
demonstrate higher QOL component scores at 12 or more months than their counterparts.  
First of all, only one individual with a primary diagnosis of PMP was represented in the 
sample, making it impossible to perform any analyses or extrapolate conclusions based 
on this primary diagnostic group.  The one individual with a diagnosis of PMP was 
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included in the “other” group.  The large number of individuals with a primary diagnosis 
of appendix cancer, however, permitted analyses and comparisons with this “other” 
group.   
A t-test was used to compare the group means of the appendiceal and “other” 
group.  Upon comparison of the QOL PCS and MCS of members of the appendiceal and 
“other” group, it was not possible to accept this second hypothesis for research question 
five.  The global QOL scores of the members of the appendiceal group did not differ 
significantly from those of the “other” group (PCS, p = 0.0993; MCS, p = 0.8776), 
possibly due, at least in part, by the necessary collapsing of non-appendiceal groups into 
an “other” category.  Please refer to Tables 29-30 for these analyses. Similarly, no 
significant differences (p = 0.099) existed between the QOL PCS of those in the 
appendiceal group (m = 48.671) and those in the “other” group (m = 44.630), nor 
between the QOL MCS of those in the appendiceal group (m = 53.897) and those in the 
“other” group (m = 53.596) (p = 0.878).  In conclusion, neither hypothesis for research 
question five was supported.  
 
Table: 29 
Physical Component Scores for Appendiceal and “Other” Groups 
site N Mean Std Dev Std Err Minimum Maximum 
appendiceal 52 48.671 9.632 1.336 22.880 60.100 
other 29 44.630 11.780 2.191 19.770 60.310 
Diff (1-2)  4.041 10.452 2.422   
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Method Variances DF t Value Pr > |t| 
Pooled Equal 79 1.67 0.099 
Satterthwaite Unequal 48.965 1.57 0.122 
 
 
Equality of Variances 
Method Num DF Den DF F Value Pr > F 
Folded F 28 51 1.50 0.206 
 
 
Table: 30 
Mental Component Scores for Appendiceal and “Other” Groups 
Site N Mean Std Dev Std Err Minimum Maximum 
appendiceal 52 53.897 7.851 1.089 27.240 66.060 
other 29 53.596 9.280 1.723 25.910 68.910 
Diff (1-2)  0.300 8.386 1.943   
 
 
Method Variances DF t Value Pr > |t| 
Pooled Equal 79 0.15 0.878 
Satterthwaite Unequal 50.403 0.15 0.886 
 
 
Equality of Variances 
Method Num DF Den DF F Value Pr > F 
Folded F 28 51 1.40 0.296 
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CHAPTER V 
CONCLUSIONS 
 
 
Overview 
 
In this chapter, implications of the findings are described.  Limitations of this 
study, implications for the counseling profession, and suggestions for future research also 
are offered. 
Discussion 
 This study represents an important contribution to the literature base concerning 
survivors of CS+HIPEC.  Given the paucity of adequately sized behavioral health 
investigations of members of this population, the addition of this study with its 
satisfactorily large number of participants permits the researcher to analyze data collected 
from survivors who had an array of disease and treatment experiences and allows readers 
to make generalizations from the findings with more confidence.   
 First of all, an examination of the descriptive statistics permits useful 
generalizations about the population.  Aside from the lack of heterogeneity relative to 
race and ethnicity, two key features of the descriptive statistics are noteworthy: the 
number of long-term survivors with each of the respective primary diagnoses as well as 
the number of individuals with each resection status.  Over sixty percent of the sample 
consisted of individuals with a primary diagnosis of cancer of the appendix, suggesting
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that individuals with a primary diagnosis of cancer of the appendix had the strongest 
representation among long-term CS+HIPEC survivors.  Similar findings related to the
 overrepresentation among long-term survivors of individuals with a primary diagnosis of 
cancer of the appendix are supported in the literature.  Levine et al. (2007) noted the 
differential clinical outcomes experienced by patients based on the pathological 
characteristics of their primary diagnosis and concluded that primary tumor site is 
correlated with improved survival.   Specifically, these researchers noted the tendency for 
patients with low grade peritoneal surface disease, including appendiceal cancer, to 
experience more desirable (i.e. longer) clinical outcomes than those with higher grade 
disease.  It is not surprising, then, to find that 60% of the current sample of long-term 
survivors had a primary tumor site of appendix.   
 Also noteworthy in the descriptive statistics was the percentage of participants 
with each designated resection status.  Again, 60% of the sample had an R0/R1 resection 
status, 30% had an R2a resection status, and 10% had an R2b resection status.  None of 
the long term survivors had an R2c resection status, and R2b statuses were represented 
strictly within the appendiceal group, not in the “other” group.  This finding is similar to 
that of Levine et al. (2007) who reported that resection status was correlated significantly 
with improved survival status and that patients who experienced a complete resection (i.e. 
R0/R1) had better outcomes than their counterparts who had incomplete resections, 
regardless of primary diagnosis.  In fact, Levine et al. (2007) recommended that those 
patients whose surgeons do not believe that an R2a resection status (or better) is feasible 
should consider foregoing this major procedure and all of its potential complications.  In 
 
 
186 
their review of procedures, three year survival rates for those with an R2c resection status 
was 14.0% (+/- 4.2), 15% (+/- 5.3%) for those with an R2b status, 38.7% (+/- 5.3%) for 
those with an R2a status, and 59.9% (+/- 3.9%) for those with an R0/R1 resection status.  
It is not surprising, then, to find this 60%, 30%, and 10% breakdown of R0/R1, R2a, and 
R2b resection statuses within the current sample, the dearth of R2c statuses, and the 
presence of individuals with an R2b status strictly within the group with the best 
prognosis (i.e. the low grade appendiceal group).   
Although potentially associated with improved survival estimates, resection status 
did not have a significant main effect on overall physical and mental component scores 
within this sample.  Tuttle et al. (2006) reported similarly that resection status was not a 
significant contributor to QOL scores within their cohort of patients at the University of 
Minnesota Cancer Center.  From these findings, one can conclude that while resection 
status may be associated with extended survival, it is not associated necessarily with 
QOL ratings among those who do survive for extended periods of time. 
Many additional noteworthy findings related to the quality of life and sleep 
quality of survivors of CS+HIPEC can be gleaned from this study as well.  First, the 
QOL subscale scores of participants revealed how they were functioning in a variety of 
domains as well as how they were functioning in comparison to the general population 
norms.  The Physical Functioning subscale scores fell significantly below the general 
population norms, while the Mental Health and Mental Component scores were 
significantly higher than general population norms.  Other scale scores were significantly 
different from the population norms at an alpha level of p = 0.05 yet did not differ at the 
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more conservative cut-off of p = 0.005 following the Bonferroni correction.  For 
example, the Role Physical and Physical Component scores were significantly lower than 
population norms at the more liberal p = 0.05 level, while Vitality and Bodily Pain scores 
were significantly higher than population norms when utilizing this alpha level.  
Although these results were not considered significant for the purposes of this 
dissertation, it is important to underscore that differences may exist between the scores of 
CS+HIPEC survivors and those of the general population within these respective 
subscales.  The remainder of the subscale scores (general health, role emotional, and 
social functioning) did not differ significantly from those of the general population.   
In a previous study, McQuellon et al. (2007) reported that all (minus the Vitality) 
subscale scores in their sample, despite significant improvement between baseline to 12 
months, remained significantly lower than the population norms.  Within the current 
sample, however, solely the Physical Functioning scores were significantly lower than 
the population norms, while the remainder of the scores did not differ significantly or 
were comparatively higher.  The substantial differences in months since procedure (i.e. 
12 months in the McQuellon et al. (2007) participants versus a range of 13-180.2 months 
in the current study) may contribute to these discrepancies. The findings from this sample 
are in closer alignment to those of Schmidt et al. (2005), who found that in their sample 
of long-term survivors (mean years since treatment = 4, range = 1-8), the Physical (p = 
0.04), Role (p = 0.002), and Social Functioning (p = 0.001) scores were significantly 
impaired relative to those of the general Norwegian population, while the Emotional and 
Cognitive Functioning scores did not differ significantly.  Given the small sample size (N 
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= 20) of Schmidt et al. (2005), interpretations should be made with caution, yet the 
physical impairments and lack of emotional impairments were similar to the findings in 
the current study.  Unlike the Schmidt et al. (2005) group, however, the current sample 
did not describe significantly impaired Social Functioning, and the Mental Health scores 
of the participants were not merely in line with the population norms; they were, in fact, 
significantly higher.  In conclusion, unlike the findings in some previous studies, the 
current group was not functioning lower than their general population counterparts in 
every QOL domain.  Rather, strictly their physical functioning was significantly lower.  
Their reported mental health was actually significantly better. 
Although it is impossible to draw explanatory conclusions from these data, it is 
possible to speculate cautiously as to why this sample differed from others described in 
the literature relative to their high Mental Health scores.  First of all, it is important to 
remain mindful of who composed the sample and why other prospective participants 
were not represented.  McQuellon et al. (2007) noted that those who are not represented 
in these post-procedure psychosocial studies are not missing at random.  It is likely that 
those who do not participate are dead or experiencing significant physical and/or 
psychological difficulties, ultimately leaving the healthiest individuals who experienced 
optimal outcomes to participate.  The more complicated and lachrymose trajectories, 
then, are likely not included in these datasets, and the data may be colored with a rosier 
disposition.   
In addition to being the best-case scenarios within their cohort, all of these 
participants shared at least a semblance of the same experience in that they traversed 
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through a mortal time zone (McQuellon & Cowan, 2007).  Although most humans 
recognize that death is a constant, inescapable companion throughout life, these 
survivors, upon receiving notification of their aggressive diagnoses, were forced to 
figuratively waltz with death (Pinkola Estes, 1990) within this mortal time zone.  That is, 
they were presented with the stark possibility of fast approaching death.  Arguably, 
reception of such an aggressive diagnosis brought to them awareness of core existential 
issues, including finitude of mortality and solitude.  Additionally, such a quickening of 
the dance pace may have brought about an acute awareness and new perspective of life.  
These survivors, whose dance pace has receded once more, may carry with them a keen 
awareness of the inevitability of death and its ability to lead.  A renewed appreciation for 
extended life and health may be a by-product of this rendezvous.  
Along these same lines, numerous researchers have investigated concepts dealing 
with positive internal changes that result within humans following trauma and adversity.  
Referred to as post-traumatic growth, Calhoun and Tedeschi (1998), for example, 
described the gradual internal paradigm shifts that may occur following internal 
disruption spurred by trauma.  Enhancement of self regard, life appreciation, life 
philosophy, and personal relationships are only a few of these areas that may be 
susceptible to gradual growth post-trauma.   
Similarly, other investigators (e.g. Sprangers and Schwartz, 1999) have examined 
a concept referred to as response shift.  The idea behind response shift is that humans are 
adept at accommodating to their new norms.  New experiences bring about shifts in 
internal standards and conceptualizations.  Within this population, the months 
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immediately post-procedure might have brought about significant suffering and life 
quality reductions, prompting a response shift.  As healing began to occur, however, life 
norms and expectations might have increased as well, producing an additional response 
shift.  Compared to their immediate post-treatment quality of life, these survivors may 
perceive their current quality of life, including mental health, as relatively high.  Their 
perception of and appreciation for life may have changed. 
In conclusion, numerous factors may have contributed to the observed Mental 
Health scores that were significantly higher than the population norms. The participants 
of this study were, by nature, the best case scenarios of the group.  Their intimate 
confrontations with mortal time, post-traumatic growth, and response shift may be 
additional contributing factors.  It is important to remember that these suggestions, 
however, are merely speculations, and that more research is needed to assess the veracity 
of these speculations. 
The contributing roles of surgical and physiological variables to long-term QOL 
scores also were examined.   As mentioned previously, resection status did not produce 
significant effects on Physical and Mental Component scores, contrary to what was 
hypothesized.  Primary tumor site, however, did demonstrate a significant main effect on 
the Physical Component scores of survivors.  Specifically, a primary diagnosis of cancer 
of the appendix yielded a significant positive effect on the long-term Physical Component 
scores of survivors.  An examination of the score parameters helps to clarify this effect.  
Holding all other variables constant, individuals with a primary diagnosis of cancer of the 
appendix can anticipate a long-term physical quality of life score this is, in general, 5.095 
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units higher (p = 0.049).  From these findings, it is possible to conclude that CS+HIPEC 
candidates who have a primary diagnosis of cancer of the appendix may experience 
benefits in their long-term physical quality of life on account of having this, rather than 
alternate, primary diagnosis.  
In addition to site and resection status, physical quality of life scores were 
examined in relation to certain demographic variables, including age at the time of 
procedure.  Pearson correlations revealed significant, albeit weak, negative relationships 
between CS+HIPEC age and Physical Functioning, Role Physical, and Physical 
Component scores.  As age at time of procedure increased, physical functioning and 
quality of life tended to decrease in survivors.  Similar relationships between age and 
these physical variables could be expected within members of the general population as 
well, however.  Interestingly, months since surgery was not associated significantly with 
QOL scores.  
Changes between baseline and long-term follow-up scores were examined as well 
in order to gain insight into movement within QOL functioning domains over time.  All 
change trends were positive, yet only Social Functioning scores demonstrated significant 
change over time.  Although not significant at the p = 0.005 level, the Mental Health 
subscale and Mental Component scores differed from baseline at a less conservative p-
value (i.e. p = 0.05).  Other researchers also have examined movement over time within 
subscale scores, with this movement highlighted best within longitudinal studies.  Similar 
to the findings in the current study, McQuellon et al. (2001) reported a significant overall 
effect on emotional (p < 0.001), physical (p = 0.003), and functional (p = 0.004) well 
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being, with scores decreasing immediately post-procedure and then increasing, relative to 
baseline, at three, six, and twelve months.  In a later study, McQuellon et al. (2007) 
reported a significant overall effect from baseline to the 12 month time point, with 
physical functioning (p = 0.001), role physical (p = 0.016), and bodily pain (p = 0.001) 
scores improving significantly. Within their group, social functioning consistently 
remained high and did not fluctuate significantly.  Additionally, they noted that 24% of 
the sample endorsed significant depressive symptoms at 12 months post-procedure.  
Similarly, Tuttle et al. (2006) reported significant improvement between baseline and 12-
month emotional well being (p = 0.003) and functional well-being (p = 0.003), yet no 
significant improvement in social functioning from baseline to 12-month follow-up.  
Finally, McQuellon et al. (2003) reported significant improvement between baseline and 
long-term follow-up in the functional (p = 0.01) and physical (p = 0.05) well being 
scores, yet not in emotional or social well being scores.   
A review of these study findings highlights the typical QOL score trends for 
members of this population.  Many researchers have noted that scores tend to drop 
immediately post-procedure and then improve over time, relative to baseline levels.  
Scores typically remain, however, below those of the population norms.  Researchers 
have reported different findings relative to what subscale scores change over time, yet 
most found significant change in the physical and functional subscale scores and no 
significant change in social functioning.  Findings around emotional well being scores 
have been mixed.  Within the current study, and unlike previous findings, the Physical 
Functioning scores did not change significantly between baseline and long-term follow-
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up measures.  These scores did, however, remain below the population norms.  Also 
dissimilar to previous findings (e.g. McQuellon et al., 2007; Tuttle et al., 2006), the 
Social Functioning scores demonstrated significant improvement over time.  The Mental 
Health scores also improved over time, ultimately exceeding the population norms.   
Again, explanations regarding these trends should be offered and interpreted as 
speculation, yet it is possible to offer some hypotheses regarding these trends.  Regarding 
the lack of significant movement with the physical subscale scores, it is possible that 
these survivors have endured many lasting physical complications and functional 
detriments, hindering significant improvement from baseline levels.  Also, it is possible 
that these scores did, in fact, improve significantly for a window of time but have 
gradually or suddenly declined with the development of new complications or advancing 
age.  In this regard, it bears repeating that survivors were surveyed at an array of times 
throughout their recovery trajectories. 
Regarding the significant improvements in Mental Health and Social Functioning 
over time, it is possible that any of the aforementioned constructs, including post-
traumatic growth and response shift, were at work.  Additionally, it is also possible that, 
in the time frame prior to the extensive procedure, participants reported significant 
distress and social withdrawal, thereby lowering these scores.  After progressing 
successfully through the hospitalization and recuperation time frames, it is possible that 
Mental Health and Social Functioning rose in tandem.  From cross-sectional data, 
however, it is impossible to discern the reasoning behind these trends. 
 
 
194 
Additional contributions to the literature base provided by this study include the 
findings related to sleep quality.  To the investigator‟s knowledge, no comprehensive 
sleep quality studies have been performed with members of this population, yet some 
previous investigators have noted the existence of symptoms related to sleep quality.  For 
example, Schmidt et al. (2005) reported that fatigue and insomnia were among the top 
three symptoms reported by survivors.  Findings from the current study represent a more 
comprehensive examination of such symptoms and provide a foundation on which to 
build future investigations.   
Contrary to what was hypothesized, the mean sleep quality score in this study (m 
= 6.3) was below the conservative clinical cut-off of eight that marks the presence of 
significant sleep quality impairments.  A t-test to compare this sample mean with that of 
other populations (i.e. bone marrow transplant, women treated for breast cancer, renal 
transplant patients, and women with benign breast problems) did not reveal any 
significant differences, while differences did exist between the mean score for this group 
and that of a group of healthy controls (p <0.001) (Carpenter & Andrykowski, 1998).  
These findings suggest that CS+HIPEC survivors experience sleep quality similar to that 
of other cancer and treatment populations but worse than that of controls.  Despite this 
mean score below the clinical cutoff, however, almost one third of the sample (31.70%) 
endorsed clinically significant levels of sleep quality impairments. With approximately 
one third of individuals reporting clinically significant sleeping problems, even using a 
conservative clinical cutoff score, ongoing assessment of sleep quality with patients and 
further research on sleep-related issues among this population is warranted. 
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Providing additional support for future sleep quality studies and interventions are 
the significant positive relationships found between global sleep quality and various QOL 
scores.  The strongest relationship, a correlation of moderate-strength (r = 0.521, p < 
0.001), was found between global sleep quality and Vitality.  These findings are not 
surprising, given that the vitality QOL subscale assesses levels of energy and fatigue.  
The comparatively weakest relationship, albeit statistically significant, existed between 
global sleep quality and social functioning (r = 0.270, p = 0.01).  In addition to revealing 
the magnitude of the relationships between these constructs, these findings also 
underscore the importance of adopting a biopsychosocial model of care with patients.  
These correlations suggest the presence of significant interrelations among the various 
domains of health, including physical, mental, and social health.  From this investigation, 
it is evident that sleep quality is related to all of the aforementioned domains.  The 
adoption of an integrative model and approach to care encourages any practitioner to 
consider the functioning of all domains of health. 
Overall, results from this investigation demonstrate that long-term survivors can 
achieve desirable quality of life.  Physical Functioning remained below what is normal 
for the general population, yet other QOL domains were no different, or even better, than 
the general population levels.  Mental Health scores were higher than those expected 
within the general population.  Additionally, the long-term survivors in this investigation 
reported significant improvement in Social Functioning and Mental Health as compared 
to baseline.  Approximately one third of participants reported impaired sleep quality.  The 
descriptive statistics revealed the overrepresentation of individuals with a primary 
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diagnosis of appendiceal cancer, suggesting the more favorable pathological 
characteristics of this primary diagnosis within the group.  Similarly, site of primary 
tumor origination had a significant main effect on long-term Physical Component scores.  
Likewise, the paucity of long term survivors with an R2c resection status designation 
suggests its comparatively poor survival prognosis.  Individuals with R2b status were 
found only within the appendiceal group.    
Although these findings and associated generalizations are of great use, a point 
highlighted by McQuellon et al. (2007) bears significant weight here as well.  McQuellon 
et al. (2007) noted that “mean scores can mask considerable individual variability” (p. 
1112), suggesting that although these statistics yield averages relative to how the group is 
functioning collectively, much individual variation exists.  Every survivorship journey is 
unique, and those functioning on considerably lower levels must not be forgotten or 
masked by means.  In other words, statistical significance must not overshadow clinical 
significance.  Group analyses may not reveal findings of statistical significance, yet the 
human suffering of one patient carries great clinical significance that must not be 
overlooked.   
Limitations of the Study 
 
 Although results of this study represent an important contribution to the literature 
concerning survivorship post-CS+HIPEC, some limitations of the study should be noted.  
First, participants of this study represented a convenience sample of individuals from not 
only a solitary medical institution but also patients of a small number of surgeons, 
thereby limiting generalizability. Similarly, in spite of the investigator‟s attempt to limit 
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exclusion criteria in order to capture the stories of as many survivors as possible, those 
who participated were those who had up-to-date contact information through the hospital, 
were in adequate health to complete the survey in a timely fashion, and, of course, were 
still living.  Information from those who did not live at least 12 months after the surgery, 
were lost to follow-up, or who were too ill to complete the instruments, therefore, was not 
represented, suggesting that participants in this study represented those with optimal 
outcomes.  
 Similarly, despite attempts to obtain a heterogeneous and inclusive sample, the 
sample was rather homogenous, as evidenced by the ethnic, racial, primary diagnosis, and 
resection status statistics.  The sample, for example, largely consisted of white, non-
Hispanic individuals, all but one with insurance.  This lack of heterogeneity reduces the 
generalizability of the study, and analyses in the current study had to be adjusted 
accordingly (e.g. due to insufficient numbers of individuals with a variety of primary 
diagnoses, the participants were classified into the primary diagnosis categories of 
“appendix” or “other” for the purposes of the analysis).  Also of note was the fact that a 
number of individuals (approximately eight) did not complete and return the consent 
forms with their packets.  All of these data were lost, and the possibility that these 
individuals differed in some way from the remaining participants who did return consent 
forms could not be ruled out. 
 An additional sampling limitation was related to the fact that baseline (i.e., pre-
procedure) data was not available for all participants. Rather, baseline QOL data was 
available for only a subset of participants (n = 41).  Given that these pre-CS+HIPEC 
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QOL data were acquired in a previous research investigation in which only a percentage 
of the current participants took part, changes in QOL scores over time could be assessed 
only in a portion of the participants.  It is unknown to what extent this would generalize 
to all participants in the study. 
 Further, it is important to remain mindful of the limitations of any cross-sectional 
research when reviewing the results of this study.  Data was collected at one time point 
along the recovery trajectory for these individuals.  Previous research studies with these 
survivors demonstrated significant changes in QOL scores across the recovery trajectory, 
with lowest scores reported during those months immediately post-procedure (e.g. 
McQuellon et al., 2001). Changes across the recovery trajectory cannot be ascertained 
from this dataset, meaning significant decreases or increases in QOL or sleep quality 
during alternate timeframes may not be captured.  Rather, a single snapshot of how these 
individuals are faring was obtained.  
 Finally, “noise”, in the form of uncontrolled variables, existed within this dataset.  
To clarify, participants in the full study ranged from 13 to 180.2 months post-
CS+HIPEC.  Although the number of months post-procedure was one variable 
considered in the analyses, it is possible that ancillary factors, unrelated to the 
CS+HIPEC procedure, may have impacted the QOL scores.  Measures could not be taken 
to control for each of these potential contributing factors, and no control group was 
available for comparison purposes.  McQuellon et al. (2003) highlighted this limitation as 
well, stating, “One vexing problem facing QOL researchers conducting long-term follow-
up studies is to what extent a disease process and subsequent treatment have affected the 
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patient‟s overall well-being compared with what changes in QOL would have occurred 
during the normal process of aging” (p. 161).  In order to clarify the role of the disease 
and treatment, score comparisons were made to available population norms and to 
baseline data for those participants (50% of total sample) on whom it was available.  It 
remains important however, when interpreting the results, to acknowledge the 
contributions of an array of other variables potentially impacting the reported QOL 
scores.  
Implications for Counseling 
 
This study represents an important addition to the body of literature concerning 
CS+HIPEC recipients.  Few studies with sufficiently large sample sizes have been 
conducted with long-term survivors of CS+HIPEC.  By acquiring data from a larger 
number of survivors, readers, including counselors who work with members of this 
population, become able to make generalizations from the results more confidently.   
Findings from this research investigation therefore have numerous implications for 
counselors working with patients and survivors of CS+HIPEC. 
First of all, results from the QOL assessments revealed how the QOL scores of 
survivors compared to those of the general population.  This multidimensional QOL data 
informs those who work with these survivors of how these individuals may be 
functioning in an array of domains, thereby enhancing practitioners‟ conceptualization 
and treatment plans.  From this dataset, one can note that survivors‟ physical functioning 
was significantly worse in comparison to that of the general population, while their 
mental health was, as a group, significantly better.  As a counselor focusing on the mental 
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health of patients and survivors, these findings are heartening; yet it is important to take 
note of the variation within the scores.  Upon examination of the range in the Mental 
Health subscale scores (e.g. 32.3 - 64.1) and Mental Component scores (e.g. 25.9 - 68.9), 
it is evident that some survivors reported Mental Health that was significantly impaired, 
with scores more than two standard deviations below the mean.  This variation and range 
of scores held true for all QOL domains, including Social Functioning and Vitality.  
These ranges should remind practitioners of the need to be mindful of the clinical 
significance of findings and the importance of individual assessment.  
Within their cancer journeys, it is possible that patients will experience both 
distress and growth of varying sorts.  For example, it is possible that positive, strength-
based aspects of life after trauma may be evident among members of this population (as 
evidenced by their Mental Health scores that were significantly higher than general 
population norms).  Counselors who, by training, also have a strength and wellness-based 
focus, may take particular interest in investigations of and clinical work with positive 
growth after adverse experiences.  These relatively high Mental Health scores serve as 
reminders to assess and clinically tend to both negative and positive experiences within 
members of this population. 
Additionally, the analysis examining the significance of change between baseline 
and follow-up scores revealed that Mental Health and Social Functioning QOL scores 
improved significantly as compared to baseline levels. These findings suggest that, as a 
group, CS+HIPEC patients may experience more distress around the time of surgery than 
one or more years post-surgery.  Based on these findings, the considerations for 
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counselors, then, include how to screen patients and survivors so that those in need of 
counseling and QOL assistance (e.g. those whose scores fall one standard deviation 
below the population mean) become evident and when, throughout this survivorship 
trajectory (e.g. immediately pre- and post-procedure), are counseling services in highest 
demand.  Screening thresholds and survivorship plans, including mental health 
counseling, could be developed for survivors in need, with this data serving as a first step 
towards those efforts. 
Additionally, prior to this study, the principal investigator was unable to locate 
any comprehensive assessments of the sleep quality of CS+HIPEC patients or survivors.  
Results of this study provide some preliminary evidence that a significant percentage of 
CS+HIPEC survivors (i.e. 31.70%) reported significant sleep quality impairments. Such 
findings suggest the potential utility of sleep quality assessments and interventions within 
this population.  The significant relationships found between sleep quality and both 
Mental Health and Role Emotional QOL in survivors also bolsters the importance of 
assessing and tending to both sleep quality and emotionality. 
The specific findings obtained from this study, such as those mentioned above, 
undeniably are important.  Yet McQuellon et al. (2007) made a vital point relative to 
making generalizations from a quantitative study performed with members of this 
population.  While extrapolations based on large amounts of aggregated data undoubtedly 
have their importance, human exceptions to these trends that are based on results from 
such analyses inevitably exist as well.  While some patients may recover more quickly 
and demonstrate higher QOL scores than the means presented in this, or other, studies, 
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others will take much longer, if ever, to reclaim a life of acceptable quality (McQuellon 
et al., 2007).  This reminder is essential, especially for those seeking to underscore the 
implications for counseling from this study.  Individuals who undergo this procedure 
have unique experiences that include varying balances of physical and mental challenges 
and growth.  Possibly more so than others, counselors are cognizant of this individuality 
and uniqueness in a person‟s experience and such uniqueness remains in existence in 
these experiences in mortal time.  So, while this data may serve to help establish 
generalizations and time points when members may be most in need of therapeutic 
services, the unique needs and experiences of each person must not be overlooked. 
 Finally, from a broader vantage point, this research investigation highlights the 
important roles and niches that mental health counselors are able to fill within a medical 
setting.  In addition to the specific research findings, the dissertation itself serves as an 
example of the importance of conducting social science research within medical settings 
and the need for availability of counseling services for these patients.  Many patients 
navigating this setting are in need of attention to mental health and quality of life, two 
major foci of counselors.  
Suggestions for Future Research 
 
 Suggestions for future research may be gleaned from the findings of this study.  
Long-term survivors of CS+HIPEC communicated QOL deficits related to physical 
functioning, and a significant percentage of these survivors reported poor sleep quality.  
Future researchers are encouraged to examine the factors that contribute to and maintain 
these impairments. Qualitative and mixed-methods studies may, in particular, help us 
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understand more fully the diversity of experiences. Additionally, despite their diagnoses 
and intensive procedures, this group of long-term survivors reported significantly higher 
Mental Health and Vitality QOL scores than their general population counterparts.  These 
findings may underscore the existence or role of response shift (e.g. Sprangers & 
Schwartz, 1999), post-traumatic growth (e.g. Calhoun & Tedeschi, 1998), resilience, or a 
number of alternate strength-based factors that warrant future research.  
Next, the quantitative data obtained in this, and previous studies, can serve as the 
groundwork on which to build future interventions with these patients.  Specifically, this 
quantitative data informs researchers‟ and clinicians‟ understanding of issues of salience 
(e.g. sleep quality), the percentage of patients who experience said issues, and how the 
percentage of patients who struggle with these respective issues varies over time.  In 
future studies, researchers should continue to collect longitudinal data, assessing how 
patients with differing primary diagnoses fare over time.  Such data, in addition to 
serving as a reference for future candidates for the procedure and those working with this 
population, should ultimately inform intervention studies.  The investigator was unable to 
locate any research detailing intervention studies with this population.  Future 
interventions could take the form of pre-operative consultations, in-hospital interventions, 
or post-operative interventions and could be comprehensive (e.g. attention to mental 
health, pain management, nutrition, and spirituality, among others) or focused symptom 
management interventions.  For instance, results from this quantitative study 
demonstrated that a significant percentage of long-term survivors may benefit from 
interventions designed to enhance sleep quality.  Such intervention studies are a logical 
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next step within this research base, and quantitative data collected from members of this 
population can serve as support for their need and potential utility.   
 Finally, despite attempts to limit the number of exclusion criteria to the study, 
these participants still represented the best case scenarios- those individuals who lived at 
least 12 months post-procedure and were sufficiently healthy to complete the 
questionnaires.  Similar to previous research investigations, the stories of those who did 
not fare as well remained excluded.  Likewise, the uniqueness inherent in these 
hospitalizations, recovery trajectories, and overall experiences may not be uncovered 
sufficiently when data are aggregated in quantitative studies.  A qualitative methodology, 
in which in-depth interviews with a smaller number of patients both during and post-
hospitalization, may permit the researcher to capture the stories and attributed meaning of 
a wider spectrum of patients (i.e. those patients who experience ideal and poor outcomes 
as well as everything in between).  Such a methodology would permit these patients to 
discuss in more detail personal issues of salience, thereby enriching this research body in 
a manner that may be especially useful for individuals considering this treatment option 
as well as those who work with these patients.  The investigator was unable to locate any 
such qualitative studies within this body of research, suggesting it may be a unique and 
useful future contribution. 
Conclusions 
In conclusion, acceptable quality of life is achievable for long term survivors of 
CS+HIPEC.  Individuals with a primary diagnosis of cancer of the appendix and with an 
R0/R1 resection status are likely to be over-represented among long-term survivors as 
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compared to those with alternate primary diagnoses or less optimal resection statuses.  
Among long-term survivors, physical health and functioning impairments are common, 
with overall physical quality of life significantly worse than that of the general 
population.  Functioning in other domains, however, may not differ significantly or may 
be higher than that of the general population.  Within this sample, overall Mental Health 
was significantly better than what is expected in the general population.  Trends in 
quality of life scores demonstrated improvement over time, with significant improvement 
in Social Functioning from baseline to long-term follow-up.   Additionally one third 
(31.70%) of participants reported significant sleep quality impairments.  Sleep quality 
was related significantly to all quality of life domains, suggesting significant 
interrelations between sleep quality and all domains of functioning.  The strongest 
relationship was found, not surprisingly, between sleep quality and Vitality.  Finally, site 
of primary diagnosis had significant effects on the overall Physical Component scores of 
participants.  Specifically, a primary diagnosis of cancer of the appendix was associated 
with significant positive contributions to long-term Physical Component scores.  
 Although one is able to draw from these findings with confidence, it is important 
to remain mindful of the inherent uniqueness of each patient‟s journey and survivorship 
trajectory.  These data were provided by patients who lived to be long-term survivors and 
who were in satisfactory health to complete the questionnaires.  The numerous 
individuals who were not alive at the time of the study or whose health impairments 
prevented them from participating were not represented.  Mean scores should never 
overshadow the variability in experiences nor the continuing need to provide 
 
 
206 
interdisciplinary services, including attention to mental health and sleep quality, to those 
in need.    
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Phone script for CCCWFU 98597 protocol: Quality of Life Assessment for 
Intraperitoneal Hyperthermic Chemotherapy Surgery Candidates   
 
"Hello, my name is ____________.  I am calling from Wake Forest University Baptist 
Medical Center to ask you to participate in a study of patients who have been treated with 
Cytoreductive Surgery + Intraperitoneal Hyperthermic Chemotherapy (CS plus IPHC).  I 
am a member of our research and clinical team. As I understand it, you completed your 
IPHC treatment here. Is that correct?"   
 
(wait for patient to respond and acknowledge; after patient acknowledges that he/she had 
his/her surgery here, proceed.) 
 
"On behalf of your treatment team, I hope you are well. How are you feeling?"  
 
(Listen to patients response and respond accordingly, offering empathy and 
encouragement as indicated) 
 
A. If patient is currently enrolled in and within the 12 to 24 month time period of 
the QOL study (CCCWFU 98597): 
 
"I also see that you are participating in our quality of life study following your treatment.  
We are interested in sending you an additional mailing of questionnaires to learn more 
about you and your life following this treatment. I would like to briefly explain the nature 
of this study. Is that OK?"                            
 
(wait for patient to respond; if patient acknowledges and is interested - continue) 
 
B. If patient is not currently enrolled in ongoing QOL study or out more than 24 
months from treatment, proceed with the following:  
 
"I would like to explain to you the project that we are conducting in order to learn more 
about how people adapt and adjust after CS plus IPHC.  May I briefly explain the nature 
of this study?"  
 
(wait for patient to respond; if patient acknowledges and is interested - continue) 
 
"We want to learn about the quality of life and adjustment of patients after treatment with 
CS + IPHC. If you agree to participate in this study, we will mail you a packet of 
questions related to your quality of life, sleep quality and treatment satisfaction. It will 
take approximately 15-20 minutes to complete these questions. We will ask you to 
complete these forms as accurately as possible and send them back to us in the self-
addressed, postage-paid envelope provided within two weeks. There are no right or 
wrong answers to the questions you will be asked. We want to learn more about how 
people who have had this procedure do following treatment, and we hope to use this 
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information to improve our work with patients. For your time and contribution, we will 
send you a $25 gas card when we receive your completed instruments. We may also call 
you to make sure you have received the questionnaire and to see if you have any 
questions." 
“Do you have any questions about the study or anything I have said so far?”  (address 
questions) 
 
“Are you interested in participating in this study?” (if  yes, proceed; if no, thank them for 
their time) 
 
“May we send you this packet of instruments?” (if person still agrees, explain the 
following:) 
 
"Enclosed in the packet, you will find a brief cover letter explaining the study, a consent 
form and the instruments. Please read the consent form and call us with any questions 
you may have prior to signing. Our contact information will be provided on the form.  If 
you do not have any questions after reading through the information, please sign the 
consent form and complete the instruments. You may call us with any questions you have 
while completing the instruments. When finished, please send the consent form and 
packet back to us in the self-addressed, postage-paid envelope. When we receive this 
packet, we will then mail you the $25 gas card." 
 
"Do you have any more questions?" (address questions) 
 
"Thank you for your time today and for your willingness to help with this study.  We 
think your contributions will make a big difference in our understanding and counseling 
of patients before, during and after CS + IPHC.  Thank you very much for your 
cooperation.  If you would like to contact one of our study team, please call Katie 
Duckworth 336-713-6952/Adrienne Hill 336-713-6927. 
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CCCWFU 98597 
 
Department of Internal Medicine, Hematology and Oncology 
 
QUALITY OF LIFE IN PATIENTS TREATED WITH INTRAPERITONEAL 
HYPERTHERMIC CHEMOTHERAPY (IPHC) FOR PERITONEAL 
CARCINOMATOSIS 
 
Richard P. McQuellon, Ph.D., Principal Investigator 
 
INTRODUCTION 
 
You are being asked to take part in a research study designed to learn more about how 
Intraperitoneal Hyperthermic Chemotherapy (IPHC) recipients manage the recovery and 
survivorship processes. This study will consist of the completion of one additional survey 
packet consisting of six questionnaires that will be mailed to your primary address. The 
questions within the survey will ask you to share information about your current quality 
of life, sleep quality and treatment satisfaction. Research studies are designed to gain 
scientific knowledge that may help other people in the future. You may ask your doctor 
or the study staff to explain any words or information that you do not understand. You 
may also discuss the study with your friends and family.   
 
WHY IS THIS STUDY BEING DONE? 
 
The purpose of this study is to learn more about the quality of life, sleep quality and 
treatment satisfaction of cancer survivors one or more years following IPHC. This 
information may be useful to patients considering IPHC and will be used in future work 
with these patients.   
 
HOW MANY PEOPLE WILL TAKE PART IN THE STUDY? 
 
Approximately 600 people who receive IPHC at Wake Forest University Baptist Medical 
Center will take part in a quality of life study.  You are one of approximately 200 of these 
people that are being asked to complete an additional quality of life survey packet 
consisting of six questionnaires. 
 
WHAT IS INVOLVED IN THE STUDY? 
 
Previously enrolled subjects have completed questionnaires before their surgeries.  This 
study will involve completing questionnaires at one time point after your surgery. You 
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will be asked to complete these questionnaires within a week of receiving them via the 
postal service and return them in the self-addressed, postage-paid envelope provided.  
These questionnaires include: (1,2) The Functional Assessment of Cancer Therapy and 
Treatment Satisfaction Scale (FACT-C; FACIT-TS); (3) the Medical Outcomes Study 
Short Form-36-Item Health Survey Questionnaire (SF-36); (4) the Pittsburgh Sleep 
Quality Index (PSQI); (5) an Informational Questionnaire; (6) and sociodemographic 
information.    These questionnaires should take approximately 15-20 minutes to 
complete.  A researcher will collect basic information from your medical chart on your 
cancer diagnosis, treatment, and history of previous medical conditions. Only the study 
staff will see this information. 
 
HOW LONG WILL I BE IN THE STUDY? 
 
You will be asked to complete one survey packet consisting of six questionnaires that you 
will receive at your home address via the mail. Study team members may call you to 
follow-up about 10 days after the questionnaire is mailed if: a.) you do not return the 
completed survey or b.) they would like to discuss some of your answers with you. After 
returning your completed packet, you are finished with this study. 
 
WHAT ARE THE RISKS OF THE STUDY? 
 
Participation in this study involves very little if any risk to you.  You can discuss any risk 
of being in this study with the study staff.  Some patients do report a heightened 
awareness of the psychological stresses involved with IPHC when reading the 
questionnaires and learning more about how quality of life is measured.  If you do 
experience any feelings of anxiety or distress that are more than usual for you or what is 
common, our study staff and practitioners will talk with you and plan with you and your 
physician how to manage this.  
 
Participating in this study may involve some information that you may consider 
confidential and private.  This may make you feel uncomfortable and there is always the 
remote risk that this information may be accidentally released.  However, efforts coding 
research records and keeping them secure so only study staff have access to them will be 
made to keep your information safe.  We cannot guarantee absolute confidentiality and 
privacy although every effort will be made to do so. 
 
ARE THERE BENEFITS TO TAKING PART IN THE STUDY? 
 
You will receive no direct medical benefit by participation in this study. We hope the 
information learned from this study will benefit other people in the future. By taking part 
in this study, you will help increase scientific knowledge about the effects of IPHC on 
overall quality of life and survivorship.  
 
WHAT OTHER CHOICES ARE THERE? 
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This is not a treatment study. Your alternative is to not participate in this study. 
 
WHAT ARE THE COSTS? 
 
There are no costs to you for taking part in this study. Any costs for your regular medical 
care which are not related to this study will be your own responsibility.  
 
WILL YOU BE PAID FOR PATICIPATING? 
 
You will receive a $25 gas card upon completion of all questionnaires.   
 
WHO IS SPONSORING THIS STUDY? 
 
This study is being sponsored by Wake Forest University Health Sciences. The 
researchers do not hold a direct financial interest in the sponsor.  
 
WHAT ARE MY RIGHTS AS A RESEARCH STUDY PARTICIPANT? 
 
Taking part in this study is voluntary. You may choose not to take part or you may leave 
the study at any time. Refusing to participate or leaving the study will not result in any 
penalty or loss of benefits to which you are entitled. If you decide to stop participating in 
the study we encourage you to talk to the investigators or study staff first to learn about 
any potential safety consequences. The investigators also have the right to stop your 
participation in the study at any time if it might be in your best medical interest.  
 
WHAT ABOUT THE USE, DISCLOSURE AND CONFIDENTIALITY OF HEALTH 
INFORMATION? 
 
By taking part in this research study, your personal health information, as well as 
information that directly identifies you, may be used and disclosed.  Information that 
identifies you includes, but is not limited to, such things as your name, address, telephone 
number, and date of birth.  Your personal health information includes all information 
about you which is collected or created during the study for research purposes. It also 
includes your personal health information that is related to this study and that is 
maintained in your medical records at this institution and at other places such as other 
hospitals and clinics where you may have received medical care.  Examples of your 
personal health information include your health history, your family health history, how 
you respond to study activities or procedures, laboratory and other test results, medical 
images, and information from study visits, phone calls, surveys, and physical 
examinations. 
 
Your personal health information and information that identifies you (“your health 
information”) may be given to others during and after the study. This is for reasons such 
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as to carry out the study, to determine the results of the study, to make sure the study is 
being done correctly, to provide required reports and to get approval for new products.   
Some of the people, agencies and businesses that may receive and use your health 
information are the research sponsor; representatives of the sponsor assisting with the 
research; investigators at other sites who are assisting with the research; central 
laboratories, reading centers or analysis centers; the institutional review board; 
representatives of Wake Forest University Health Sciences and North Carolina Baptist 
Hospital; representatives from government agencies such as the Food and Drug 
Administration (FDA), the Department of Health and Human Services (DHHS) and 
similar agencies in other countries. 
 
Some of these people, agencies and businesses may further disclose your health 
information. If disclosed by them, your health information may no longer be covered by 
federal or state privacy regulations.  Your health information may be disclosed if required 
by law. Your health information may be used to create information that does not directly 
identify you. This information may be used by other researchers. You will not be directly 
identified in any publication or presentation that may result from this study. 
If this research study involves the treatment or diagnosis of a medical condition, then 
information collected or created as part of the study may be placed in your medical 
record and discussed with individuals caring for you who are not part of the study. This 
will help in providing you with appropriate medical care.  In addition, all or part of your 
research related health information may be used or disclosed for treatment, payment, or 
healthcare operations purposes related to providing you with medical care. 
 
When you sign this consent and authorization form you authorize or give permission for 
the use of your health information as described in the consent form. This authorization 
does not have an expiration date. You can revoke or take away your authorization to use 
and disclose your health information at any time. You do this by sending a written notice 
to the investigator in charge of the study at the following address: 
 
Richard P. McQuellon, Ph.D. 
Wake Forest University Health Sciences 
Department of Internal Medicine/ Hematology Oncology 
Medical Center Boulevard 
Winston-Salem, N.C. 27157 
 
If you withdraw your authorization you will not be able to be in this study. If you 
withdraw your authorization, no new health information that identifies you will be 
gathered after that date. Your health information that has already been gathered may still 
229 
 
be used and disclosed to others. This would be done if it were necessary for the research 
to be reliable. You will not have access to your health information that is included in the 
research study records until the end of the study. 
 
WHOM DO I CALL IF I HAVE QUESTIONS OR PROBLEMS? 
 
Contact the study investigator, DR. RICHARD MCQUELLON, at (336) 716-7980. 
 
The Institutional Review Board (IRB) is a group of people who review the research to 
protect your rights. If you have a question about your rights as a research participant, you 
should contact the Chairman of the IRB at (336) 716-4542. 
 
You will be given a signed copy of this consent form. 
 
 
SIGNATURES 
 
I agree to take part in this study. I authorize the use and disclosure of my health 
information as described in this consent and authorization for. If I have not already 
received a copy of the Privacy Notice, I may request one or one will be made available to 
me. I have had a chance to ask questions about being in this study and have those 
questions answered. By signing this consent and authorization form, I am not releasing or 
agreeing to release the investigator, the sponsor, the institution or its agents from liability 
for negligence.  
 
___________________________________________________ 
Subject Name (Printed) 
 
___________________________________________________ __________________ 
Subject Signature        Date 
 
___________________________________________________ __________________ 
Person Obtaining Consent       Date 
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Dear __________ 
 
We are writing to follow up on a phone conversation we had about the quality of life 
study we are conducting.  A questionnaire is enclosed in this packet.  This questionnaire 
is designed to help us learn about your overall quality of life, sleep quality, satisfaction 
with treatment, and other aspects of your functioning and well being following 
cytoreductive surgery plus intraperitoneal  hyperthermic chemotherapy (CS + IPHC).  It 
will likely take you approximately 15-20 minutes to complete these instruments.  As we 
mentioned in the phone conversation we will send you a $25.00 gas card once we receive 
your completed questionnaires.  
 
Please complete this questionnaire and the consent form within one week and return it in 
the enclosed self-addressed, postage-paid envelope.  Your answers to these questions will 
help us understand more about how people adjust after CS + IPHC.  Your contributions 
will make a big difference in our work here, especially in helping people understand the 
nature of this treatment. 
 
If you have any questions, please contact Katie E. Duckworth at 336-713-6952 or 
Adrienne Hill at 336-716-6927. 
 
Yours Sincerely, 
 
Richard P. McQuellon, Ph.D. 
Professor and Director, Psychosocial Oncology  
and Cancer Patient Support Programs 
336-716-7980 
 
RPM/sll 
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From: Dana Kopec [dkopec@qualitymetric.com]    Sent: Mon 8/10/2009 
2:13 PM 
To: Katie Duckworth 
CC: 
Subject: QualityMetric University Order Form CT119211 
Attachments: University Order Form.docx (56KB)   University Disease-Specific ORDER 
FORM-01.09.docx (54KB) 
 
Dear Katharine, 
 
Thank you for completing our Survey Request Form.  You qualify for the Office of Grants and 
Scholarly Research‟s (OGSR) Academic Research Licensing Program.  The intent of the program 
is to provide our health survey tools royalty-free and offer scoring materials at discounted costs to 
the academic research community. 
Please fill out the appropriate form with the survey(s) and scoring products you are interested in 
for your study.  Once I receive the completed form back I will send you a formal quote. 
If you are in financial need of a discount please let me know when returning the completed order 
form. 
NO formatting or editing changes can be made to the survey: (Very Important - Please 
Read) 
In order to obtain licensing from QualityMetric NO changes can be made to the survey forms. 
Any format and/or language changes have the potential to affect the survey data received.  
Therefore, to maintain the validation and integrity of the SF Health Surveys, no language or 
formatting changes are allowed.  The format of the survey was scientifically engineered to 
facilitate accurate and unbiased data, as well as keeping the SF Health Survey in a visual format 
that is comprehensible to the patient/participant, including those who may be impaired and/or 
elderly.  You should administer the survey in the exact format you will receive it in.  The 
only item the Licensee may add is a header with patient identification and / or 
administration information. If you do wish to add a header please ask for a sample copy of 
the survey to edit and then submit this to your account represenative for review prior to 
confirming a quote.  Other than this, QualityMetric can not guarantee the validity and/or 
reliability of data obtained from using modified surveys and we will not be able to license any 
modified survey form.  Once the licensing process is completed, you will receive a clean set of 
Survey Forms in a word and pdf. file.  This is the form you will be administering.  Please do not 
use any forms you may already have access to as the ones we send you are the most current 
versions. 
  
Kind Regards, 
  
  
_________________________________________________________  
 
 
 
 
 
 
Dana Kopec 
Administrator-Office of Grants and Scholarly Research 
QualityMetric Health Outcomes Solutions 
24 Albion Road, Bldg. 400 | Lincoln, RI 02865 
P: 401.642-9267 | F: 401.642.9356 
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From: navapi@qualitymetric.com [navapi@qualitymetric.com]  Sent: Tue 10/6/2009 
4:47 PM 
To: Katie Duckworth; eperrin@qualitymetric.com 
CC: 
Subject: Quality Metric Files 
Attachments: 
 
 
Dear Katharine Duckworth, 
 
Below is a link to a compressed (zipped) archive file that contains your survey files. 
Click on the link to download your file. 
 
NOTE 1: Please verify that the survey forms, versions and languages that you receive are 
all correct. If there is any problem, contact your Qualitymetric representative 
immediately. 
 
NOTE 2: If you receive Microsoft Word versions of the surveys, in addition to the Adobe 
Acrobat version, please print a hard copy of both the Adobe Acrobat and Microsoft Word 
files for each translation and compare them carefully before administering the surveys to 
your patients to verify that they are identical. Your computer may not have all the fonts 
installed to display and print the Microsoft Word document correctly. If you do not have 
Adobe Acrobat Reader installed on your computer, you can download a FREE copy at 
http://www.adobe.com/support/downloads/main.html. 
 
File(s) will be available for download until 05 November 2009: 
 
Attachment: QualityMetric-QM002117-20091006-164717.zip, 174.25 KB    
 
You have received attachment link(s) within this email sent via Accellion Secure File 
Transfer. To retrieve the attachment(s), please click on the link(s). 
Accellion File Transfer 
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From: Elisabeth Perrin [mailto:eperrin@qualitymetric.com]         Sent: Mon 8/24/2009 2:42 PM 
To: Katie Duckworth 
Subject: QualityMetric License Agreement #CT119211 OP002988 
 
Dear Katie, 
Thank you for your intent to license the QualityMetric health survey tools.  Attached is 
your license agreement. 
Follow the instructions below to execute the license agreement.  Once we receive the 
signed license agreement, we will respond with a prepayment request.  Once we receive 
payment we will complete your order. 
Instructions: 
1.    Sign the first page of the license agreement.  
2.    Return the signed first page of the agreement by fax to me at 401-642-9356 or you 
may return a scanned copy via e-mail. 
Note: It is not necessary to mail the signed licensed agreement if you fax it.  A fax copy 
is considered a legal copy.   
Cancellation: The licensee is obligated to follow the payment terms upon execution of the 
signed license agreement.  We reserve the right to cancel the license agreement within 60 
days from the date issued if we do not receive payment.  If we cancel the license 
agreement, the licensee will be required to complete another license application if they 
wish to move forward.  Please also note that there is no pricing guarantee; and current 
licensing fees will be applicable.  
Changes to the license agreement:  If there is updated information or incorrect data on the 
license agreement, please notify me in writing, and I will update the agreement. Please do 
not return the license agreement signed with any changes that have not been approved by 
QualityMetric Incorporated.  Please note that changes to the license agreement will delay 
the processing of your license. 
 
Kind Regards, 
 
Elisabeth  
 
 
  
  
 
 
 
 
 
Elisabeth Perrin 
Administrative Assistant 
Office of Grants and Scholarly Research (OGSR) 
24 Albion Road, Bldg 400 | Lincoln, RI 02865 
Phone: 401.334.8800 ext 256 | Fax: 401.642.9356 
www.QualityMetric.com 
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NON-COMMERCIAL LICENSE AGREEMENT 
Office of Grants and Scholarly Research (OGSR) 
 
License Number: CT119211 / OP002988 
Effective Date: August 24, 2009 
Licensee Name:  Wake Forest University 
Licensee Address:  Psychosocial Oncology Program 
Katharine Duckworth 
c/o Richard McQuellon 
Medical Center Boulevard 
Winston Salem, NC 27157-1082 
Requested Administrations: 200    Approved Administrations: Two Times Requested 
Administrations 
Approved Use: Non-commercial academic research - unfunded – “Quality of Life Assessment for
 Intraperitoneal Hyperthermic Chemotherapy Surgery Candidates.” 
Term: Beginning on October 1, 2009 and ending on September 30, 2012 
Licensed Surveys: As indicated in Appendix B attached 
Manuals: Licensee must purchase (or have purchased) from QM a copy of the manuals indicated 
 in Appendix B attached 
Royalty Fee: None, because this License is granted in support of the non-commercial
 Approved Use below  
Administrative Fee: $450.00 
 
Licensee accepts and agrees to the terms of this Non-Commercial License Agreement (the 
“Agreement”) from the Office of Scholarly Grants and Research (OGSR) of QualityMetric 
Incorporated (“QM”) as of the Effective Date.  
 
Subject to the terms of this Agreement, including the QualityMetric Non-Commercial License 
Terms and Conditions attached as Appendix A: (a) QM grants to Licensee, and Licensee 
accepts, a non-exclusive, non-transferable, nonassignable, non-sublicensable worldwide license 
to use, solely for the Approved Use and during the License Term, the Licensed Surveys in the 
authorized Modes and Approved Languages indicated on Appendix B and to administer the 
Licensed Surveys only up to the Approved Administrations (and to make up to such number of 
exact reproductions of the Licensed Surveys necessary to support such administrations) in any 
combination of the specific Licensed Surveys and 
Approved Languages and Modes and to use any related software provided by QM and (b) 
Licensee agrees to pay the Administrative Fee and other applicable charges in accordance with 
the attached invoice. Capitalized terms used in this Agreement and not otherwise defined herein 
shall have the meanings assigned to them in Appendix A. The appendices attached hereto are 
incorporated into and made a part of this Agreement for all purposes. 
Wake Forest University 
Psychosocial Oncology Program 
Katharine Duckworth 
c/o Richard McQuellon 
Medical Center Boulevard 
Winston Salem, NC 27157-1082 
Signature:_____________________________________________ 
Name:________________________________________________ 
Title:_________________________________________________ 
 For additional information about QM’s OGSR , go to http://www.qualitymetric.com/advancing/  
 
Filename: Wake Forest University - Katharine Duckworth - CT119211 OP002988 Page 1 of 4 
Template: License Agreement (OGSR) - 09-2008 
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From: Elisabeth Perrin [eperrin@qualitymetric.com]                         Sent: Wed 10/28/2009 
11:49 AM 
To: Katie Duckworth 
Subject: Your QualityMetric Health Outcomes Scoring Software 2.0 Activation Key 
Attachments: Installation GuideV2.pdf(822KB) 
 
Dear Katharine Duckworth 
 
Thank you for purchasing the QualityMetric Health Outcomes(TM) Scoring 
Software 2.0.  Enclosed in this email is the Activation Key you will 
need to enter in order to enable functionality in your software.  The 
details of your purchase are as follows: 
 
Product Version:  Health Outcomes SS 2.0 - 1 year 
Purchase Date:  10/16/09 
SF-8 Survey License Count:  0 
SF-10 Survey License Count:  0 
SF-12 Survey License Count:  0 
SF-12v2 Survey License Count:  0 
SF-36 Survey License Count:  0 
SF-36v2 Survey License Count:  0 
 
Activation Key(s): 
EBD1A-EDCB9-F285C-BD7C6 
 
You may download the QualityMetric Health Outcomes Scoring software at 
the following location: 
http://www.qualitymetric.com/download/SFScoringSoftwareV2Setup.exe 
 
Please save and/or print this message. In order to register and install 
your Activation Key your computer will need an active Internet 
connection.  Please refer to the attached installation document if you 
require a detailed instructions. 
 
Attached to this email message you will also find a copy of the 
Installation Instructions for the QualityMetric QualityMetric Health 
Outcomes(TM) Scoring Software 2.0.  The attached file is in .pdf format 
and requires that you have Adobe Acrobat Reader installed on you 
computer.  You may download Acrobat Reader for free at www.adobe.com. 
If you have any questions or concerns, please feel free to contact us at 
webmaster@qualitymetric.com. 
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Wednesday, November 11, 2009 
 
Permission Granted Notification 
Client Number: 15558 
Request Number: 25015 
 
 
 
Katie Duckworth 
The University of North Carolina at Greensboro 
Dept of Counseling & Educational Development 
228 Curry Building -PO Box 26170 
Greensboro, NC 27402-6170 USA 
 
 
In response to your request to use: 
Journal       Citation    Year   Specific 
Item 
Journal of the American Medical Association   273(1):59-65   1995   Figure 
 
 
 
 
 
 
PERMISSION has been GRANTED for the following use: 
Reproduction for use in a dissertation likely to be published in Dissertation Abstracts - 
2009/2010. 
Rights granted herein are non-exclusive for reproduction in print, online and electronic 
media as specified in this request. If the permission requested is for inclusion of AMA 
material in a book or CD-ROM, such 
permission is granted for the single edition only as specified in this request. Your credit 
line must include the name of the publication, issue date, volume and page number, as 
well as "Copyright © (Year of Publication) American Medical Association. All rights 
reserved." 
 
 
 
 
 
 
 
 
 
American Medical Association Journal Permissions 
515 N State St., 11th Floor Chicago, IL 60654 
Tel. (312) 464-2513 Fax (312) 464-5834 email: permissions@ama-assn.org 
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Correspondence regarding the Wilson and Cleary Model (1995): 
 
From: Katie Duckworth [mailto:kduckwor@wfubmc.edu] 
Sent: Tue 11/10/2009 3:45 PM 
To: Wilson, Ira 
Subject: permission to reproduce model 
Dr. Wilson, 
Hello, my name is Katie Duckworth. I am a part-time employee within the Cancer Patient 
Support/Psychosocial Oncology Programs here at Wake Forest University Baptist Medical Center and am 
also a doctoral student in the middle of dissertation. In my dissertation, I am examining the QOL and sleep 
quality of long term survivors of peritoneal metastases from a variety of primary origins who were treated 
here with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CS+HIPEC). I am 
referencing/incorporating your HRQOL model within my dissertation and am requesting permission to 
reproduce a diagram of the model within the text as well. I want to thank you in advance for your 
consideration of this request. 
Sincerely, 
Katie Duckworth 
 
Katie E. Duckworth, MA 
Doctoral intern 
Psychosocial Oncology & Cancer Patient Support Program 
Wake Forest University Baptist Medical Center 
kduckwor@wfubmc.edu 
pager: 806-6682 
office: 336-713-6952 
 
 
From: Wilson, Ira [mailto:IWilson@tuftsmedicalcenter.org]  
Sent: Tuesday, November 10, 2009 7:28 PM 
To: Katie Duckworth 
Cc: Cleary, Paul 
Subject: RE: permission to reproduce model 
Katie, 
It is fine with me, but you have to ask Jama, since they own the copyright. 
Ira Wilson 
 
From: Cleary, Paul [paul.cleary@yale.edu] 
Sent: Tue 11/10/2009 8:16 PM 
To: Wilson, Ira; Katie Duckworth 
Cc:  
Subject: RE: permission to reproduce model 
 
 
Ditto.  Good luck with your dissertation! 
  
Paul 
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Your Health and Well-Being 
 
This survey asks for your views about your health.  This information 
will help keep track of how you feel and how well you are able to do 
your usual activities.  Thank you for completing this survey! 
For each of the following questions, please mark an  in the one box 
that best describes your answer. 
1. In general, would you say your health is: 
Excellent Very good Good Fair Poor 
     
  1  2  3  4  5 
 
2. Compared to one year ago, how would you rate your health in 
general now? 
Much better 
now than one 
year ago 
Somewhat 
better now 
than one year 
ago 
About the 
same as one 
year ago 
Somewhat 
worse now 
than one year 
ago 
Much worse 
now than one 
year ago 
     
 1  2  3  4  5 
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3. The following items are about activities you might do during a 
typical day. Does your health now limit you in these activities?  If so, 
how much? 
  Yes, 
limited 
a lot 
Yes, 
limited 
a little 
No, not 
limited 
at all 
 
   
 
a  Vigorous activities, such as running, lifting  
 heavy objects, participating in strenuous  
 sports ......................................................................... 1 ................. 2 ................. 3 
 
b   Moderate activities, such as moving a  
 table, pushing a vacuum cleaner,  
 bowling, or playing golf ............................................ 1 ................. 2 ................. 3 
 
c   Lifting or carrying groceries ..................................... 1 ................. 2 ................. 3 
 
d  Climbing several flights of stairs .............................. 1 ................. 2 ................. 3 
 
e  Climbing one flight of stairs ...................................... 1 ................. 2 ................. 3 
 
f  Bending, kneeling, or stooping .................................. 1 ................. 2 ................. 3 
 
g Walking more than a mile ......................................... 1 ................. 2 ................. 3 
 
h Walking several blocks ............................................. 1 ................. 2 ................. 3 
 
i Walking one block ..................................................... 1 ................. 2 ................. 3 
 
j  Bathing or dressing yourself ...................................... 1 ................. 2 ................. 3 
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4. During the past 4 weeks, have you had any of the following 
problems with your work or other regular daily activities as a 
result of your physical health? 
 Yes No 
   
a  Cut down on the amount of time you spent  
 on work or other activities ....................................................... 1.................... 2 
 
b  Accomplished less than you would like .................................. 1.................... 2 
 
c  Were limited in the kind of work or other  
   activities .................................................................................. 1.................... 2 
d  Had difficulty performing the work or other  
 activities (for example, it took extra effort)  ............................ 1.................... 2 
 
5. During the past 4 weeks, have you had any of the following 
problems with your work or other regular daily activities as a result 
of any emotional problems (such as feeling depressed or anxious)? 
 Yes No 
   
a  Cut down on the amount of time you spent  
on work or other activities ..................................................... 1 ..................... 2  
 
b  Accomplished less than you would like ................................ 1 ..................... 2 
 
c  Did work or other activities less carefully  
   than usual ............................................................................... 1 ..................... 2 
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6. During the past 4 weeks, to what extent has your physical health or 
emotional problems interfered with your normal social activities 
with family, friends, neighbors, or groups? 
Not at all Slightly Moderately Quite a bit Extremely 
     
 1  2  3   4  5 
 
7. How much bodily pain have you had during the past 4 weeks? 
None Very mild Mild Moderate Severe Very Severe 
      
 1  2  3  4  5  6 
 
8. During the past 4 weeks, how much did pain interfere with your 
normal work (including both work outside the home and 
housework)? 
Not at all A little bit Moderately Quite a bit Extremely 
     
 1  2  3  4  5 
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9. These questions are about how you feel and how things have been 
with you during the past 4 weeks.  For each question, please give the 
one answer that comes closest to the way you have been feeling.  
How much of the time during the past 4 weeks... 
 All of 
the 
time 
Most 
of the 
time 
A good 
bit of 
the 
time 
Some 
of the 
time 
A little 
of the 
time 
None 
of the 
time 
 
      
 
a   Did you feel full of pep? ........................... 1 ....... 2 ....... 3 ....... 4 ........ 5 ........ 6 
 
b  Have you been a very nervous person? … 1 ........ 2 ....... 3 ....... 4 ........ 5 ........ 6 
      
 c  Have you felt so down in the  
 dumps that nothing could cheer you up? … 1 ..... 2 ....... 3 ....... 4 ........ 5 ........ 6 
   
 
d  Have you felt calm and peaceful? ............. 1 ....... 2 ....... 3 ....... 4 ........ 5 ........ 6 
 
 
e  Did you have a lot of energy? ................... 1 ....... 2 ....... 3 ....... 4 ........ 5 ........ 6 
 
 
f  Have you felt downhearted and blue? …… 1 ...... 2 ....... 3 ....... 4 ........ 5 ........ 6 
  
 
g  Did you feel worn out? ............................. 1 ....... 2 ....... 3 ....... 4 ........ 5 ........ 6 
 
h  Have you been a happy person?................ 1 ....... 2 ....... 3 ....... 4 ........ 5 ........ 6 
 
i  Did you feel tired? ..................................... 1 ....... 2 ....... 3 ....... 4 ........ 5 ........ 6 
 
 
 
 
245 
 
10.  During the past 4 weeks, how much of the time has your physical 
health  or emotional problems interfered with your social activities 
(like visiting friends, relatives, etc.)? 
All of the 
time 
Most of the 
time 
Some of the 
time 
A little of the 
time 
None of the 
time 
     
 1  2  3   4  5 
 
 
 
11.   How TRUE or FALSE is each of the following statements for you? 
 Definitely 
true 
Mostly 
true 
Don't 
know 
Mostly 
false 
Definitely 
false 
 
     
a  I seem to get sick a little easier 
 than other people .................................... 1  ........... 2 ........... . 3 ......... 4 ........... 5 
b  I am as healthy as anybody I  
 know ....................................................... 1  ........... 2 …..….. 3…. ..... 4 ........... 5 
c  I expect my health to get 
 worse ...................................................... 1  ........... 2  . ..........  3  .......... 4 ........... 5 
d  My health is excellent ............................ 1  ........... 2  ...........  3  .......... 4 ........... 5 
 
 
 
Thank you for completing these questions! 
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Subject’s Initials_____  ID# _____  Date______  Time _______AM/PM 
 
PITTSBURGH SLEEP QUALITY INDEX 
 
INSTRUCTIONS: 
The following questions relate to your usual sleep habits during the past month 
only. Your answers should indicate the most accurate reply for the majority of 
days and nights in the past month. 
Please answer all questions. 
1. During the past month, what time have you usually gone to bed at night? 
BED TIME ___________ 
 
2. During the past month, how long (in minutes) has it usually taken you to fall 
asleep each night? 
NUMBER OF MINUTES ___________ 
 
3. During the past month, what time have you usually gotten up in the morning? 
GETTING UP TIME ___________ 
 
4. During the past month, how many hours of actual sleep did you get at night? 
(This may be different than the number of hours you spent in bed.) 
HOURS OF SLEEP PER NIGHT ___________ 
 
For each of the remaining questions, check the one best response. Please answer all 
questions. 
 
5. During the past month, how often have you had trouble sleeping because you .  
 
a) Cannot get to sleep within 30 minutes 
 
Not during the Less than Once or twice Three or more 
past month_____ once a week_____ a week_____ times a week_____ 
 
b) Wake up in the middle of the night or early morning 
 
Not during the Less than Once or twice Three or more 
past month_____ once a week_____ a week_____ times a week_____ 
 
c) Have to get up to use the bathroom 
 
Not during the Less than Once or twice Three or more 
past month_____ once a week_____ a week_____ times a week_____ 
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d) Cannot breathe comfortably 
 
Not during the Less than Once or twice Three or more 
past month_____ once a week_____ a week_____ times a week_____ 
 
e) Cough or snore loudly 
 
Not during the Less than Once or twice Three or more 
past month_____ once a week_____ a week_____ times a week_____ 
 
f) Feel too cold 
 
Not during the Less than Once or twice Three or more 
past month_____ once a week_____ a week_____ times a week_____ 
 
g) Feel too hot 
 
Not during the Less than Once or twice Three or more 
past month_____ once a week_____ a week_____ times a week_____ 
 
h) Had bad dreams 
 
Not during the Less than Once or twice Three or more 
past month_____ once a week_____ a week_____ times a week_____ 
 
i) Have pain 
 
Not during the Less than Once or twice Three or more 
past month_____ once a week_____ a week_____ times a week_____ 
 
j) Other reason(s), please 
describe________________________________________________________ 
 
How often during the past month have you had trouble sleeping because of this? 
 
Not during the  Less than   Once or twice  Three or more 
past month_____ once a week_____   a week_____  times a week_____ 
 
6. During the past month, how would you rate your sleep quality overall? 
Very good ____________ 
Fairly good ____________ 
Fairly bad ____________ 
Very bad ____________ 
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7. During the past month, how often have you taken medicine to help you sleep 
(prescribed or "over the counter")? 
 
Not during the  Less than   Once or twice  Three or more 
past month_____  once a week_____   a week_____  times a week_____ 
 
8. During the past month, how often have you had trouble staying awake while 
driving, eating meals, or engaging in social activity? 
 
Not during the  Less than   Once or twice  Three or more 
past month_____  once a week_____  a week_____  times a week_____ 
 
9. During the past month, how much of a problem has it been for you to keep up 
enough enthusiasm to get things done? 
No problem at all     __________ 
Only a very slight problem   __________ 
Somewhat of a problem   __________ 
A very big problem     __________ 
 
10. Do you have a bed partner or room mate? 
No bed partner or room mate   __________ 
Partner/room mate in other room   __________ 
Partner in same room, but not same bed __________ 
Partner in same bed    __________ 
 
If you have a room mate or bed partner, ask him/her how often in the past month 
you have had . . . 
 
a) Loud snoring 
 
Not during the  Less than   Once or twice  Three or more 
past month_____  once a week_____   a week_____   times a week_____ 
 
b) Long pauses between breaths while asleep 
 
Not during the  Less than   Once or twice  Three or more 
past month_____  once a week_____  a week_____  times a week_____ 
 
c) Legs twitching or jerking while you sleep 
 
Not during the  Less than   Once or twice  Three or more 
past month_____  once a week_____   a week_____  times a week_____ 
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d) Episodes of disorientation or confusion during sleep 
 
Not during the  Less than   Once or twice  Three or more 
past month_____  once a week_____  a week_____  times a week_____ 
 
e) Other restlessness while you sleep; please describe 
________________________________________________________________
_____________________________________________ 
 
Not during the  Less than   Once or twice  Three or more 
past month_____  once a week_____  a week_____  times a week_____ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ: Psychiatry Research, 28:193-213, 1989. 
lmw:F5.PSQ (4/2002) 
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QUALITY OF LIFE IN PATIENTS TREATED WITH INTRAPERITONEAL 
HYPERTHERMIC CHEMOTHERAPY (IPHC) FOR PERITONEAL 
CARCINOMATOSIS 
CCCWFU 98597 
 
SOCIODEMOGRAPHIC DATA SHEET   
 
Patient‟s Name Date   
 
 
Address  Gender  Female Male 
  
Phone  
Diagnosis Date of Diagnosis   
Physician      
Age Date of Birth     
 
1.a.   What is your ethnicity:  (Check One) 
  (H) Hispanic 
  (N) Non-Hispanic 
 
1.b. What is your race?  (Check all that apply) 
  (W) White  (A) Asian      (P) Pacific Islander/Hawaiian 
  (B) Black  (NA) Native American  
 
2.       What is your marital status? (Check one) 
  (1) Single  (4) Divorced 
  (2) Married  (5) Widowed 
  (3) Separated  
 
 
3. With whom do you live? (Check All That Apply) 
 
  (1) Wife/Husband  (5) Parent(s)Parent in law 
  (2) Girlfriend/Boyfriend _________(6) Others (specify,  ) 
  (3) Live Alone  
  (4) Children (Ages: / / / ) 
  
4. What is the highest grade you finished in school? (Check One) 
  (1) 1-8 grades  (5) Junior College Degree 
  (2) 9-11 grades   (6) College Degree (BA./B.S.) 
  (3) High school grad  (7) Some Post-College Work  
  (4) Some college (8) Advanced Degree 
 
ID # 
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5. What is your current employment status? (Check One) 
 
  (1) Homemaker  
  (2) Disabled (Usual Occupation  )  
  (3) Unemployed  
  (4) Retired 
  (5) Currently working full-time  
  (6) Currently working part-time  
  (7) Student 
 
6. A. What is your occupation?     
 
B. What is your spouse‟s occupation?     
 
7. What is your annual family income?         (Check One) 
 
  (1) 0-4,999   (6) 40,000-49,999 
  (2) 5,000-9,999  (7) 50,000-59,999 
  (3) 10,000-19,999  (8) 60,000-69,999 
  (4) 20,000-29,999  (9) 70,000 and over 
  (5) 30,000-39,999  
 
8. What type of health insurance do you have? (Check All That Apply) 
 
  (1) Medicaid  ___(6)IndividualHlthInsurance 
  (2) Medicare Only ___(7)Group Health Insurance 
  (3) Medicare +Supplemental  ___(8) V.A./Military 
  (4) Disability Insurance ___(9) No Insurance 
  (5) HMO (Partners, QualChoice, etc.) ___(10) Other, Specify  
 
 
 
 
 
 
 
 
 
 
 
 
252 
 
INFORMATION ABOUT YOUR ILLNESS 
What are the 3 or 4 most troubling symptoms or problems that you now have? Rate the 
severity of each on a 1-10 scale, with 1 being very mild and 10 being as severe as you could 
imagine. 
 
SYMPTOM/PROBLEM 1-10 RATING 
 
      
 
      
 
      
 
 
 
Are you currently receiving any treatments?  YES       NO   
If Yes, what are the treatments?         
 
Physician:    
 
Date of your most recent treatment:    
 
 
 
WHO Performance Scale 
Performance Status-Patient Rated 
 
Circle the number that best describes your current activity level: 
 
0 I have normal activity 
 
 1 I have some symptoms, but I can walk and I do not spend any extra time
 in bed 
 
2 I need some time in bed, but it is less than 50 % of normal daytime  
 
3 I need to be in bed greater than 50 % of normal daytime 
 
 4 I am unable to get out of bed 
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Additional Questions CCCWFU 98597 
Cytoreductive Surgery (CS) + Intraperitoneal Hyperthermic Chemotherapy (IPHC) 
Part I: Please circle the number that best indicates how much you agree with the 
statements below. 
 
1.) I regret my decision to undergo this surgery + heated chemotherapy (IPHC). 
 
not at all  a little bit  somewhat  quite a bit  very much 
1  2  3  4  5 
 
2.) My sleep quality prior to surgery + heated chemotherapy (IPHC) was poor. 
 
not at all  a little bit  somewhat  quite a bit  very much 
1  2  3  4  5 
 
3.) Before learning about surgery + heated chemotherapy (IPHC), I was told by my 
doctors that there was nothing more I could do for treatment. 
 
not at all  a little bit  somewhat  quite a bit  very much 
1  2  3  4  5 
 
4.) After surgery + heated chemotherapy (IPHC) I was given good information and 
counseling about how to return to normal eating.  
 
not at all  a little bit  somewhat  quite a bit  very much 
1  2  3  4  5 
 
6.) After surgery + heated chemotherapy (IPHC) I was given good information and 
counseling about how to return to normal activity.  
 
not at all  a little bit  somewhat  quite a bit  very much 
1  2  3  4  5 
 
7) After surgery + heated chemotherapy (IPHC) I was given good information and 
counseling about exercise and physical rehabilitation.  
 
not at all  a little bit  somewhat  quite a bit  very much 
1  2  3  4  5 
 
8) After surgery + heated chemotherapy (IPHC) I was given good information and 
counseling about my emotional reaction to the treatment and hospitalization.  
 
not at all  a little bit  somewhat  quite a bit  very much 
1  2  3  4  5 
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Part II   
 
Please circle the answer (yes or no) that applies to you.  
 
1.) Additional treatment options were given to me at the time I chose surgery and heated 
chemotherapy (IPHC).   Yes    No 
 
2.)  Before I had surgery + heated chemotherapy (IPHC) I was told all that I needed to 
know about what to expect.    Yes    No 
 
3.) After surgery + heated chemotherapy (IPHC) I talked to a nutritionist about my diet. 
Yes   No  
 
4.) After surgery + heated chemotherapy (IPHC) I talked to a physical therapist about 
exercising to help my recovery.  Yes   No 
 
5.) After surgery + heated chemotherapy (IPHC) I talked to a counselor about my 
emotional reactions to treatment. Yes   No 
 
Part III 
 
Please answer the questions below. If you need more space, use the back of this 
questionnaire. 
 
1.) Were you ever told by your medical team that you had only a certain amount of time 
to live due to the nature of your diagnosis?   What was said? 
 
____________________________________________________________________ 
 
____________________________________________________________________ 
 
2.) From hospitalization through follow-up care, what has been the most difficult aspect 
of your surgery + heated chemotherapy (IPHC) experience? 
 
____________________________________________________________________ 
 
____________________________________________________________________ 
 
3.) Could anything have been done to improve the quality of your experience?  
 
____________________________________________________________________ 
 
____________________________________________________________________ 
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4.) What information would you give to someone considering having this surgery + 
heated chemotherapy (IPHC)? 
 
_______________________________________________________________ 
 
____________________________________________________________________ 
 
5.) Please list other family members who were previously diagnosed with cancer. What 
were their diagnoses? 
 
____________________________________________________________________ 
 
____________________________________________________________________ 
 
 
Please make any additional comments that could help us improve patient care: 
 
 
 
Thank You for your help 
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Pilot Study 
Research Questions and Hypotheses 
 This pilot study was conducted to field test the procedural aspects of the 
investigation as well as the instrumentation and corresponding instructions.  Similarly, in 
order to test data analysis procedures for each of the research questions established for 
the full study, the pilot data was analyzed accordingly.  Although the pilot sample is of an 
insufficient size from which to draw conclusions, the preliminary results are listed below.   
Research Question 1: What are the QOL subscale scores (i.e. Physical Functioning, Role 
Functioning, Bodily Pain, General Health, Vitality, Social Functioning, Mental Health, 
Reported Health Transition) of participants, as measured by the Medical Outcomes Study 
36-Item Short-Form Health Survey (SF-36) instrument, and how do they compare to 
those of general population norms? 
Hypothesis 1a: The QOL subscale scores of participants will be lower than the 
standardized population norms. 
Research Question 2: Regarding those participants for whom pre-surgical data is 
available, what differences exist between pre-surgical QOL subscale scores and 12 or 
more-month QOL scores for participants who received CS+HIPEC and have survived? 
Hypothesis 2a: Post-surgical, 12-month Physical Functioning (PF), Role Physical 
(RP) and Bodily Pain (BP) subscale scores will be significantly higher than those 
acquired from Participants pre-surgery. 
Research Question 3: What is the sleep quality of participants, as defined by one‟s global 
and component scores on the Pittsburgh Sleep Quality Index (PSQI)? 
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Hypothesis 3a: Global PSQI scores of the majority of CS+HIPEC patients will be 
above the recommended clinical threshold of eight, indicating poor sleep quality. 
Research Question 4: What relationship exists between sleep quality and QOL subscale 
scores? 
 Hypothesis 4a: A significant positive relationship will exist between global sleep
 quality scores and the QOL subscale scores. 
Research Question 5: What are the respective contributions of age at CS+HIPEC and 
resection status (RO/R1, R2a, R2b, and R2c) in predicting QOL subscale scores at 12 or 
more months in participants with varying primary tumor sites? 
Hypothesis 5a: Patients who achieved a better resection status will demonstrate 
higher QOL scores at 12 or more months. 
Hypothesis 5b: Patients with appendiceal tumors and pseudomyxoma peritonei 
will demonstrate higher QOL scores at 12 or more months. 
Participants 
 The names of approximately ten percent (n=19) of the potential full-study 
participants were selected at random from the master database containing the names of all 
CS+HIPEC recipients from Wake Forest University Baptist Medical Center.  Of these 19 
individuals, telephone contact was made with 17, and all 17 gave verbal consent to 
participate and have the survey mailed to their home address. Within ten days time, 13 
individuals (76.47% of the 17 individuals who were contacted) returned the completed 
instruments. If all potential participants, including those not contacted via telephone 
within the window of pilot study time, are included (i.e. 13/19), the overall response rate 
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was 68.42%.  This response rate was surprisingly large given the nature of survey 
research and the characteristics of the sample.  It is important to note that one participant 
returned the completed survey following the end of the pilot study timeframe, suggesting 
the potential need to extend the data collection window.  Also, one of the 17 individuals 
who gave verbal consent to participate called following the reception of the packet to 
verbalize that she was too ill and deconditioned to complete the survey.  She returned the 
survey without providing any data.  In conclusion, the pilot data presented here were 
provided by 13 individuals who had CS+HIPEC at Wake Forest University Baptist 
Medical Center at least 12 months prior to the pilot study date.  Further demographic 
information is found in Table 2.  
Instrumentation 
 After giving verbal consent to participate over the telephone, prospective 
participants were sent a cover letter, a long form consent, the battery of instruments 
(including the Medical Outcomes Study 36-item Short Form Health Survey (SF-36), the 
Pittsburgh Sleep Quality Index (PSQI), a Sociodemographic Questionnaire, and a Patient 
Information Questionnaire), and a self-addressed, postage-paid envelope.  Also, in the 
initial phone interview, patients were asked to indicate on the packet if the process 
required an excess of 20 minutes or if any particular items were confusing.   
Procedures 
 In this order, requests to complete this study were submitted to and approved by 
the Human Subjects Review Board at Wake Forest University Baptist Medical Center 
followed by that of The University of North Carolina at Greensboro. Following 
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notification of approval from the Board at the second institution, packets were prepped 
for mailing, and prospective participants‟ names were randomly selected from the 
hospital master database containing names of all individuals who have had CS+HIPEC at 
WFUBMC.  Calls to secure verbal consent were made over a period of one week‟s time, 
and packets were mailed the day that verbal consent to participate was secured from a 
respective individual.  A total of ten days were allocated for data collection.  As packets 
were received, they were perused for any missing data, and data were entered into secure 
databases created by the investigator.  Responses to single missing items were acquired 
over the telephone.  Finally, within a two week time period from when the completed 
packet was received by the investigator, each participant was sent a letter of gratitude for 
her or his participation, a copy of her or his signed consent form, and a $25 gift card to 
Shell gas stations.  
Data analysis and Overview of Results 
 Frequencies were computed for the demographic questions and are presented in 
Table A. Results for the hypotheses are outlined below.  
 Hypothesis 1a. To answer hypothesis 1a, descriptive statistics were calculated for 
each of the eight QOL subscale scores as well as the overall mental and physical 
component scores (MCS, PCS; see results in Tables B-D).  The SF-36 scoring software 
utilizes norm-based scoring that relies on a linear T-score transformation with a mean of 
50 and standard deviation of 10 (Ware, n.d.).   Upon comparing the mean scores on the 
two higher-ordered clusters (i.e. MCS and PCS), it is apparent that, collectively, the pilot 
participants are faring better mentally (MCS mean = 51.6, SD = 10.9) than physically 
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(PCS mean = 44.2, SD = 12.1).  Given the diagnostic and treatment history of these 
individuals, the lower PCS scores are not surprising. Within the PCS, the lowest mean 
subscale score was on RP (mean = 43.2, SD = 13.8), followed by PF (mean = 45.2, SD = 
11.1).  Surprisingly, the mean MCS of these pilot participants is above that which might 
be anticipated for a person in the general population (mean of 50).  However, for each of 
the subscale scores, it is important to note the range of scores in addition to the mean or 
median scores. The presence of outlier scores that are approximately two to three 
standard deviations below the mean on most subscales suggests that some of these 
survivors are reporting significant emotional and physical suffering while others are not.  
Although it is not possible to make any generalizations based on such a small sample, it 
will be important to consider variability of scores among the full study sample. 
Additionally, Cronbach‟s alpha (see Table F) ranged from 0.794 (RE) to 0.961 
(RP), suggesting acceptable evidence of internal consistency with this sample. Pearson 
Product Moment Correlation coefficients also were calculated between each of the 
subscales, and the results are located in Table 6.  With the exception of correlations 
between the GH and RE subscales and the MH and PF subscales, all subscales were 
correlated significantly. Finally, some items demonstrated poor discriminant validity with 
this small pilot sample, correlating significantly higher with alternate scales than with 
their hypothesized scales (e.g. GH02= 0.39 with GH versus 0.61 with SF).  
 Hypothesis 2a. To test hypothesis 2a, a paired t-test was performed (see Table G) 
to examine differences in mean baseline and 12 or more month follow-up PF, RF, and BP 
subscale scores in the subset of participants for whom baseline data were available (n = 
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9).  No significant differences were found, presumably due to the small sample size. 
Although the findings were not statistically significant, it is interesting to note that the 
mean change scores for PF (-2.1), RP (-2.4), and BP (-6.7) were all negative, indicating 
worse physical functioning and physical role functioning as well as increased bodily pain 
at the follow-up measurement as compared to the baseline measurement. These findings 
are contrary to what was hypothesized and may simply be an artifact of the small sample. 
 Hypothesis 3a.  To answer hypothesis 3a, descriptive statistics were calculated in 
order to acquire the mean subscale and overall PSQI scores (see Table H). The mean 
overall PSQI score for pilot participants was 9.2 (SD 5.0), which is above eight, the more 
conservative cutoff point selected for this study.  Only 38.46% of this pilot sample scored 
below the recommended cutoff of eight, suggesting roughly 61% of these individuals 
currently report poor sleep quality (see Table J). Likewise, this overall score of 9.2 is well 
above the mean score found for individuals without sleep-related concerns (mean = 2.67, 
SD 1.70) in the Buysse et al. (1989) study.  The highest mean subscale scores (high 
scores indicate worse sleep quality) were on the sleep latency (mean = 1.7, SD = 1.0) and 
sleep disturbance (mean = 1.7, SD = 0.9) subscales.  It takes these pilot participants an 
average of 34.6 minutes to fall asleep, and the most common sleep disturbances  include, 
in this order, bathroom-related awakenings, middle-of-the-night or early morning 
awakenings, poor sleep latency, pain, and the sensation of being too cold.  
 Hypothesis 4a.  To answer hypothesis 4a, Pearson correlation coefficients were 
calculated to determine the relationship that exists between global sleep quality scores 
and the QOL subscale scores (see Table K).  Given that a lower QOL subscale score 
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indicates poorer QOL, while a higher PSQI score indicates poorer sleep quality, a 
negative correlation between the two variables actually signifies that these variables 
move together (i.e. a positive relationship).  Significant negative correlations were found 
between overall PSQI scores and PF (-0.647, p = 0.017), RP (-0.700, p = 0.008), GH (-
0.837, p = 0.000), VT (-0.774, p = 0.002), and PCS (-0.761, p = 0.003), suggesting 
positive relationships between sleep quality and the aforementioned QOL subscale and 
component scores.  For example, as the PF subscale score went down (indicating worse 
physical functioning), the PSQI score went up (indicating worse sleep quality).  In 
summary, the hypothesis that significant positive relationships between overall PSQI 
scores and QOL subscale scores was met relative to physical functioning, role physical, 
general health, vitality, and the overall physical component score.  
 Hypothesis 5a.  Finally, insufficient data was obtained in the pilot study to 
answer research question five.  Specifically, due to the scarcity of data for some cells 
needed in the model (i.e. tumor site and resection status), the ANOVA was not run.  
However, an examination of the QOL means when divided by resection status 
demonstrates some noteworthy trends (see Table L) that appear to support hypothesis 5a.  
For example, the mean PF scores for those with a resection status of R0/1 (n = 10) versus 
R2a (n = 1) versus R2b (n = 2) were 48 (SD = 8.9), 36.2, and 32.0 (SD = 14.8), 
respectively. Similar trends are noted across other subscales.  Results of the Kruskal-
Wallis Test support the existence of significant differences between the three groups (i.e. 
R0/1, R2a, and R2b) relative to VT (p = 0.038), SF (p = 0.034), and RE (p = 0.038).  
Although a regression model to gauge the respective contributions of resection status and 
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tumor site to QOL was not run, these initial findings suggest that QOL differences may 
exist between those with varying resection statuses.  
 Hypothesis 5b. Again, hypothesis 5b was not tested given the characteristics of 
the pilot sample. Within the sample, seven individuals had a primary diagnosis of 
appendiceal cancer, two had a primary diagnosis of colon cancer, and the remaining 
individuals had a primary cancer diagnosis of liver, mesothelioma, sarcoma, or “other”.  
It is noteworthy that over 50% of the pilot sample had a primary diagnosis of appendiceal 
cancer, potentially suggesting that those with carcinomatosis of appendiceal origin may 
be better represented among the long-term survivors (i.e. they might have longer life 
expectancies post-CS+HIPEC).   
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Table A 
Sociodemographic Description of the Pilot Study Sample (N = 13) 
Variable Mean Median Range n 
Age 60.15  32-81 13 
Age at CS+HIPEC 54.46  31-77 13 
CS+HIPEC Date  8/2005 5/1993- 
9/2008  
13 
Gender          
            Female 
            Male 
    
8 
5 
Race 
            Black 
            White 
 
 
   
1 
12 
Ethnicity 
             Hispanic 
             Non-Hispanic 
    
1 
12 
ECOG Performance Status 
            0 
            1 
    
7 
6 
Resection Status 
            R0/1 
            R2a 
            R2b 
    
10 
1 
2 
State of Residence 
            FL 
            NC 
            NJ 
            SC 
            VA 
    
1 
9 
1 
1 
1 
Diagnoses 
            Appendix 
            Colon 
            Liver 
            Mesothelioma 
            Sarcoma 
            Other 
    
7 
2 
1 
1 
1 
1 
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Table B 
Means and Medians of SF-36 Subscales 
Variable N Mean Std Dev Median Minimum Maximum 
PF_NBS 13 45.2 11.1 44.6 21.5 57.1 
RP_NBS 13 43.2 13.8 49.2 28.0 56.2 
BP_NBS 13 49.7 11.7 46.5 33.2 62.8 
GH_NBS 13 45.3 13.1 43.9 26.5 64.0 
VT_NBS 13 47.6 13.1 44.3 32.5 70.4 
SF_NBS 13 50.5 10.2 57.1 24.6 57.1 
RE_NBS 13 48.9 11.0 55.3 23.7 55.3 
MH_NBS 13 51.0 12.2 50.4 25.5 64.1 
PCS_NBS 13 44.2 12.1 41.3 27.9 59.2 
MCS_NBS 13 51.6 10.9 53.9 30.7 64.7 
 
 
 
Figure A. Norm-based Subscale Scores of Pilot Sample 
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Table C 
Norm-based Physical Component Scores of the SF-36 
PCS-NBS Frequency Percent Cumulative 
Frequency 
Cumulative 
Percent 
27.87 1 7.69 1 7.69 
28.29 1 7.69 2 15.38 
30.39 1 7.69 3 23.08 
33.54 1 7.69 4 30.77 
37.24 1 7.69 5 38.46 
40.69 1 7.69 6 46.15 
41.25 1 7.69 7 53.85 
51.77 1 7.69 8 61.54 
54.99 1 7.69 9 69.23 
55.90 1 7.69 10 76.92 
56.07 1 7.69 11 84.62 
58.00 1 7.69 12 92.31 
59.16 1 7.69 13 100.00 
 
 
 
Figure B. Norm-based Physical Component Scores 
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Table D 
Norm-based Mental Component Scores of the SF-36 
PCS-NBS Frequency Percent Cumulative 
Frequency 
Cumulative 
Percent 
30.71 1 7.69 1 7.69 
31.34 1 7.69 2 15.38 
41.91 1 7.69 3 23.08 
48.36 1 7.69 4 30.77 
51.60 1 7.69 5 38.46 
53.40 1 7.69 6 46.15 
53.86 1 7.69 7 53.85 
54.02 1 7.69 8 61.54 
58.02 1 7.69 9 69.23 
60.25 1 7.69 10 76.92 
60.38 1 7.69 11 84.62 
61.99 1 7.69 12 92.31 
64.67 1 7.69 13 100.00 
 
 
 
Figure C. Norm-based Mental Component Scores 
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Table E 
Pearson Correlation Coefficients, SF-36 Subscales, N=13 
 PF_NBS RP_NBS BP_NBS GH_NBS VT_NBS SF_NBS RE_NBS MH_NBS 
PF_NBS 1.000 0.871 
0.0001 
0.701 
0.0076 
0.727 
0.0049 
0.869 
0.0001 
0.701 
0.0076 
0.743 
0.0036 
0.546 
0.0534 
RP_NBS 0.871 
0.0001 
1.000 0.748 
0.0033 
0.766 
0.0023 
0.898 
<.0001 
0.579 
0.0381 
0.664 
0.0133 
0.608 
0.0273 
BP_NBS 0.701 
0.0076 
0.748 
0.0033 
1.000 0.586 
0.0354 
0.813 
0.0007 
0.662 
0.0137 
0.688 
0.0093 
0.813 
0.0007 
GH_NBS 0.727 
0.0049 
0.766 
0.0023 
0.586 
0.0354 
1.000 0.830 
0.0004 
0.616 
0.0249 
0.500 
0.0820 
0.651 
0.0159 
VT_NBS 0.869 
0.0001 
0.898 
<.0001 
0.813 
0.0007 
0.830 
0.0004 
1.000 0.683 
0.0100 
0.660 
0.0131 
0.762 
0.024 
SF_NBS 0.701 
0.0076 
0.579 
0.0381 
0.662 
0.0137 
0.616 
0.0249 
0.683 
0.0100 
1.000 0.730 
0.0047 
0.774 
0.0019 
RE_NBS 0.743 
0.0036 
0.664 
0.0133 
0.688 
0.0093 
0.500 
0.0820 
0.660 
0.0131 
0.730 
0.0047 
1.000 0.770 
0.0021 
MH_NBS 0.546 
0.0534 
0.608 
0.0273 
0.813 
0.0007 
0.651 
0.0159 
0.762 
0.024 
0.774 
0.0019 
0.770 
0.0021 
1.000 
 
 
 
Table F 
Scale Reliability and Homogeneity Estimates 
Scale Number 
of Items 
Cronbach’s  
Alpha 
Average Inter-item  
Correlation 
PF 10 0.932 0.580 
RP 4 0.961 0.859 
BP 2 0.953 0.911 
GH 5 0.851 0.534 
VT 4 0.951 0.829 
SF 2 0.865 0.763 
RE 3 0.794 0.563 
MH 5 0.822 0.481 
 
 
 
Table G 
Change at follow-up: PF, RP, and BP 
Variable N Mean Std Dev Median Minimum Maximum  p-value 
PF 9 -2.1 7.3 -2.1 -14.1 8.4 0.4119 
RP 9 -2.4 10.0 0.0 -28.3 7.1 0.4998 
BP 9 -6.7 10.9 -9.0 -25.3 12.0 .1043 
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Table H 
Pittsburgh Sleep Quality Index Global and Subscale Scores 
Subscale N Mean Std Dev Minimum Maximum 
Sleep Quality 13 1.3 0.9 0.0 3.0 
Sleep Latency 
Minutes to Fall 
Asleep:  
 
13 1.7 
34.6 
1.0 0.0 
5 
3.0 
90 
Sleep Duration 13 1.2 1.0 0.0 3.0 
Habitual Sleep 
Efficiency 
13 1.3 1.3 0.0 3.0 
Sleep Disturbance 13 1.7 0.9 0.0 3.0 
Use of Sleep 
Medication 
13 1.4 1.6 0.0 3.0 
Daytime 
Dysfunction 
13 0.7 0.6 0.0 2.0 
Total PSQI 13 9.2 5.0 1.0 16.0 
 
 
 
 
 
 
 
Table I 
Pittsburgh Sleep Quality Index Global Score Mean Comparisons 
Group N Mean PSQI Global Score Std Dev 
CS+HIPEC Survivors* 13 9.2 5.0 
Controls (Buysse et al., 1989) 52 2.67 1.70 
Heterogeneous Cancer Sample 
(Beck et al., 2004) 
214 8.15 4.70 
MDD (Buysse et al., 1989) 34 11.09 4.31 
DIMS (Buysse et al., 1989) 45 10.38 4.57 
MDD- Major Depressive Disorder 
DIMS- Disorder of Initiating and Maintaining Sleep 
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Table J 
Pittsburgh Sleep Quality Index Clinical Cut-off >8 
PSQI Global  
Score 
Frequency Cumulative  
Frequency 
Cumulative  
Percent 
1 2 2 15.38 
5 1 3 23.08 
6 1 4 30.77 
7* 1 5 38.46 
9* 1 6 46.15 
10 1 7 53.85 
11 1 8 61.54 
12 1 9 69.23 
13 1 10 76.92 
14 1 11 84.62 
15 1 12 92.31 
16 1 13 100.00 
 
 
Table K 
Correlations: QOL Subscale Scores and Global Sleep Quality Scores 
QOL Subscale/ 
Component 
Score 
PSQI Global 
Score 
PF -0.647 
0.017* 
RP -0.700 
0.008* 
BP -0.389 
0.189 
GH -0.836 
0.000* 
VT -0.774 
0.001* 
SF -0.494 
0.086 
RE -0.259 
0.392 
MH -0.411 
0.163 
PCS -0.761 
0.003* 
MCS -0.361 
0.226 
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Table L 
Means by Resection Status 
Resection 
Status 
N Obs Variable N Mean Std Dev Minimum Maximum 
RO/1 10 PF_NBS 
RP_NBS 
BP_NBS 
GH_NBS 
VT_NBS 
SF_NBS 
RE_NBS 
MH_NBS 
PCS 
MCS 
10 
10 
10 
10 
10 
10 
10 
10 
10 
10 
48.8 
47.8 
52.9 
49.4 
52.1 
54.4 
52.2 
55.2 
47.9 
55.5 
8.9 
12.4 
11.1 
11.8 
11.4 
5.9 
7.1 
8.7 
11.2 
7.0 
32.0 
28.0 
37.5 
32.2 
34.9 
40.9 
34.3 
39.1 
27.9 
41.9 
57.1 
56.2 
62.8 
64.0 
70.4 
57.1 
55.3 
64.1 
59.2 
64.7 
R2a 1 PF_NBS 
RP_NBS 
BP_NBS 
GH_NBS 
VT_NBS 
SF_NBS 
RE_NBS 
MH_NBS 
PCS 
MCS 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
36.2 
28.0 
46.5 
36.8 
32.5 
46.3 
55.3 
50.4 
30.4 
53.9 
. 
. 
. 
. 
. 
. 
. 
. 
. 
. 
36.2 
28.0 
46.5 
36.8 
32.5 
46.3 
55.3 
50.4 
30.4 
53.9 
36.2 
28.0 
46.5 
36.8 
32.5 
46.3 
55.3 
50.4 
30.4 
53.9 
R2b 2 PF_NBS 
RP_NBS 
BP_NBS 
GH_NBS 
VT_NBS 
SF_NBS 
RE_NBS 
MH_NBS 
PCS 
MCS 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
32.0 
28.0 
35.3 
28.9 
32.5 
32.7 
29.0 
30.0 
32.8 
31.0 
14.8 
0.0 
3.0 
3.3 
0.0 
11.5 
7.4 
6.4 
6.3 
0.4 
21.5 
28.0 
33.2 
26.5 
32.5 
24.6 
23.7 
25.5 
28.3 
30.7 
42.5 
28.0 
37.5 
31.2 
32.5 
40.9 
34.3 
34.5 
37.2 
31.3 
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Table M 
Estimation of Scores: Physical Component Scores, No Interaction 
Parameter Estimate  
Standard 
Error t Value Pr > |t| 
Intercept 40.286 B 4.503 8.95 <.0001 
site      appendiceal 5.095 B 2.547 2.00 0.049 
site      other 0.000 B . . . 
resect    R0/R1 4.071 B 4.149 0.98 0.330 
resect    R2a 3.567 B 4.371 0.82 0.417 
resect    R2b 0.000 B . . . 
 
 
 
 
 
Table N 
Estimation of Scores: Mental Component Scores, No Interaction 
Parameter Estimate  
Standard 
Error t Value Pr > |t| 
Intercept 56.410 B 3.644 15.48 <.0001 
site      appendiceal -0.045 B 2.061 -0.02 0.982 
site      other 0.000 B . . . 
resect    R0/R1 -2.814 B 3.358 -0.84 0.404 
resect    R2a -3.098 B 3.537 -0.88 0.383 
resect    R2b 0.000 B . . . 
 
 
